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Abstract
Introduction: Though adjuvant chemotherapy improves survival following surgery, 
pancreatic cancer carries a poor prognosis. Alternatives are required to the current drug 
regimens consisting of S-phase dependent drugs such as gemcitabine. PLK1 is a passenger 
protein involved in G2/M phases which presents a novel target to inhibit in combination 
with current therapies, which may help overcome inate and acquired resistance.
Aim: To evaluate the potential role of a novel PLK1 inhibitor, BI 6727 in pancreatic cancer –
both as monotherapy and in combination with gemcitabine in vitro.
Methods: The IC50 concentrations of both drugs were established in Suit-2, BxPC-3, Panc-1 
and MiaPaCa-2 pancreatic cancer cell lines and isobolar analyses undertaken with a variety 
of combination therapies. Cell cycle analyses were performed with Flow Activated Cell 
Sorting, with apoptosis and necrosis quantified on the basis of phosphatidylserine cell 
surface exposure, propidium iodide staining and cleavage of caspase-3.  
Results: IC50 ranges for BI 6727 and gemcitabine were 53-77nM and 11-34nM respectively 
across four pancreatic cell lines. Flow cytometry of MiaPaCa-2 cells demonstrated G2 arrest 
with BI 6727 and S-phase accumulation with gemcitabine monotherapy. Isobolar analyses 
showed that when added together the combination of drugs was additive, but BI 6727 
pretreatment followed by combination was synergistic. Western blotting for cleaved 
caspase-3 showed evidence of apoptosis with gemcitabine monotherapy but none with BI 
6727 treatment. Although membrane inversion was seen with synergistic drug combinations 
there was no evidence of cleaved-caspase-3, suggesting a modified form of apoptosis.
Conclusion: BI 6727 is effective against a variety of pancreatic cancer cells in vitro. Synergy is
demonstrated in MiaPaCa-2 cells when BI 6727 is administered prior to combination 
therapy with gemcitabine, though mode of cell death does not appear to be caspase-
dependent. This supports the concept that PLK1 inhibition can overcome gemcitabine 
resistance in some cells by allowing resistant cells to initiate gemcitabine induced apoptosis, 
although this is dependent on drug phasing and the full apoptotic pathway may not be 
achieved.
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Chapter 1 - Introduction
The Pancreas
Structure
The pancreas is an elongated organ measuring 12-15cm which lies horizontally in the 
retroperitoneum, posterior to the stomach. The gland is broadly anatomically divided into 
the head, uncinate, neck, body and tail. The widest part - the head, lies in the concavity of 
the duodenum which has an inferior projection known as the uncinate process. Medial to 
the head is a constriction described as the pancreatic neck, leading to the body, which 
represents the mid-portion of the pancreas. Adjacent to the body is the tail which tapers 
and terminates next to the spleen in the left upper quadrant1 2 3.
Embryologically, the human pancreas develops from the dorsal and ventral pancreatic buds 
which fuse at 7-8 weeks. These buds possess two ductal systems which anastomose during 
fusion with multiple anatomical variants described in the literature4. Classically, a main 
pancreatic duct originates in the tail, draining the gland’s secretions medially. This duct then 
drains into the two ductal systems at the site of their embryological fusion. Firstly, the 
segment of duct originating from the dorsal bud, named the Accessory duct of Santorini5
(Giovanni Dominico Santorini 1681-1737, Italian anatomist), drains into the minor papilla. 
Alternatively, secretions will pass downstream from the main pancreatic duct into the Duct 
of Wirsung (Johann Wirsung 1589-1643, German anatomist), which originates from the 
ventral bud and drains into major papilla, where it meets the common bile duct6 7 8 9. These 
two structures drain into the second part of the duodenum via a protrusion of the Ampulla 
of Vater10 (Abraham Vater 1684–1751, German anatomist). The secretion of bile and 
pancreatic juices is controlled by a circumferential smooth muscular layer known as the 
Sphincter of Oddi11 (Ruggero Oddi 1864-1913, Italian anatomist and physiologist).
Exocrine and Endocrine Function
Histologically, the pancreatic parenchyma can be grossly divided into its exocrine and 
endocrine components. The majority of the pancreas is composed of acinar cells, which are 
arranged in clusters around interlobular ducts that lead to the main pancreatic duct12. Acini 
are exocrine cells which secrete approximately 2.5 litres of bicarbonate-rich fluid per 24 
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hours. This fluid contains digestive enzymes such as pancreatic amylase and lipase in 
addition to several proenzymes such as proteases13.
The endocrine function of the pancreas is dependent on islet cells which group to form the 
Islets of Langerhans14 (Paul Langerhans 1847-88, German pathologist). These cells only 
account for approximately 1-2% of pancreatic mass15 and secrete hormones including 
insulin, glucagon, somatostatin and pancreatic polypeptide into the bloodstream16.
The Incidence of Pancreatic Cancer
Despite accounting for less than 3% of all cancer diagnoses, pancreatic cancer (ICD Code:  
ICD-10 C25) is now the 4th leading cause of cancer-related deaths in the developed world17.  
In 2014, 8080 people in England were diagnosed with the disease making it the 10th
commonest cancer in the country. Incidence of the disease has remained relatively 
unchanged over the past 40 years. For males and females, current figures suggest an 
incidence of 10.7 and 8.7 respectively per 100,000, with mortality rates being only 
marginally lower (Figure 1). Currently, of the 21 most common cancers in the United 
Kingdom, pancreatic cancer has the lowest life expectancy18. Figures for patients diagnosed 
in England between 2005 and 2009 suggest a 5-year survival rate of only 3.7%19. 
Figure 1: Pancreatic cancer incidence and mortality rates, England, 1971-2011
The incidence of pancreatic cancer has remained relatively unchanged over the past 40 
years. Taken without permission from the Office of National Statistics18
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Risk Factors
In addition to advancing age18, other recognized risk factors for developing pancreatic 
cancer include obesity20 21 22 23 and smoking24 25 26. Two meta-analyses also suggest that 
diabetes mellitus is a risk factor in the development of the disease27 28. However, it is now 
argued that diabetes is a consequence of pancreatic cancer29, which may be of potential 
benefit in screening and the early detection of the malignant process30.
The evidence surrounding the association between alcohol consumption and pancreatic 
cancer is conflicting. Several case-control and cohort studies have found no association 
between the two whilst other studies have suggested an increased risk in heavy 
consumers31. Nevertheless, alcohol excess accounts for the vast majority of chronic 
pancreatitis cases32, which is now a recognized risk factor in developing pancreatic cancer33. 
A recent meta-analysis declared a thirteen-fold relative risk for developing the disease, with 
a time course of one or two decades between developing both diseases34. 
Exclusive of lifestyle factors, few other genetic and hereditary factors can increase the risk 
of pancreatic cancer (Table 1) including hereditary pancreatitis35 36, cystic fibrosis 37 38 39 and 
familial pancreatic cancer40 41 42. Presently, both European43 and American44 registers for 
familial pancreatic cancer have been established with view to offering screening, 
surveillance and in extreme cases, prophylactic surgery for high-risk individuals. 
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Table 1: Related mutational genes and their respective risks in developing pancreatic 
cancer 
Setting of Inherited Pancreatic Cancer Gene Pancreatic Cancer Risk until 70 years (%)
Hereditary tumour predisposition syndromes
Peutz-Jeghers syndrome SK11/LKB1 36
Atypical multiple mole melanoma 
syndrome CDKN2a 17
Hereditary breast and ovarian cancer BRCA1, BRCA2 3 to 8
Li-Fraumeni TP53 <5
Hereditary nonpolyposis colorectal 
cancer MLH1, MSH2 <5
Familial adenomatous polyposis APC <5
Ataxia telangectasia ATM <5
Tumour syndromes  with chronic inflammation/dysfunction of the gland
Hereditary pancreatitis PRSS1, SPINK1 40
Cystic fibrosis CFTR <5
Familial pancreatic cancer syndrome BRCA2, PALB2, ? ~40
Several genes are associated with an increased risk of developing pancreatic cancer. 
Modified from Fendrich et al45
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Pancreatic Tumours
Pancreatic tumours can be broadly divided into being of exocrine or endocrine origin with 
further classification with regards to their malignancy.
Endocrine Pancreatic Tumours
Neuroendocrine pancreatic tumours appear to arise from Islet cells and account for <5% of 
all primary pancreatic malignancies46. ‘Functional’ tumours are associated with a clinical 
syndrome47 and are classified according to the hormone that they produce (insulinoma, 
gastrinoma, glucagonoma, somatostatinoma and Vasoactive Intestinal Peptide [VIP]oma). 
‘Non-functioning’ tumours, typically produce a precursor or negligible quantity of hormone 
and are most commonly found in the head of the pancreas48. Non-functioning tumours have 
a poorer prognosis, with one large series49 concluding that individuals with functional 
tumours survive for twice as long as those with non-functioning tumours (median survival of 
54 months vs. 26 months). It must also be noted that long term survival can also be 
achieved in the metastatic patient with a 5-year survival of 19.5% in the same series. This 
highlights the importance of distinguishing these rare endocrine tumours from their 
exocrine counterparts which have a comparably dismal prognosis.
Exocrine Pancreatic Tumours
A wide variety of benign, pre malignant and malignant exocrine pancreatic lesions have 
been recognised (Table 2). However, ductal adenocarcinoma and its variants represent up to 
90% of all pancreatic tumours50 and is widely what is understood by the term ‘pancreatic 
cancer’.
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Table 2: Malignant tumours of the exocrine pancreas
Malignant Exocrine Pancreatic Tumours
Epithelial tumours:
Ductal adenocarcinoma
• Mucinous noncystic carcinoma (Mucinous Adenocarcinoma)
• Signet-ring cell carcinoma
• Adenosquamous carcinoma
• Undifferentiated (anaplastic) carcinoma
• Mixed ductal-endocrine carcinoma
• Osteoclast-like giant cell tumour
Serous cystadeoncarcinoma
Mucinous cystadenocarcinoma
Intraductal papilliary-mucinous carcinoma
Invasive papilliary-mucinous carcinoma
Acinar cell carcinoma
Pancreatoblastoma
Solid-pseudopapilliary carcinoma
Extremely Rare:
Clear cell carcinoma (clear cell adenocarcinoma)
Oncocytic carcinoma (oxyphilic adenocarcinoma)
Choriocarcinoma (NOS)
Non-epithelial tumours
Secondary tumours
There are several subtypes of malignant exocrine pancreatic tumours with pancreatic 
ductal adenocarcinoma being by far the commonest. Pancreatic intraepithelial neoplasia 
(PanIN) is now thought to be the precursor to the development of most ductal 
adenocarcinomas51.
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Pancreatic Cancer in the Clinical Environment
Clinical Presentation
The presenting symptoms and signs of pancreatic cancer are often vague and can be 
extremely variable. Upper abdominal and back pain can be a feature with patients often 
complaining of loss of appetite or nausea. Tumours of the pancreatic head commonly lead 
to obstructive jaundice being the main presenting feature, but such tumours may also cause 
pancreatitis, gastric outlet obstruction or gastrointestinal bleeding. Individuals with systemic 
manifestation of the neoplastic process may present with diabetes, venous thrombosis, 
weight loss or abdominal distension secondary to ascites52. Occasionally, asymptomatic 
patients may be found to have a pancreatic lesion following radiological imaging for 
unrelated reasons.
Clinical Signs
Signs of the disease may be absent though inspection of the patient may reveal a myriad of 
signs. The patient may be jaundiced, with evidence of pruritis or dark urine to indicate 
cholestasis. They may appear pale and cachexic or wear loose fitting clothes indicating 
recent weight loss. Examination of the abdomen may reveal a palpable abdominal mass, 
hepatomegaly, abdominal distension with shifting dullness or lymphadenopathy53.  
Imaging in Pancreatic Cancer
The aims when assessing any patient with a possible malignant disease are to alleviate any 
symptoms, diagnose and stage the disease and finally to determine their treatment options 
such as potentially curative surgery. Studies have shown that computed tomography (CT) 
imaging is highly sensitive in detecting pancreatic tumours54 and has therefore become the 
imaging procedure of choice for evaluating any suspected pancreatic lesion55. An equivocal 
CT with a continuing suspicion for a pancreatic lesion should lead to an endoscopic 
ultrasound (EUS), which is superior in detecting early tumours as small as 2-3mm56. 
In addition to revealing any obvious distant metastases, an arterial and portal-phase CT will 
enable visualisation of the tumour in relation to both the adjacent organs and vasculature. 
Evaluating a primary pancreatic tumour with regards to local invasion is a critical process, as 
surgical resection is currently the only potentially curative treatment. On the contrary, it is 
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not desirable to subject patients with irresectable disease to a trial dissection, as this 
inevitably leads increased hospital morbidity and mortality57.
Borderline Resectable Pancreatic Cancer
Radiologically assessing a pancreatic tumour in relation to its adjacent vasculature - the 
common hepatic artery, coeliac axis, superior mesenteric artery, vein and portal vein is both 
a critical and challenging process. CT examination has a varied accuracy of 62-92% in 
assessing vascular involvement58 in pancreatic cancer, with magnetic resonance 
cholangiopancreatography (MRCP) adding little in assessing tumour resectability59. In the 
absence of metastatic disease, a clear plane between the tumour and this vasculature 
indicates a resectable cancer. However, any apparent contact between the two no longer 
contraindicates curative surgery60. The International Study Group of Pancreatic Surgery 
(ISGPS)61 have definined ‘bordeline resectable’ with regards to the arterial and venous 
involvement of tumours.
Endoscopic Techniques and Obtaining a Definitive Diagnosis 
Frequently, tumours of the pancreatic head will obstruct the bile duct leading to jaundice, 
pruritis and occasionally cholangitis. Biliary drainage can be achieved prior to resection with 
the endoscopic insertion of a stent. However, an endoscopic retrograde 
cholangiopancreatography (ERCP) should not be routinely performed on all patients with 
pancreatic cancer. Obtaining a definitive histological diagnosis is not always necessary prior 
to resection, especially if there is a history of chronic pancreatitis.  However, a definitive 
diagnosis must be reached if neo-adjuvant or palliative chemotherapy is to be administered. 
An ERCP with brushings is a notoriously unreliable technique in establishing a diagnosis, 
with a large meta-analysis determining a sensitivity of 41.6% and a negative predictive value 
of 58%62. For this reason, an expert panel recently strongly recommended that in the 
absence of jaundice, an endoscopic ultrasound and fine needle aspiration (EUS-FNA) should 
be the preferred method of obtaining confirmation of malignancy63.
The Staging of Pancreatic Cancer
The Union for International Cancer Control (UICC) has formulated the 7th Edition staging 
system for pancreatic cancer64 (Table 3 and Table 4). Staging of the disease is critical in 
guiding each patient’s treatment and prognosis, in addition to its importance for audit and 
research purposes.   
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Table 3: The Union for International Cancer Control (UICC)’s TNM staging of pancreatic 
cancer
Tumour
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour limited to the pancreas and <2cm at its greatest diameter
T2 Tumour limited to the pancreas and >2cm at its greatest diameter
T3
Tumour extends beyond the pancreas but not involving the coeliac axis of superior 
mesenteric artery
T4 Tumour involves the coeliac axis or superior mesenteric artery
Lymph Nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Metastases
M0 No distant metastasis 
M1 Distant metastasis 
The TNM classification is widely applied to a spectrum of malignant diseases and has been 
modified for pancreatic cancer. 
26 | P a g e
Table 4: The UICC TNM staging of pancreatic cancer
Stage Tumour Lymph Nodes Metastasis
0 Tis N0 M0
IA T1 N0 M0
IB T2 N0 M0
IIA T3 N0 M0
IIB T1 N1 M0
T2 N1 M0
T3 N1 M0
III T4 Any N M0
IV Any T Any N M1
The individual components of the TNM classification is then collated to stage the disease, 
graded from stages 1 to 4.
The Multidisciplinary Team
Multidisciplinary teams were introduced to overcome shortfalls in UK cancer care65. All 
confirmed or suspected cases of pancreatic cancer are now routinely discussed in a 
multidisciplinary meeting. This usually weekly, collective discussion involves a spectrum of 
healthcare professionals ensures a timely diagnosis and treatment in accordance with the 
best available evidence. 
The Surgical Management of Pancreatic Cancer
Kausch reported the first successful two-stage pancreatoduodenectomy in 191266, which 
was undertaken for an ampullary cancer. It was not until 1946 that Whipple published his 
single-stage procedure that it now known by his name67. The classic ‘Kausch-Whipple’ 
involves excision of the common bile duct, gallbladder, pancreatic head, pylorus and the 
duodenum. This has been modified over time, with preservation of the pylorus performed if 
possible – the ‘pylorus-preserving Kausch-Whipple’. This avoids the need for a ‘Roux-en-Y’ 
reconstruction though no difference in morbidity, mortality or long-term survival is noted68.
Less common are tumours of the body or tail of the pancreas. These tumours account for 
approximately a third of all pancreatic tumours69, but are less likely to be resectable and 
have a poorer prognosis in comparison to lesions of the head70. These distal lesions are 
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subject to a left/distal pancreatectomy and splenectomy, ensuring the removal of the 
lymphatic chain adjacent to the splenic vessels. 
Morbidity and Mortality of Surgical Resection for Pancreatic Cancer
The first published series of pancreaticoduodenectomies included 12 patients with an 
operative mortality rate of 43%71. With continuing improvements in surgical techniques and 
perioperative care, this figure has dropped significantly with two series of over 100 patients 
even reporting no mortality72 73. 
Given the complexity of pancreatic surgery, the National Health Service recommended that 
specialist pancreatic teams cover a minimum catchment area of a million patients to deliver 
optimal care74. One of the reasons for this is to ensure an adequate case-load for specialist 
centres. There is plentiful evidence to support that high volume centres reduce surgical 
mortality rates, and are better equipped to deal with any complications that occur75 76. 
Recent Advances in the Surgical Management of Pancreatic Cancer
The first laparoscopic pancreaticoduodenectomy was reported in 199477 and more recent 
times have seen the advent of a robotic technique78. Three recent meta-analyses have 
compared minimally invasive pancreaticoduodenectomy (MIPD) with open surgery79 80 81. 
All three agreed that though the former procedure takes significantly longer, MIPD leads to 
less intraoperative blood loss, a shorter hospital stay, comparable oncological results, 
morbidity and mortality compared to the open technique. However, to date, no randomised 
study has been published comparing techniques.
Consistent with other surgical specialties, Enhanced Recovery after Surgery (ERAS) 
guidelines have been published specifically for patients undergoing 
pancreaticoduodenectomy82. These guidelines aim to reduce the length of hospital stay 
after surgery without compromising morbidity and mortality. A 2013 meta-analysis83
suggests that this is possible in a range of pancreatic procedures, with lower morbidity rates 
noted in patients undergoing ERAS compared with standard postoperative care. 
New Treatments
The fundamental problem with surgical treatment of pancreatic cancer is that the disease 
has inevitably spread by the time of detection and so even though the primary can be 
removed this will only give a temporary benefit unless systemic treatment is applied to 
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remove the metastatic deposits. In order to understand how current therapies work and 
how they can be improved it is necessary to understand the molecular basis of the disease.
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The Development of Pancreatic Cancer
Though pancreatic cancer can arise from intraductal papilliary mucinous neoplasms or 
mucinous cystic neoplasms, it is believed that the vast majority will originate from non-
invasive precursor lesions called pancreatic intraepithelial neoplasia (PanIN). PanINs are 
non-invasive and usually less than 5mm in size, therefore being asymptomatic. Though 
multiple terminologies were initially utilised to describe these lesions, the current PanIN 
classification in use was introduced in 200184 85. 
Histology of PanINs
PanINs can be classified into four broad categories depending on their histological 
appearance. PanIN-1A and PanIN-1B are low-grade lesions displaying only minimal atypia, 
with the former appearing flat and the latter papilliary in appearance. PanIN-2 are papilliary 
lesions, showing a greater degree of cytological and architectural atypia compared to lower 
grade lesions. PanIN-3, often described as ‘carcinoma in-situ,’ shows severe cytological and 
architectural atypia86. 
Genetic Alterations in the Development of Pancreatic Adenocarcinoma from PanINs
Pancreatic adenocarcinoma is thought to develop from normal epithelium, which gradually 
progresses through the histological stages of PanIN described above, before developing 
invasive properties. Simultaneously, the lesion will undergo a variety of genetic alterations87
with the most prevalent discussed below (Figure 2).
Telomere Shortening
Telomeres are DNA-protein structures located at the ends of chromosomes, preventing 
inter or intra-chromosomal adhesion88. The shortening of telomeres is a recognised event 
with ageing89, with a small portion of DNA lost with each cell division. Shortened telomeres 
increase the risk of fusion, leading to the instability of chromosomes and carcinogenesis90. 
Evidence of shortened telomeres even in in PanIN-1 suggests that this may be one of the 
earliest events in pancreatic carcinogenesis91 92. 
KRAS2
A mutation in the KRAS2 oncogene is seen in over 90% of pancreatic adenocarcinomas and 
KRAS2 was the first gene to be studied in detail with regards to its association with the 
development of the disease.  KRAS2 mutations in pancreatic adenocarcinoma are located at 
30 | P a g e
p.G12 in 98% of cases, with the remaining seen in either p.G13 or p.Q6193. Once active, 
KRAS will stimulate downstream pathways such as the mitogen-activated kinase (MAPK)94
pathway, encouraging cellular proliferation and evading apoptosis – the hallmarks of 
cancer95.  
KRAS mutations in healthy control tissue are uncommon, with studies showing a strong 
correlation between the degree of PanIN dysplasia and frequency of KRAS mutations96. It is 
the earliest genetic mutation seen in the PanIN-carcinoma sequence, being a common 
finding in PanIN-1A lesions97.
CDKN2A
A further mutation often seen in early PanIN is in the tumour suppressor p1698. Its encoding 
gene, CDKN2A is located on the short arm of chromosome 9 and almost all pancreatic 
adenocarcinoma have lost its function99. This can be by mutation of both alleles or by a 
combination of mutation of one allele and promoter methylation in the other. At the G1-S 
phase transition, p16 inhibits the phosphorylation of the retinoblastoma tumour suppressor 
gene (Rb) by cyclin-dependent kinases 4 and 6100, decelerating the progression of cells into 
S-phase. This control over Rb phosphorylation is lost when p16 is inactivated, resulting in 
the loss of control over cell cycle arrest101, contributing to carcinogenesis102.
TP53
The TP53 gene, located on chromosome 17p codes for p53103. Described as the guardian of 
the genome104, mutations in TP53 are the commonest known in human cancer105 and are 
seen in 50-70% of pancreatic cancers106. The tumour suppressor p53 propagates several 
pathways involving cell cycle checkpoints and apoptosis in response to cellular insults, in 
addition to multiple other events107. The absence of this function leads to malfunctions in 
cellular processes such as cell division and death108. Mutations in TP53 are usually not seen 
until PanIN-3 lesions, suggesting that this is a late genetic event in the development of 
pancreatic cancer109. 
DPC4 (Also known as SMAD4)
The tumour-suppressor gene DPC4 is located on chromosome 18q and codes for the SMAD4 
protein110. As with p53, loss of SMAD4 function is a late event in pancreatic carcinogenesis 
as DPC4 mutations are absent in PanIN-1 and PanIN-2 lesions, but is seen in around a third 
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of PanIN-3 and 55% of pancreatic ductal adenocarcinoma specimens111. SMAD4 mediates 
transforming growth factor-β (TGF-β) signalling, which when activated, stimulates other 
SMAD proteins to form complexes with SMAD4 which translocate to the nucleus112. These 
complexes bind to specific areas of DNA to control the activity of particular genes113. This 
regulates cell proliferation, explaining why SMAD4 is recognised as a tumour suppressor, as 
loss of its function leads to uncontrolled cellular growth and division.
MUC1 and MUC5AC
Mammary-type mucin 1 (MUC1) is expressed in most human glandular epithelial tissue 
throughout the gastrointestinal tract114. In normal pancreatic tissue, it is expressed by 
pancreatic ducts and centroacinar cells and works as an anti-adhesive to maintain luminal 
patency115. For reasons currently unclear, MUC1 is almost absent in PanIN-1 and PanIN-2 
lesions. However, it is expressed in a large proportion of PanIN-3 lesions and it is almost 
universally present in invasive pancreatic carcinoma116 which suggests a significant role in 
the PanIN-adenocarcinoma sequence.
In contrast to MUC1, there is no expression of MUC5AC by normal pancreatic tissue. 
However, early-stage PanINs frequently express MUC5AC and is seen in up to 92% of 
pancreatic adenocarcinoma117. 
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Figure 2: The PanIN to adenocarcinoma pathway with its associated mutations
Early cellular changes in the PanIN to carcinoma sequence include telomere shortening 
with mutations commonly seen in KRAS2, CDKN2A and MUC5A. Late changes often not 
seen until PanIN-3 and adenocarcinoma include mutations in MUC1, TP53 and DPC4. 
Diagram taken without permission from Wilentz et al118.
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33 | P a g e
Apoptosis
Background
Apoptosis is a mode of programmed cell death characterised by morphological and 
biochemical changes including cell shrinkage, condensation of chromatin, nuclear DNA 
fragmentation and the disintegration of the cell into fragments, called ‘apoptotic bodies’ 
which can be eliminated by phagocytosis119 120. Classically, two major apoptotic signal 
transduction pathways exist – the extrinsic or ‘death receptor’ pathway and the intrinsic or 
‘mitochondrial’ pathway. However, in 2012 The Nomenclature Committee on Cell Death 
aimed to standardise definitions regarding the modes of cell death. In addition to the 
plethora of other cell death subroutines, they have further classified apoptosis into four 
subtypes: extrinsic apoptosis by death receptors, extrinsic apoptosis by dependence 
receptors, caspase-dependent intrinsic apoptosis and caspase-independent intrinsic 
apoptosis121.
Caspases are a family of cysteinyl aspartate–specific proteases, which are divided into two 
types. First are the initiator caspases (e.g. caspase-2, 8 and 9), which are the apical caspases 
in the apoptosis cascade. Secondly are the executioner caspases (e.g. caspase-3, 6 and 7), 
whose activation is usually dependent on the activity of initiator caspases122.
Extrinsic Apoptosis
Death Receptor Pathway
The death receptor pathway is activated at the plasma membrane when ligands from the 
tumour necrosis factor (TNF) family, such as CD95 or TNF-related apoptosis-inducing ligand 
(TRAIL) become bound to their respective death receptors – CD95-ligand (CD95L) and TRAIL 
receptor 1 and 2 (TRAIL-R1 and TRAIL-R2). This results in the recruitment of adaptor 
molecules, such as Fas-associated death domain 123 which forms death-inducing signaling 
complexes (DISC) with procaspase 8124. Upon the formation of this complex, caspase-8 
oligomerizes and is activated by autocatalysis. Caspase-8 is an initiator caspase, and in its 
activated form can stimulate apoptosis via two parallel cascades depending on the cell 
type125. In type I cells such as lymphocytes, it can directly cleave and activate caspase-3, an 
executioner caspase126 . Alternatively, in type II cells such as hepatocytes or pancreatic β-
cells, caspase-8 cleaves a pro-apoptotic Bcl-2 family protein called BH3-interacting domain 
death agonist (Bid)127. This results in a mitochondria-permeabilizing protein, known as 
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truncated Bid (tBid), which translocates to mitochondria128. This loss of membrane integrity 
of the mitochondria leads to the release of cytochrome c into the cytoplasm, which can be 
instigated by several factors including cytotoxicity, heat shock, oxidative stress, and DNA 
damage129. In the presence of ATP, cytochrome c forms the ‘apoptosome’ with APAF1 and 
caspase-9130 131. This functions to cleave and thereby activate effector caspases-3, -6, and -7
to execute apoptosis132. 
Dependence Pathway
The activation of the dependence pathway is reliant on the absence of ligands for 
dependence receptors such as Patched, DCC and UNC5B. These receptors interact with 
alternative adaptor proteins, forming complexes to both instigate mitochondrial outer 
membrane permeabilization and caspase-9 activation133 134, which in turn will activate 
caspase-3.
Intrinsic Apoptosis
Caspase-dependent
Intrinsic apoptosis is a mitochondria-centred process which, in addition to engaging pro-
apoptotic signalling, involves the anti-apoptotic cascade, enabling cells to tolerate and 
recover from certain degrees of stress. The pro-apoptotic BCL-2 associated x protein (BAX) 
and BCL-2 antagonist killer 1 (BAK1), which are members of the B-cell lymphoma 2 (BCL-2) 
family, causes the mitochondrial membrane to become porous135. As a result, DIABLO 
(direct inhibitor of apoptosis protein-binding protein with low pI/SMAC), cytochrome c and 
high temperature requirement protein A2 (HTRA2) are released into the cytosol. 
Cytochrome c again activates caspase-3 through forming the ‘apoptosome’ while DIABLO 
and HTRA2 promote caspase activation by inhibiting cellular inhibitor of apoptosis proteins 
(IAPs)136.
Caspase-independent 
Apart from DIABLO, cytochrome c and HTRA2, a further two proteins are released from the 
mitochondria after the transmembrane potential of mitochondria is overcome. Apoptosis-
inducing factor (AIF) and endonuclease G (ENDOG) can both induce caspase-independent 
apoptosis by their intranuclear translocation to cause DNA fragmentation. HTRA2 can be 
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both caspase-dependent and independent, and induces the latter by cleaving cytoskeletal 
proteins121.
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Adjuvant Therapy in Pancreatic Cancer
Major Chemotherapy Trials
In 1993, a Norwegian group137 was first to publish a randomised study assessing the role of 
adjuvant chemotherapy in resected pancreatic cancer. Median survival improved to 23 
months with adjuvant chemotherapy in comparison to 11 months in those undergoing 
observation alone (p = 0.04). 
The landmark ESPAC-1138 (European Study Group for Pancreatic Cancer) study was designed 
to determine whether adjuvant chemoradiotherapy or adjuvant chemotherapy (5-FU and 
Folinic Acid) alone had a role in improving survival following pancreatic cancer resection. 
This was the first adequately powered randomised trial to assess adjuvant therapy in 
pancreatic cancer, recruiting 541 patients over a six-year period in 61 centres 
internationally. 285 patients were randomised in a two-by-two factorial design to receive 
chemoradiotherapy alone, chemotherapy alone, both or observation; with a further 256 
patients also randomised to receive chemoradiotherapy, chemotherapy, or observation.
The final analysis of the 2X2 ESPAC-1 data139 was based on 237 deaths in 289 patients with a 
median follow up of 47 months (IQR 33-62 months). Median survival was 20.1 months 
(95%CI: 16.5-22.7) amongst patients who had undergone chemotherapy vs. 15.5 months 
(95%CI: 13-17.7) in those who had not (HR = 0.71, 95%CI: 0.55-0.92, p = 0.009). The 
estimated two and five year survival was 40% vs. 21% and 21% vs. 8% respectively in those 
who received chemotherapy against patients which had not. The cohort of 75 patients that 
received chemotherapy alone fared significantly better than those who underwent just 
observation (n = 69). 
Takada et al140 randomised patients to receive surgery alone or adjuvant chemotherapy 
with 5-FU and Mitomycin C and showed no significant improvement in 5-year survival or 5-
year disease free survival. Unusually, this study utilised oral 5-FU as opposed to the usual 
intravenous form which may offer a reason for its ineffectiveness. Kosuge and colleagues 
(JSAP)141 randomised patients having undergone an R0 resection to either adjuvant cisplatin 
or 5-FU and found no significant difference in median survival, 5-year survival and 5-year 
disease-free survival in comparison to patients undergoing surgery alone. As only 89 
patients were recruited over 8 years, this resulted in an underpowered study.
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In 1997, Burris et al142 published their randomised control trial comparing the nucleoside 
analogue gemcitabine with 5-FU in advanced pancreatic cancer. In addition to 
demonstrating a clinical benefit with regards to pain relief, weight and performance status, 
those receiving gemcitabine achieved a one-year survival rate of 18% as opposed to 2% with 
5-FU. These findings resulted in the recruitment of patients for CONKO-001143 between 
1998 and 2004. This study randomised 368 patients to receive either adjuvant gemcitabine 
or observation alone. Gemcitabine significantly improved disease-free survival following 
pancreatic cancer resection whether patients had undergone an R0 or R1 resection. With 
regards median overall survival, the gemcitabine benefit was only marginal in comparison to 
the observation group (22.8 months vs. 20.2 months, p = 0.005)144. This minimal difference 
is potentially explained by the authors by the fact that almost all patients that relapsed in 
the observation group received gemcitabine or a further line of chemotherapy. However, 
this study established gemcitabine as the favoured adjuvant chemotherapeutic agent 
particularly due to its excellent toxicity profile in comparison to 5-FU. 
Coincidentally, at the same time as CONKO-001143, a further study to compare adjuvant 
gemcitabine and observation was being undertaken. One hundred and nineteen patients 
were recruited between 2002 and 2005 for JSAP-2145. Gemcitabine resulted in a median 
disease-free survival of 11.4 months (95%CI: 8-14.5) against 5 months (95%CI: 3.7-8.9) in the 
observation group (HR = 0.60, 95%CI: 0.40-0.89, p = 0.01).  This however, did not convert to 
a significant benefit in overall survival as the study was underpowered. 
Following on from the ESPAC-1 study, the group undertook another randomised controlled 
trial, ESPAC-3 to compare 5-FU and folinic acid (as per the ESPAC-1 regime), gemcitabine (as 
per CONKO-001 regime) and surgery alone in resected pancreatic cancer. During 
recruitment however, the publication of ESPAC-1 proved the undoubted benefit of adjuvant 
chemotherapy. This resulted in the observation arm being forfeited and the study was 
renamed ESPAC-3(v2)146. 
ESPAC-3(v2) was the largest study of its kind, recruiting 1088 patients with pancreatic ductal 
adenocarcinoma in 159 centres worldwide over a seven year period. With a median follow-
up of 34.2 months (range 0.4-86.3, IQR 27.1-43.4), no significant difference was shown in 
overall survival or progression-free survival between the two treatment groups. However, 
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gemcitabine halved the number of serious treatment-related adverse events compared to 
its opposing arm (14% vs. 7.5% of patients, p < 0.001).  It was also noted a more favourable 
outcome was achieved in patients with node positive disease or an R1 resection when 
administered gemcitabine. This firmly established the drug as the current gold standard in 
the adjuvant treatment of pancreatic cancer.
A meta-analysis in 2009147 combined data from a subgroup of ESPAC-3(v1) with ESPAC-1 2X2 
and ESPAC-1 Plus (a subgroup of 192 patients in a randomised comparison between 5-FU 
and observation +/- chemoradiation). Chemotherapy improved overall survival at one, two 
and five years, providing robust evidence for the continued use of 5-FU and folinic acid in 
the adjuvant setting alongside gemcitabine. 
The JASPAC-01 trial148 enrolled 385 patients between 2007 and 2010 to compare adjuvant 
gemcitabine with S-1, a combination of the fluorinated pyrimidine Tegafur with 5-chloro-
2,4-dihydroxypyridine and oteracil potassium, in resected pancreatic cancer. Promising 
interim results were presented in 2012149 with an overall 2-year survival of 53% and 70% in 
the gemcitabine and S-1 groups respectively (HR = 0.56, 95%CI: 0.42-0.74, p < 0.0001). S-1 
also proved superior with regards to recurrence-free survival at 2-years with 49% of patients 
remaining disease-free compared with 29% in the gemcitabine cohort (HR = 0.56, 95%CI: 
0.43-0.71, log-rank p < 0.0001). S-1’s comparatively low toxicity in addition to the fact that 
S-1 is orally administered, would be partly responsible for the superior quality of life scores 
in this group (p < 0.0001).Though the authors conclude that S-1 should be considered the 
new standard treatment for resected pancreatic cancer, its efficacy is yet to be investigated 
in a randomised study in a Western population. It has been stated that due to the metabolic 
differences between Asian and Caucasian populations, gastrointestinal side effects are far 
greater in the latter leading to lower tolerated doses of S-1150.
In recent months, results from the international, multicentre, phase III trial, ESPAC-4 have 
been presented151. Between 2008 and 2014, 732 patients were recruited and randomised to 
receive either adjuvant gemcitabine or a combination of gemcitabine and capecitabine. This 
landmark study showed an improved median survival with combination therapy as opposed 
to gemcitabine alone (28 vs. 25.5 months, p = 0.032). This benefit was seen without a 
statistically significant increase in toxicity related events, suggesting that this drug regime 
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will soon become the standard of care against, against which all others are to be compared
(Table 5).
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Table 5: Major adjuvant chemotherapy trials in pancreatic cancer
Final analysis Survival (95%CI) Disease-free survival (DFS)(95%CI)
Year 
published Author/Group Treatment arms (n)
T3
(%)
N+ 
(%)
R0 
(%) Median survival (months)
1-year 
survival (%)
2-year survival
(%)
3-year 
survival (%)
5-year 
survival (%) Median DFS (months)
1-year DFS 
(%)
2-year DFS
(%)
3-year 
DFS (%)
5-year
DFS (%)
1993 Bakkevold137
5-FU/Doxorubicin/
MitomycinC (30) N/A
N/
A 100 23 N/A 70 27 4 N/A N/A N/A N/A N/A
Surgery alone (31) 11 (p=0.02) N/A 45 30 8 ( =0.1) N/A N/A N/A N/A N/A
2001 ESPAC-1138 (All patients)
5-FU/Folinic Acid +/-
CRT (238) N/A 53 82 19.7 (16.4-22.4) N/A N/A N/A N/A N/A N/A N/A N/A N/A
No chemotherapy +/-
CRT (235)
14 (11.9-16.5) (HR = 0.66,
0.52-0.83, p=0.0005) N/A N/A N/A N/A N/A N/A N/A N/A N/A
2002 Takada140 5-FU/MitomycinC (89) N/A 85 58 n/a N/A N/A N/A 11.5 N/A N/A N/A N/A 8.6
Surgery alone (84) N/A N/A N/A
18 (log rank 
NS) N/A N/A N/A N/A
7.8 (log rank 
p=0.84)
2004 ESPAC-1139 (2x2 final analysis)
5-FU/Folinic Acid 
(147) N/A 54 82 20.1 (16.5-22.7) N/A 40 N/A 21 N/A N/A N/A N/A N/A
No chemotherapy +/-
CRT (142)
15.5 (13-17.7) (HR = 0.71,
0.55-0.92, p=0.009) N/A 30 N/A 8 N/A N/A N/A N/A N/A
2006 JSAP141 (Kosuge) Cisplatin/5-FU (45) N/A 27 100 12.50 N/A N/A N/A 26.40 N/A N/A N/A N/A N/A
Surgery alone (44) 15.8 N/A N/A N/A
14.9 
(p=0.94) N/A N/A N/A N/A N/A
2007 CONKO-001143 (Oettle) Gemcitabine (179) 22.1 (18.4-25.8) 72.5 47.5 34 22.5 13.4 (11.4-15.3) 58 30.5 23.5 16.5
Surgery alone (175) 86 72 83 20.2 (17-23.4) (p=0.06) 72.5 42 20.5 20.5 6.9 (6.1-7.8) (p<0.001) 31 14.5 7.5 5.5
2008 CONKO-001 Final144 (Neuhaus) Gemcitabine (179) 22.8 N/A N/A 36.5 21 13.4 N/A N/A 23.5 16
Surgery alone (175) 20.2 (p=0.005) N/A N/A 19.5 9 6.9 (p<0.001) N/A N/A 8.5 6.5
2009 JSAP-2145 (Ueno)
Gemcitabine +/- RT 
(58) 86 69 84 22.3 (16.1-30.7) 77.6 48.3 N/A 23.9 11.4 (8-14.5) 49 27.2 N/A N/A
Surgery alone +/- RT 
(60)
18.4 (15.1-25.3) (HR = 0.77,
0.51-1.14, p=0.19) 75 40 N/A 10.6
5 (3.7-8.9) (HR = 0.6,
0.4-0.89, p=0.01) 26.7 16.7 N/A N/A
2009
Collated data ESPAC-1, ESPAC-1 
Plus, ESPAC-3(v1)147
5-FU/Folinic Acid 
(233) N/A 55 75 23.2 (20.1-26.5) 77 49 N/A 24 N/A N/A N/A N/A N/A
Surgery alone (225)
16.8 (14.3-19.2) (HR = 0.7,
0.55-0.88, p=0.003) 63 37 N/A 14 N/A N/A N/A N/A N/A
2010 ESPAC-3(v2)146
5-FU/Folinic Acid 
(551) N/A 72 65 23 (21.1-25) 78.5 (75-82) 48.1 (43.8-52.4) N/A N/A 14.1 (12.5-15.3)
56.1 (51.8-
60.3) 30.7 (26.7-34.6) N/A N/A
Gemcitabine (537)
23.6 (21.4-26.4) (HR = 0.94,
0.81-1.08, p=0.39)
80.1 (76.7-
83.6) 49.1 (44.8-53.4) N/A N/A 14.3 (13.5-15.6)
61.3 (57.1-
65.5) 29.6 (25.6-33.5) N/A N/A
2013 JASPAC-01148 S-1 (187) 87 63 87 46.3 N/A 70 N/A N/A 23.2 N/A 49 N/A N/A
Gemcitabine (191) 25.5  (p<0.0001) N/A
53 (HR = 0.56, 0.42-
0.74, p<0.0001) N/A N/A 11.2 (log rank p<0.0001) N/A
29 (HR = 0.56, 0.43-0.71, 
log rank p<0.0001) N/A N/A
2017 ESPAC-4151 Gemcitabine N/A 80 40 25.5 (22.7-27.9)
80.5 (76-
84.3) 52.1 (46.7-57.2) 13.1 (11.6-15.3)
20.9 
(16.5-
25.7)
11.9 (7.8-
16.9)
Gemcitabine/
Capecitabine
28 (23.5-31.5) (HR 0.82, 0.68-
0.98, p=0.032)
84.1 (79.9-
87.5) 53.8 (48.4-58.8)
13.9 (12.1-16.1) (HR 
0.86, 0.73-1.02, 
p=0.082)
23.8(19.2-
28.6)
18.6 (13.8-
24)
Several major studies have investigated the role of adjuvant chemotherapy in resected pancreatic cancer over the past three decades. Table modified from Jones et al152
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Meta-analysis of Adjuvant Chemotherapy Trials
A meta-analysis assessing adjuvant therapy in pancreatic cancer was published in 2005. 
Stocken et al153 included five randomised trials (Bakkevold et al137, ESPAC-1138, Takada et 
al140, EORTC154 and GITSG155 156) to evaluate the effects of both chemotherapy and 
chemoradiotherapy in the adjuvant setting (n = 939)(Table 6). With the exception of GISTG, 
the authors collected individual patient data from each of these studies (n = 875) to produce 
as accurate a results as possible. When collating results from the three chemotherapy trials, 
heterogeneity was affected with the inclusion of the Japanese results, which the authors 
suggest was due to the large number of R1 resections included in that particular study. 
Nevertheless, analysis of the dataset both including and excluding this study resulted in 
reductions of 25% (HR = 0.75, 95%CI: 0.64-0.9, p = 0.001) and 35% (HR = 0.65, 95%CI: 0.54-
0.8, p < 0.001) respectively in the risk of death with adjuvant chemotherapy. Median 
survival was estimated to be 19 months (95%CI: 16.4-21.1) with chemotherapy and 13.5 
months (95%CI: 12.2-15.8) without. 
A later meta-analysis157 included the five randomised trials comparing adjuvant 
chemotherapy to observation (Bakkevold et al137, ESPAC-1138, Takada et al140140, JSAP141 and 
CONKO-001143). Median survival data was available from all studies with the exception of 
Takada et al, with no significant heterogeneity between the remaining four conflicting 
studies (p = 0.07). Meta-analysis indicated a significant survival benefit of 3 months (95%CI: 
0.3-5.7, p = 0.03) in patients receiving adjuvant chemotherapy as opposed to observation. 
However, adjuvant treatment translated into only a 3.1% benefit in 5-year survival which 
proved insignificant.
A third meta-analysis looked specifically at adjuvant therapy in relation to resection 
margins158. This meta-analysis was supportive of adjuvant chemotherapy, indicating a 25% 
reduction in the risk of death with treatment as opposed to observation (HR = 0.75, 95%CI: 
0.64-0.9, p = 0.001). Patients undergoing a clear-margin resection benefited from a 7-month 
survival increase with chemotherapy (median survival of 20.8 months vs. 13.8 months), but 
the effect was less pronounced in R1 resections (median survival of 15 months vs. 13.2 
months). This finding was in agreement with Stocken who noted that chemotherapy was 
less effective in patients with a positive resection margin.
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A published network meta-analysis159 examined overall survival in patients receiving 
adjuvant gemcitabine or 5-FU in comparison to observation. Results suggested that adjuvant 
therapy with either gemcitabine (n = 774) or 5-FU (n = 876) showed a survival benefit in 
comparison with observation alone (n = 670) with hazard ratios of 0.68 (95%CI: 0.44-1.07) 
and 0.62 (95%CI: 0.42-0.88) respectively. No significant survival difference was noted in 
comparing adjuvant gemcitabine and 5-FU, though grades 3-4 non-haematological toxicity 
was almost four-times as common in patients receiving the latter drug.
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Table 6: Meta-analyses of adjuvant chemotherapy trials in pancreatic cancer
Survival (95%CI)
Year 
published Author Arm (n) Median survival (months)
2-year survival 
(%) 5-year survival (%)
2005 Stocken153 CT (348) 19 (16.4-21.1) 38 19
No CT (338) 13.5 (12.2-15.8) 28 12
2007 Boeck157 CT (482) 3 month (0.3-5.7) survival benefit _______ 3.1% (-4.6-10.8) survival benefit
No CT (469) with CT vs no CT (p = 0.03) with CT vs no CT (p > 0.05)
2008 Butturini158 R0 Resections
CT (236) 20.8 (17.7-23.2) 42 (35-48) 22 (17-28)
No CT (222) 13.8 (12.2-16.4) 27 (21-33) 10 (5-14)
R1 Resections
CT (109) 15 (11.7-18.1) 29 (20-38) 14 (7-21)
No CT (114) 13.2 (10.5-17.6) 31 (22-40) 17 (10-24)
2013 Liao159 Hazard ratio for death (95%CI)
Fluorouracil (876) 0.62 (0.42-0.88)
Observation (670)
Gemcitabine 
(774) 0.68 (0.44-1.07)
Observation (670)
Gemcitabine 
(774) 1.1 (0.70-1.86)
Fluorouracil (876)
CT: Chemotherapy. 
A handful of meta-analyses have examined the benefit of adjuvant chemotherapy following a pancreatic cancer resection. Table modified 
from Jones et al.152
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Major Chemoradiotherapy Trials in Pancreatic Cancer
The Gastrointestinal Study Group (GITSG) was the first randomised trial evaluating the role 
of adjuvant therapy in pancreatic cancer155 156. In non-resectable patients, previous studies 
had shown the benefit of both radiotherapy160 and 5-FU combined with radiotherapy161 and 
on this basis GITSG compared adjuvant 5-FU chemoradiation versus no adjuvant therapy. 
Though the study population was small, final analysis of the data revealed a substantial 
median survival benefit with treatment and following this evidence, chemoradiotherapy 
became a standard adjuvant treatment option for pancreatic cancer patients in the United 
States162. A decade later, the findings from GITSG were supported by a prospective, non-
randomised study in which Yeo et al163 demonstrated an improved median and one-year 
benefit with adjuvant chemoradiotherapy in comparison to observation with a median and 
one-year survival of 19.5 months and 80%, in comparison to 13.5 months and 54% in those 
undergoing observation alone (p = 0.003). 
The EORTC study154 was undertaken across twenty-nine European centres and included 218 
patients who had undergone resection for pancreatic or ampullary lesions. One hundred 
and fourteen of these were for pancreatic head cancers and those tumours graded as ≥T3 or 
N1b nodal disease were excluded. Patients were assigned surgery alone or to additionally 
receive two four-week cycles of adjuvant 5-FU and concurrent radiotherapy.  When 
considering the pancreatic group alone, median two and five-year survival was improved in 
the treatment group. The pattern of recurrent locoregional and distant metastases was 
similar in both groups, suggesting that adjuvant radiotherapy is ineffective against 
pancreatic/ampullary cancer. 
ESPAC-1 showed no survival benefit in those receiving chemoradiotherapy. These findings 
were echoed when evaluating patients in the 2X2 study design alone, comparing those 
patients receiving chemoradiotherapy alone (median survival of 15.8 months (95%CI: 13.5-
19.4) with all others (median survival 17.8 months (95%CI: 14-23.6): this did not reach 
statistical significance.
Final analysis of the 2X2 data showed that chemoradiotherapy had a negative effect on 
patient survival with a median survival of 15.9 months (95%CI: 13.7-19.9) in those that 
received chemoradiotherapy and 17.9 months (95%CI: 14.8-23.6), p = 0.05 in patients that 
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did not. Estimated 5-year survival was 10% in the chemoradiotherapy cohort in comparison 
to 20% in those patients who received none.  In those patients randomised outside the 2X2 
study design, median survival was only 13.9 months (95%CI: 12.2-17.3) amongst the 73 
patients who had received chemoradiotherapy. This was in comparison to a median survival 
of 16.9 months (95%CI: 12.3-24.8) in those who underwent surgery alone and 21.6 months
(95%CI: 13.5-27.3) in those who underwent adjuvant chemotherapy without any 
chemoradiation. Estimated 5-year survival in these individual treatment groups was 7%, 
11% and 29% respectively. Though this is strongly suggestive that adjuvant chemoradiation 
has a negative impact on survival, ESPAC-1 was underpowered to directly assess these 
smaller cohorts outside the 2X2 design. The authors suggest that the lack of survival benefit 
with chemoradiation may be due to a delay in administering the treatment to patients who 
were also receiving chemotherapy. Some have argued that the radiotherapy given during 
ESPAC-1 was substandard and not subject to rigorous quality control, though the survival 
rates achieved in the individual groups were similar to those achieved in other major 
studies164.
Following the publication of their interim findings in 2008165, the final 5-year analysis of the 
RTOG 97-04 study was published in 2011166. Patients were stratified to receive either 
gemcitabine or 5-FU both prior to, and after 5-FU based chemoradiation. No significant 
difference was identified in overall or disease-free survival in the final analysis. Worth 
noting, is though completion rates for designated treatments were equally high (87% in the 
5-FU group and 90% in the gemcitabine group), those in the latter group experienced 
greater numbers of haematological (p < 0.001) and Grade 4 events (p < 0.001) secondary to 
acute toxicity. A subgroup analysis from RTOG was undertaken observing those with 
pancreatic head tumours. The difference in median survival between both groups was not 
statistically significant, being 17.1 months in the 5-FU group and 20.5 months in the 
gemcitabine group (HR = 0.933, 95%CI: 0.76-1.15, log rank p = 0.51). However, following 
adjustment for stratification variables including nodal status, tumour size and surgical 
margins, multivariate analysis suggested a benefit with gemcitabine over 5-FU (HR = 0.80, 
95%CI: 0.63-1.00, p = 0.05). 
A Phase III randomised trial published in 2012 compared adjuvant chemoradiation, including 
5-FU, cisplatin and interferon α-2b (Group 1) with adjuvant 5-FU and folinic acid without 
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chemoradiation (Group 2). CapRI167 followed a similar Phase II trial which reported a 
promising 5-year survival rate of 55%168. Overall survival and disease free survival was not 
significantly different between the two groups. However, the median survival data from the 
per-protocol population are amongst the best published, being 32.1 months (95%CI: 22.8-
42.2) in group 1, and 28.5 months (95%CI: 19.5-38.6) in group 2 (HR = 1.2, 95%CI: 0.49-2.95, 
p = 0.49). Selection bias was unlikely, given that 97% of tumours were T3 and above, 79% of 
patients had nodal disease and only 61% of patients underwent an R0 resection. The 
authors conceded that these impressive survival figures are unlikely to be due to adjuvant 
therapy alone, and acknowledge that the vast majority of patients underwent an aggressive 
soft tissue clearance during their resection in Heidelberg. Nevertheless, these results seem 
to have been achieved at the expense of very high levels of toxicity, with 85% of patients 
receiving chemoradioimmunotherapy experiencing grades 3 or 4 toxicity which were mainly 
haematological in origin. In a separate study169 this controversial regime led to a 93% grade 
3 and 4 gastrointestinal toxicity rate, leading to its abandonment (Table 7).
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Table 7: Major adjuvant chemoradiotherapy trials in pancreatic cancer
Final analysis Survival (95%CI) Disease-free survival (95%CI)
Year published Author/Group Treatment arms (n) T3 N+ R0 Median survival (months) 2-year survival (%) 3-year survival (%) 5-year survival (%) Median DFS (months) 2-year DFS (%)
1985 GITSG156 156 CRT (21) 37 28 100 21 43 (0.25-0.63) N/A N/A N/A N/A
Surgery alone (22) 10.9 18 (0.08-0.36)
1999 EORTC154 5-FU/RT (104) 21 46 77 24.5 51 (41-61) N/A 28 (17-39) 17.4 38 (28-48)
Surgery alone (103) 19 (log rank p = 0.208) 41 (31-51) 22 (12-32) 16 (p = 0.643) 37 (27-47) (p = 0.643)
5-FU/RT (60) 0 51 N/A 17.1 37 (24-50) N/A 20 (5-35) N/A N/A
Surgery alone (54) 12.6 (log rank p = 0.099) 23 (11-35) 10 (0-20)
2001 ESPAC-1 (All patients)138 CRT +/- 5-FU/Folinic Acid (175) N/A 56 82 15.5 (13.5-17.4) N/A N/A N/A N/A N/A
No CRT +/- 5-FU/Folinic acid (178) 16.1 (13.1-20.1) (HR = 1.18, 0.9-1.55, p = 0.24)
ESPAC-1 (2x2 design only) CRT +/- 5-FU/Folinic Acid (142) N/A N/A N/A 15.8 (13.5-19.4) N/A N/A N/A N/A N/A
No CRT +/- 5-FU/Folinic acid (143) 17.8 (14-23.6) (HR = 1.3, 0.96-1.77, p = 0.09)
2004 ESPAC-1 (2x2 final analysis)139 CRT +/- 5-FU/Folinic Acid (145) N/A 53 82 15.9 (13.7-19.9) 29 N/A 10 N/A N/A
No CRT +/- 5-FU/Folinic acid (144) 17.9 (14.8-23.6) (HR = 1.28, 0.99-1.66, p = 0.05) 41 20
ESPAC-1 (Individual Treatment Groups) 5-FU/Folinic Acid (75) 21.6 (13.5-27.3) 29
CRT + 5-FU/Folinic Acid (72) N/A N/A N/A 19.9 (14.2-22.5) N/A N/A 13 N/A N/A
Observation (69) 16.9 (12.3-24.8) 11
CRT (73) 13.9 (12.2-17.3) 7
2006 RTOG 97-04165 CRT + 5-FU (230) 75 66 66 No significant difference N/A N/A N/A N/A N/A
CRT + Gemcitabine (221)
CRT + 5-FU (201) N/A N/A N/A 16.9 N/A 22 N/A N/A N/A
CRT + Gemcitabine (187) 20.5 (HR = 0.82, 0.65-1.03, p = 0.09) 31
2011 RTOG 97-04 (5-year analysis)166 CRT + 5-FU (230) 75 66 66 No significant difference 35 23 19 No significant difference N/A
CRT + Gemcitabine (221) HR = 0.933, 0.76-1.145, p = 0.51 40 27 19
CRT + 5-FU (201) N/A N/A N/A 17.1 34 21 18 (13-24) N/A N/A
CRT + Gemcitabine (187) 20.5 42 28 22
2012 CapRI (Schmidt)
167
167
5-FU/Cisplatin/Interferon α-2b → RT → 5-FU (53) 97 79 61 32.1 (22.8-42.2) N/A N/A N/A 15.2 (10.3-24.8) N/A
5-FU/Folinic acid (57) 28.5 (19.5-38.6) (HR = 1.2, 0.49-2.95, p = 0.49) 11.5 (9.8-17.6) (p = 0.61)
The role of adjuvant chemoradiotherapy in pancreatic cancer is a controversial topic with many conflicting studies. Table modified from Jones et al.152
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Meta-analysis of Adjuvant Chemoradiotherapy Trials
In addition to the analysis of adjuvant chemotherapy data, Stocken et al153 also pooled 
individual patient data from ESPAC-1 2X2138, ESPAC-1 Plus139 and EORTC154 to assess the 
benefit of adjuvant chemoradiotherapy. Despite borderline heterogeneity, no significant 
difference in the risk of death was observed with chemoradiotherapy. The GISTG trial155 156
was unfortunately unable to provide individual patient data and therefore summary data
was utilised. Though heterogeneity was increased by the addition of the GISTG summary 
data to the individual data from other studies, the pooled HR again showed no difference in 
the risk of death between those receiving chemoradiotherapy and those not.
Butturini’s meta-analysis158 on adjuvant therapy and resection margins noted no significant 
survival advantage with chemoradiation in patients with clear resection margins (HR = 1.19, 
95%CI: 0.95-1.49). Though remaining statistically insignificant, there was evidence of a small 
survival benefit with adjuvant chemoradiation in patients receiving an R1 resection (HR = 
0.72, 95%CI: 0.47-1.10).
Liao et al’s meta-analysis159 was the first to directly compare chemoradiation combined with 
either 5-FU or gemcitabine with each treatment in isolation. No survival advantage was 
demonstrated by adding chemoradiation to either adjuvant 5-FU or gemcitabine with all 
hazard ratios approaching 1. However, the addition of chemoradiation to 5-FU (HR = 2.85, 
95%CI: 0.15-61.44) or gemcitabine (HR = 36.49, 95% CI: 0.34-3235.7) dramatically increased
toxic events in comparison to the use of the chemotherapeutic agent alone. The authors 
conclude that on the basis of their results, future trials with chemoradiation are not 
required citing toxicity, resistance and early tumour dissemination as possible reasons why 
chemoradiotherapy to the tumour bed may be ineffective in pancreatic cancer (Table 8).
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Table 8: Meta-analyses of adjuvant chemoradiotherapy trials in pancreatic cancer
Survival (95%CI)
Year 
published Author Arm (n) Median survival (months) 2-year survival (%) 5-year survival (%)
2005 Stocken153 CRT 15.8 (13.9-18.1) 30 12
No CRT 15.2 (13.1-18.2) 34 17
2008 Butturini158 R0 Resections
CRT (188) 15.9 (14-18.5) 30 (23-36) 10 (5-15)
No CRT (183) 15.8 (13.4-20.1) 38 (31-45) 20 (13-26)
R1 Resections
CRT (53) 14.7 (11.5-20.5) 30 (17-42) 18 (7-29)
No CRT (53) 11.2 (9.4-16.7) 19 (8-31) 8 (0-16)
2013 Liao159 Hazard ratio for death (95%CI)
_______________________________
Chemoradiation (169) 0.91 (0.55-1.46)
Observation (670)
Chemoradiation + 5-FU (323) 0.87 (0.27-2.69)
5-FU (876)
Chemoradiation + 5-FU (323) 0.59 (0.19-1.74)
Chemoradiation (169)
Chemoradiation + Gemcitabine 
(221) 0.82 (0.4-1.71)
Chemoradiation + 5-FU (323)
Meta-analyses show no benefit to adjuvant chemoradiotherapy in pancreatic cancer. Table modified from Jones et al.152
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Treatment of Advanced Disease
Background
For the majority of patients, curative treatment by tumour resection is not an option due to 
locally advanced or metastatic disease. In such patients, systemic chemotherapy has been 
shown to prolong survival in comparison to supportive management170. Other palliative 
management options include analgesia, nerve blocks, radiotherapy, surgical bypass and 
endoscopic stenting to avert biliary and gastrointestinal obstruction.
Gemcitabine
In 1997, the nucleoside analogue, gemcitabine was established as the palliative agent of 
choice in pancreatic cancer by Burris et al142 who demonstrated a survival benefit in 
comparison with 5-FU (median survival of 5.6 months vs. 4.4 months). The treatment was 
generally well tolerated, and though gemcitabine led to an increased risk of toxicity, this 
was statistically insignificant. Recent chemotherapy trials in pancreatic cancer have been 
required to demonstrate the superiority of any novel treatment to gemcitabine 
monotherapy. This could be achieved by either one of two strategies: by combining 
gemcitabine with a new drug, or by directly comparing a novel monotherapy against 
gemcitabine.
Erlotinib
The eGFR inhibitor Erlotinib was the first drug to be shown to be of benefit in combination 
with gemcitabine in patients with advanced pancreatic cancer. In this study (the PA.3 trial), 
a Canadian group randomised 569 patients with both locally advanced and metastatic 
disease to receive gemcitabine, or gemcitabine plus erlotinib171. Though overall survival was 
significantly improved with combination therapy (median survival of 6.2 vs. 5.9 months), in 
real-terms this is only a fortnight’s benefit. This marginal benefit also came at the expense 
of toxicity, with six treatment-related deaths reported during the study – all within the 
combination therapy group. Eight patients from the study (7 from the erlotinib cohort) also 
developed interstitial lung disease and the risk-benefit of this drug combination remains a 
controversial topic172.
Interestingly, a small subset of patients responded unusually favourably to a combination of 
erlotinib and gemcitabine. It was noted that some patients developed a rash, with those 
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individuals with a rash of Grade ≥2 in severity recording s median survival of 10.5 months 
and 1-year survival of 43% in comparison with 5.3 months and 16% respectively in patients 
with no rash. This finding was replicated in a further study173, which led to a dose-escalation 
study174 which unfortunately showed no further benefit.
FOLFIRINOX
FOLFIRINOX is a chemotherapy regime consisting of four drugs – Folinic acid, 5-FU, 
irinotecan and oxaliplatin. This combination of drugs could be justified by preclinical studies,
which demonstrated either single agent efficacy against pancreatic cancer, or synergistic 
activity in combination with a fellow agent. Following promising results from phase I and II 
trials175 176, a large randomised trial was undertaken to compare FOLFIRINOX with 
gemcitabine monotherapy as the first-line treatment of patients with metastatic pancreatic 
cancer, with the results published in 2011. This French study (ACCORD-4 Trial) enrolled 342 
patients aged between 18 and 75 with a performance status of either 0 (fully active) or 1 
(restricted only by physically strenuous activity) with histologically proven metastatic 
pancreatic adenocarcinoma. Compared with gemcitabine, treatment with FOLFIRINOX 
resulted in a superior tumour response rate (9.4% vs. 31.6%), median overall survival (6.8 vs. 
11.1 months) and one-year survival (20% vs. 48%)177. The production of these results during 
the interim analysis led to the premature termination of the study.
Despite this study’s encouraging results, criticisms have been made. The first is its highly 
exclusive inclusion criteria, selecting only the fittest patients under the age of 76. A 
Canadian group undertook a retrospective analysis of 100 consecutive patients of theirs 
with metastatic pancreatic cancer and demonstrated that only 26 of these would have been 
eligible with nearly two-thirds of patients excluded on the basis of inadequate performance 
status and over one-fifth excluded due to advanced age178. Secondly is the issue of toxicity, 
with one study reporting that one-third of patients receiving FOLFIRINOX were hospitalised 
as a direct result179, with a further paper reporting the discontinuation of treatment in a 
similar proportion of patients180. In contrast to these findings, further data published from 
the index study181 disclosed that quality of life impairment was significantly reduced in the 
FOLFIRINOX group compared to gemcitabine indicating its acceptability to patients. 
However, it is widely acknowledged that though FOLFIRINOX is viewed amongst the most 
effective palliative treatments, it is a viable option for only a minority of patients182. Its 
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survival benefit must be balanced against its associated toxicities which is a decision that 
must be made on a patient by patient basis. 
In locally advanced disease, the outcomes of FOLFIRINOX treatment have only been 
reported in small retrospective series179 183 184 185. These studies show that in certain 
patients, FOLFIRINOX can induce adequate tumour shrinkage to enable an R0 resection, 
with some studies also administering chemoradiation. However, no long term survival is 
reported and one study stated that 3 out of 5 patients developed metastatic disease within 
5 months of an R0 resection following neoadjuvant FOLFIRINOX185.
Nab-Paclitaxel (Abraxane®)
In a murine model, albumin-bound paclitaxel demonstrated synergistic anti-tumour activity 
in combination with gemcitabine186. On this basis, the combination was introduced in a 
phase I-II clinical trial as a first line treatment in patients with metastatic pancreatic cancer. 
Results showed an acceptable safety profile and an impressive median survival of 12.2 
months187.
In 2013, the results of an international, phase III randomised trial (MPACT) was published, 
based on 692 deaths in 861 patients188 with metastatic pancreatic cancer with more mature 
data published in 2015189. In the original paper, median survival for patients receiving 
gemcitabine alone was 6.7 months, in comparison to 8.5 months in patients receiving a 
combination of gemcitabine and nab-paclitaxel. One-year survival was also significantly 
improved with combination therapy (35% vs. 22%), in addition to the drug-response rate 
(23% vs. 7%), the median time to treatment failure (5.1 vs. 3.6 months) and progression-free 
survival (5.5 months vs. 3.7 months). Toxicity was generally comparable in both treatment 
groups and though combination therapy led to an increased risk of myelosuppression and 
peripheral neuropathy, these were reversible190. 
In contrast to the FOLFIRINOX vs. gemcitabine study, 10% of this study’s patients were aged 
>75 with 8% of its cohort possessing a performance status of >1. On this basis, nab-
paclitaxel has been approved in combination with gemcitabine for the treatment of 
metastatic pancreatic cancer and can be a valuable option in patients deemed unsuitable 
for FOLFIRINOX. 
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As with FOLFIRINOX, studies are ongoing in patients with borderline resectable 
(NCT01470417191) and locally advanced disease (NCT02301143192) to determine the efficacy 
of nab-paclitaxel combined with gemcitabine, with some positive anti-tumour findings 
already reported in patients with resectable disease193. 
Gemcitabine and Capecitabine
Capecitabine is a fluoropyrimidine which has been shown to exert synergistic antitumour 
activity when combined with gemcitabine194. A meta-analysis of three randomised 
controlled trials (n = 935) compared gemcitabine with gemcitabine plus capecitabine 
(Gemcap) in advanced pancreatic cancer195. This showed an overall survival benefit with the 
latter treatment (HR = 0.86, 95%CI: 0.75-0.98, p = 0.02) with no intertrial heterogeneity. 
Selected Negative Clinical Studies Utilising Gemcitabine Combination Therapy 
Despite promising preclinical early clinical results, a handful of novel agents have been 
trialled in large randomised phase II and III trials in combination with gemcitabine in 
metastatic pancreatic cancer. The anti-VEGF agent Bevacizumab196, the EGFR receptor 
inhibitor Cetuximab197, the anti-IGFTR antibody ganitumab, the TRAIL-R2 targeting 
conatumumab198 and lastly the tyrosine-kinase inhibitor axitinib199 have all failed to show 
any significant survival benefit in this setting.
Selected Ongoing Phase III Trials in Pancreatic Cancer
It is extremely encouraging to see several Phase III trials that, at the time of writing, are
recruiting patients to further investigate the role of novel therapies in the various stages of 
pancreatic cancer.
Adjuvant Therapy for Resected Pancreatic Cancer
Given its promising results in the advanced setting, FOLFIRINOX is currently subjected to a 
two armed Phase III trial in opposition to gemcitabine in resected pancreatic cancer with the 
aim of recruiting 490 patients with a primary outcome of disease-free survival at three years 
(NCT01526135200).
One of the more recent Phase III studies to commence recruiting is the ‘Apact’ study to trial 
adjuvant gemcitabine vs. gemcitabine plus nabpaclitaxel (NCT01964430201). Based on such 
positive results in the advanced cancer setting, this international trial aims to recruit 800 
patients with an estimated completion date in 2020.
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After displaying a borderline benefit in overall survival and progression-free survival 
compared to gemcitabine in advanced pancreatic cancer, the tyrosine-kinase inhibitor 
erlotinib is being investigated in the adjuvant setting. A Phase II trial202 combined these two 
compounds in the adjuvant setting achieving a respectable median disease-free survival of 
14 months. Furthermore, a single-institution Phase II trial203 (n = 48) has also shown that 
erlotinib can be safely utilised alongside capecitabine and chemoradiotherapy. Currently, 
erlotinib is being trialled both in combination with gemcitabine vs. gemcitabine alone 
(DRKS00000247204) and in a separate trial, this will be followed by a course of either 
capecitabine or 5FU-based chemoradiotherapy (NCT0103649205). 
Platinum compounds have previously been safely utilised in various pancreatic cancer trials 
and particularly encouraging results have been achieved in the neoadjuvant setting206 207. 
On this basis, phase III trials are now incorporating platinum agents into their chemotherapy 
regimens. The Hyperthermia European Adjuvant Trial (HEAT) study (NCT01077427208) will 
compare adjuvant gemcitabine to adjuvant gemcitabine plus capecitabine plus regional 
hyperthermia treatment – a regime that has previously been utilised with low reported 
toxicity. It has been shown that heat can increase the cytotoxicity of certain 
chemotherapeutic agents209 including gemcitabine210 in in vitro experiments with pancreatic 
cancer cell lines. One phase II study211 combined gemcitabine with regional heat treatment 
in the treatment of both metastatic and locally advanced disease. Median survival was 8 
months in the entire study population, but extended to 17.7 months in those with localised 
disease. More recently, a retrospective analysis of 23 patients with gemcitabine refractory 
inoperable disease was published212 whereby patients received gemcitabine plus cisplatin 
alongside regional hyperthermia biweekly for four months. Though 21/23 patients suffered 
from metastatic disease at recruitment, a median overall survival of 12.9 months was 
achieved.
Lastly, a trial utilising the immunotherapeutic agent algenpantucel-L in the adjuvant setting 
has recently completed recruitment and is comparing gemcitabine +/- 5FU chemoradiation 
both with, and without this novel agent (NCT01072981213). A phase II trial214 combining 
algenpantucel-L with gemcitabine and 5FU-based chemoradiotherapy yielded a 1-year 
disease-free survival of 62% and a one-year survival of 86%.  
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Neoadjuvant Therapy for Resectable, Borderline Resectable and Locally Advanced 
Pancreatic Cancer
The majority of patients with resectable pancreatic cancer will progress immediately to 
resection followed by adjuvant chemotherapy - commonly gemcitabine. An ongoing study 
led by the University of Zurich (NCT01314027215) is using this as their control arm, with a 
second cohort of patients receiving neoadjuvant gemcitabine and oxaliplatin prior to 
resection. 
Two phase III trials are currently recruiting to further delineate the role of FOLFIRINOX in the 
management of locally advanced, unresectable pancreatic cancer. An American study 
(NCT01926197216) will investigate the progression-free survival benefit of combining 5-FU 
chemoradiation with FOLFIRINOX vs. FOLFIRINOX alone. A German group (NCT01827553217)
will administer neoadjuvant FOLFIRINOX to all recruited patients. This will be followed by a 
randomisation to receive either further FOLFIRINOX or gemcitabine-based 
chemoradiotherapy, with a primary outcome of overall survival. 
A further phase III trial (NCT01836432218) is inclusive of patients with borderline resectable 
and unresectable disease. Individuals in the control arm will receive FOLFIRINOX followed by 
5-FU chemoradation, with the second arm receiving the immunotherapy algenpantucel-L in 
combination with FOLFIRINOX prior to the chemoradiation.
Future Directions and Biomarkers in Pancreatic Cancer
Genetic analysis has revealed that, on average, pancreatic cancers possess 63 exomic 
alterations across a dozen cellular signalling pathways219. This vast heterogeneity between 
tumours goes some way in explaining globally poor responses to current neoadjuvant and 
adjuvant therapies. There is an urgent need to identify biomarkers to predict patient 
response to both current and novel treatments in order to personalise therapy to each 
patient and tumour. The identification of such a biomarker in breast cancer (HER2220) has 
dramatically improved survival with the development of specifically targeted therapies. For 
this reason, current and future studies in pancreatic cancer are strongly advised to include 
biomarkers as an element of their trials221.
Some progress has already been made in this regard with the secreted protein acidic and 
rich in cysteine (SPARC). Tumour SPARC expression has been shown to have no correlation 
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with the efficacy of nab-Paclitaxel plus gemcitabine or gemcitabine monotherapy in 
metastatic cancer222. On the other hand, elevated tumour levels of the gemcitabine-
transporter, human nucleoside transporter equilibrative type 1(hENT1) has been associated 
with improved survival in ESPAC-3 patients administered adjuvant gemcitabine223. This was 
not supported by data from a cohort of patients with metastatic disease224, though a later 
publication raised concerns regarding the antibody used (SP120 rabbit monoclonal 
antibody)225.
Immunotherapy
Checkpoint inhibitors and other form of immunotherapy promise much for the future 
treatment of pancreatic cancer, but as yet there have been no successful trials. In mouse 
models, depletion of macrophages or fibroblasts expressing Fibroblast Activation Protein 
(FAP) restores immune control226. FAP positive fibroblasts express CXCL12 which can form a 
dimer with HMGB1 (expressed by pancreatic cancer cells) to activate the suppressor CXCR4 
on T-Effs (T-effector cells). In mouse models, inhibition of CXCR4 using AMD3100 (Plerixafor) 
allowed accumulation of T-Effs in the tumour227.
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Gemcitabine
Background
The development of gemcitabine (2’,’-difluoro 2’deoxycytidine or dFdC) in the 1980s at Lilly 
Research Laboratories (Eli Lilly and Co., USA)228, has arguably been the single most 
important step in the improved survival of patients with pancreatic cancer. Interestingly, the 
drug was originally developed as an antiviral but showed such impressive anti-tumour 
activity in the preclinical setting that it was developed as a chemotherapeutic agent.
Cellular Transport of Gemcitabine
Gemcitabine is an intravenously delivered drug and its intracellular delivery is dependent on 
human nucleoside transporters (hNTs), which are split into two distinct types – the sodium-
dependent concentrative type (hCNT) and the sodium independent equilibrative type 
(hENT)229. Both hNT types are involved in the transport of gemcitabine into cells, including 
two of the three former type (hCNT1 and hCNT3), and two from four (hENT1 and hENT2) of 
the latter. The majority of gemcitabine uptake is dependent on hENT1 with the remaining 
three contributing to a lesser extent230 231. hENTs differs from hCNTs on the basis that the 
former can pump gemcitabine in both directions across the cell membrane232. 
The Activation of Gemcitabine Metabolites
Gemcitabine is a prodrug, which requires intracellular phosphorylation into its active 
metabolites. It is first phosphorylated by deoxycytidine kinase (dCK) to gemcitabine 
monophosphate (dFdCMP), which is recognised as the rate-limiting step in producing 
gemcitabine metabolites (Figure 3). Further phosphorylation of dFdCMP to gemcitabine 
diphosphate (dFdCDP) is undertaken by pyrimidine nucleoside monophosphate kinase 
(UMP-CMP kinase)233. Gemcitabine triphosphate (dFdCTP) results from a final 
phosphorylation234. Though it remains unclear which enzyme is responsible, nucleoside 
diphosphate kinase has previously been implicated in this step235.
The Inactivation of Gemcitabine Metabolites
Gemcitabine and its individual metabolites can be inactivated at various stages, though the 
resulting compounds may exert further toxic effects. dFdC deamination by cytidine 
deaminase (CDA), produces 2’-2’- difluoro-2’-deoxyuridine (dFdU). In addition to being itself 
cytotoxic, dFdU also regulates multiple gemcitabine activities. dFdU monophosphate 
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(dFdUMP) has been shown to inhibit thymidylate synthase236 which causes imbalances in 
the deoxynucleotide tri- phosphate (dNTP) pool237, leading to DNA damage238.
Gemcitabine’s monophosphate form (dFdCMP) can be inactivated by either deamination by 
deoxycytidylate deaminase (dCTD) or by de-phosphorylation by 5-nucleotidases (5’-NTs)239.  
5’NTs catalyse the conversion of nucleotides to nucleosides, are also therefore involved in 
maintaining dNTP pools. 
The Mechanism and Effects of Gemcitabine
Masked Chain Termination
Gemcitabine has several intracellular targets, of which many inhibit the synthesis of DNA. 
DNA polymerase, which assembles nucleotides into DNA, is inhibited by dFdCTP240, which 
itself is also incorporated into DNA. The addition of this extra nucleotide into the DNA chain 
results in the termination of its elongation, a process described as ‘masked chain-
termination241’. Due to dFdCTP’s non-terminal position in the chain, it will elude any DNA 
repair mechanism242. A gemcitabine metabolite, again thought to be dFdCTP also 
incorporates into RNA, though its effects are unclear at present243.
The Self-potentiating Effects of Gemcitabine
Gemcitabine metabolites exhibit inhibitory effects on several enzymes, resulting in feedback 
loops to enhance its own actions. dFdCDP inhibits ribonucleotide reductase (RR), resulting in 
a reduction in the dNTP pool and therefore a drop in dCTD and dCTP levels244. dCTP is a 
potent inhibitor of dCK, and it has been shown that this enzyme’s phosphorylation of dFdC
is the rate-limiting step in the production of gemcitabine metabolites245. Therefore, the 
inhibition of RR by dFdCDP results in the increased action of dCK in phosphorylating 
gemcitabine.
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Figure 3: Gemcitabine metabolism
A schematic diagram exhibiting the transport mechanisms of gemcitabine, its intracellular 
metabolism and key downstream effects.
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The Cell Cycle Effects of Gemcitabine
As a result of its DNA damaging effects, gemcitabine has been previously shown to induce 
the S-phase cell cycle checkpoint246. Mammalian cellular stress during S-phase activates 
Chk1 and Chk2 through the ATM (Ataxia Telangiectasia) pathway247, activating both the G1 
and G2/M checkpoints and causing cell cycle arrest248. In addition to the S-phase 
checkpoint, gemcitabine has also been shown to induce the G1 and G2/M checkpoints in 
pancreatic cancer cells via the Chk1 and Chk2 pathways. Downstream effects of these 
pathways result in cdc25A degradation and cell cycle arrest249. 
Multiple publications involving a variety of malignant cell lines show that gemcitabine 
causes a transient S-phase arrest at lower concentrations, with higher drug concentrations
leading to the termination of cell cycle progression250 251 252. 
The Induction of Apoptosis by Gemcitabine
Though gemcitabine is an S-phase specific agent253, its effects in killing cells is not confined 
to this. Loss of viability has been demonstrated in cells incubated with gemcitabine for only 
4 hours, indicating that its metabolites are retained for several hours, allowing for the 
majority of the cell population to proceed through the cell cycle241. In addition, the drug’s
destructive effects have been shown to be effective in cell populations undergoing log-
phase growth and in confluence254. Several pathways have been implicated in gemcitabine-
induced apoptosis255 and it has been demonstrated that this process is caspase-dependent 
in pancreatic cancer256 257. The activation of the p38 mitogen-activated protein kinase 
(MAPK) pathway, which interacts closely with the tumour-suppressor p53, has also been 
shown to be involved258.
Gemcitabine Resistance and Combination Therapies
As with many chemotherapeutic agents, gemcitabine resistance can either be 
predetermined or acquired259. In accordance with gemcitabine’s mechanism of action, 
diminished levels of hENT1223 260, hCNT1261 and dCK262, and elevated expression of both RR 
subunits, RRM1263 and RRM2264 have all been proposed as markers of gemcitabine 
resistance.
Due to the high prevalence of gemcitabine resistance in pancreatic cancer patients, the 
development of novel agents to be utilised as an alternative monotherapy or in combination 
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with gemcitabine is imperative. Gemcitabine lacks cross-resistance with other 
chemotherapy drugs and is therefore an ideal option for combination therapy. Both in vivo
and in vitro, it has already demonstrated synergy with several other drugs including 
cisplatin, taxanes, antifolates and trastuzumab243.
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Polo-like kinases
Background
Polo like kinases (PLKs) are a family of serine/threonine kinases. First to be discovered was 
‘polo’ in Drosophila melanogaster265 during a screen for mutants affecting spindle pole 
behaviour in the 1980s266. With the exception of plants and apicomplexans, polo-like kinases 
are found in all eukaryotes, and in humans are simply recognised numerically as PLK1-5. 
Based on phylogeny, three subfamilies of Polo-like kinases are now recognised – PLK1, PLK2 
(originally known as Snk) and PLK4 (originally known as SAK - Snk akin kinase267). Differing 
orthologs of PLKs are seen in various species, such as plo1, Cdc5 and polo as variants of PLK1 
and zyg-1, sak and Plx4 as variants of PLK4. The PLK2 subfamily, which in humans includes 
PLK2, PLK3 (previously known as Fnk or Prk) and PLK5, is only seen in vertebrates and in 
some bilaterians (animals with bilateral symmetry such as the sea urchin). Though Xenopus 
contains an ortholog (Plx5), PLK5 is only seen in the mammalian genome, with neither 
variant seen in birds or fish268. 
PLK1 localizes to chromosomes during early mitosis, before transferring to the spindle 
midzone during late mitosis269. Such proteins, which also include Aurora and inner 
centromere protein (INCENP), are proposed to control mitotic events, including 
chromosome segregation and cytokinesis and are referred to as passenger proteins270.
Structure and Function of Polo-like kinases
Brief Structure
Polo-like kinases are proteins that broadly consist of an N-terminal serine/threonine kinase 
catalytic domain and a C-terminal, which encompasses either one or two Polo-box domains 
(PBDs)271. Adjoining the kinase and polo-box domains is a linker region and a small segment 
known as the polo-box cap272 273. Utilising ATP; an active serine/threonine kinase 
phosphorylates the hydroxyl group from the side chain of serine or threonine amino acid 
residue present on a protein or substrate. This produces ADP and a phosphorylated protein. 
The Kinase Domain
Kinase domains consist of two lobes made of polypeptide chains, connected by a ‘hinge 
region’ to allow rotation274. These chains accommodate ATP molecules for binding in a 
cavity between both limbs. This ATP-binding pocket structure is highly conserved among all 
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PLKs275, with the ATP-binding site motif being Gly-X-Gly-X-Phe-Ala (where X represents any 
amino acid) in comparison to Gly-X-Gly-X-X-Gly commonly encountered in other kinases276. 
As similar ATP-binding pockets are exhibited by all protein kinases277, this can provide a 
challenge in developing highly specific kinase inhibitors278.  
The kinase domains are conserved among all PLKs with the exception of PLK5.  Due to a stop 
codon in exon 6, human PLK5 only possesses a short form of the kinase domain compared 
to its murine equivalent which contains a complete kinase domain268. This has led human 
PLK5 being described in the literature as ‘kinase-dead’279 or possessing a ‘pseudokinase’280. 
The first step in the activation of the kinase domain is the cessation of the Polo-box’s 
inhibitory effect upon the kinase. This is achieved by a phosphopeptide ligand occupying the 
PBD which leads to the release of the catalytic domain. Like many other kinases, PLKs are 
activated through phosphorylation by specific proteins. In PLKs, this process requires the 
phosphorylation of a threonine on a short segment of the catalytic kinase domain. This 
region is known as the T-loop, alternatively named the activation loop281. 
The Polo-box Domain
The Polo-box is a conserved amino-acid motif which both regulates the function of the 
kinase domain and dictates its substrate specificity272 282. PLKs 1, 2, 3 and 5279 each have two 
Polo-boxes at their C-terminus with PLK4 only possessing one283. Alternatively, PLK4 has an 
additional ‘crypto Polo-box’ which has weaker homology with the Polo-box domain283 284 285
and for this reason does not form a Polo-box domain binding pocket like other PLKs278. The
region containing both Polo-boxes is jointly known as the Polo-box domain286. 
Polo-boxes function by folding on each other to create a ‘pincer’ which contains a 
phosphopeptide-binding motif281. This motif has a strong affinity for the Ser-pSer/pThr-Pro-
X sequence268 272 273 present on targeted substrates, suggesting that other kinases such as 
cyclin-dependent (CDK) and mitogen-activated protein kinases (MAPKs) primarily 
phosphorylate substrates prior to docking in PLKs271.
The first known function of the PBD is to be auto-inhibitory with respect to its dependant 
kinase domain287. Following the binding of a phosphorylated target-protein to the Polo-box 
domain, the inhibitory effects of the PBD on the kinase domain is ceased288. Its second 
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dominant role is in the subcellular localisation of PLKs289. This crucial function distributes 
PLKs to locations within the cell to execute vital processes at various stages of the cell cycle.
Polo-like kinase 1
The Crystal structure of the PLK1 Kinase domain
Kothe et al290 recently established the crystal structure of a p.T210V mutant of the human 
Plk1 kinase domain complexed with an ATP analogue and a pyrrolo-pyrazole inhibitor. The 
structure consists of 9 β strands and 6 α-helices. Their structure displays a typical kinase fold 
which accommodates an ATP-binding site within. This binding site is located in a cleft 
formed by a β-sheet from the N-terminal lobe and an α-helix from the C-terminal lobe. Both 
these lobes are related by a hinge region which interacts with bound ligands (Figure 4).
The activation loop within the kinase domain assumes a structure similar to other active 
kinases291 and consists of residues 194-221. Both Thr210 and Ser137 have also been 
associated with the activation of PLK1 and are later discussed further.
The Crystal structure of the PLK1 Polo-box domain 
Polo-like kinase 1 possesses two Polo-boxes, the first consisting of residues 411-489 and the 
second 511-592. Each PBD has been shown to comprise a six-stranded β-sheet and one α-
helix. These are respectively recognised as β1-6 and αB in Polo-box 1 and β7-12 and αD in 
Polo-box 2 (Figure 5). Though the two PBDs are structurally similar, they show low 
homology, exhibiting only 12% sequence identity273.
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Figure 5: The crystal structure of the polo-box domain of PLK1
Crystal structure of the polo-box domain of PLK1. Both polo-box domains consist of a six-
stranded β-sheet and one α-helix.Labelled is the linker region and the phosphopeptide 
binding site between both polo-boxes. Taken without permission from Cheng et al273.
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Figure 4: The crystal structure of the kinase domain of PLK1
Crystal structure of the kinase domain of PLK1 consisting of 9 β strands and 6 α-helices. 
Residue 210 is highlighted within the activation loop, with residue 137 also highlighted due to 
its association with PLK1 activation. Taken from Kothe et al290 without permission.        
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The Crystal Structure of the PLK1 Polo-cap and the Linker regions 
Elia et al272 determined the boundaries of the PBD by digesting the entire C-terminal with a
protease and trypsin which indicated that the last 40 or so residues of the linker between 
the kinase domain and first Polo-box were part of the PBD. This additional region was 
named the Polo-cap (Pc).
The Polo-cap consists of a single α-helix, αA and a short 310 helix which connects to the first 
β-strand of Polo-box 1 via a linker region (L1). The Pc envelops Polo-box 2 harnessing it to 
Polo-box 1, and these two Polo-boxes are further connected by a second linker region (L2) 
which assists in orientating the entire domain272. Similar to the polo-boxes’ β-sheets, both 
linker regions run antiparallel to each other (Figure 6).
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Figure 6: The protein structure of PLK1
Schematic representation of PLK1 with its key residues highlighted – based on Cheng273, Kothe290 and Elia272. The kinase domain (Residues 1-
303) contains K82 responsible for ATP-binding and the activation loop (T-loop) at 194-221. Phosphorylation of both Ser137 and Thr210 have 
been implicated in kinase activation. Between the kinase and PBD there is a short linker region (306-330) and the D-box which is responsible 
for the destruction of PLK1 at the completion of mitosis. Cheng identified the polo-box domain as residues 345-603 but electron density at 
residues 345-372 and 593-603 were absent. The polo-cap joins to the first polo-box by Linker 1 and has been demonstrated to tether both 
polo-boxes together in 3D. Polo-box 1 (411-489) and polo-box 2 are joined by a linker region (493-507). Within the PBD, residues 414, 490, 
538 and 540 have all been identified as important for phosphoselectivity and phosphopeptide binding. 
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Phosphopeptide binding to the Polo-box domain
The first step in kinase activation consists of the attachment of a phosphopeptide to the 
PBD which occurs in a cleft between both Polo-boxes involving αB, β1, β7, β9 and β10. The 
binding peptide makes several specific contacts with PBD residues273 as a result of the 
second polo-box’s His-538(β9) and Lys-540(β10) side-chain ‘pincer’271. The significance of 
these two residues in phosphospecific binding was demonstrated by their mutation to 
Alanine, which prohibited this process282.
The contact between the binding peptide and PBD is both non-polar and polar in nature, 
with residues Leu490 and Trp414 dominating the latter. In addition to being in direct 
contact, the phosphate component also interacts with the PBD through a complex network 
of organised hydrogen-bonded water molecules273 282.
Activation of the PLK1 Kinase Domain
It has been shown that deletion of the C-terminus of PLK1 significantly increased kinase 
activity287 292 and it is now widely accepted that the PBD has an inhibitory effect on the 
kinase domain in PLKs. Occupancy of the PBD by a phosphorylated ligand seems to relieve 
this inhibitory effect upon the kinase domain, enabling its activation through 
phosphorylation. However, the precise mechanism of this process remains unclear at 
present. 
Following the termination of the PBDs inhibitory effect on the kinase domain, it is required 
to be phosphorylated to become active. This process occurs in the T-loop, on the 
evolutionary conserved Thr210 residue (Figure 7)293.
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Figure 7: The polo-box domain’s inhibitory effect upon the kinase domain
(A) The polo-box prevents phosphopeptide binding to the ligand. (B) A phosphopeptide ligand occupies a cleft between both polo-boxes, 
releasing its inhibitory effects upon the kinase domain. The kinase domain is now free to bind to ligands, but will require phosphorylation to 
become active. 
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Other modes of PLK1 activation
Exclusive to the conventional mode of activation described above, mutations in PLK1 have 
also been shown to activate its own kinase domain. In HeLa cells, a mutation in Thr210 to 
aspartic acid mimics phosphorylation of the T-loop, resulting in kinase activity287 294. Further 
to this, a similar mutation in Ser137, located at the end of the hinge region outside of the T-
loop also leads to kinase activation294 295. Initial doubts as to whether this site was 
phosphorylated in vivo296 have now been resolved, when it was demonstrated that 
phosphorylation of both Thr210 and Ser137 residues occurs in mitosis297. 
The mutual inhibitory effect between the kinase and polo-box domains
Interestingly, the PBDs inhibitory effect upon its kinase seems mutual. Elia et al282 showed
that an isolated PBD bound with high affinity and specificity to pSer/pThr-containing 
peptides, but this reduced ten-fold in the presence of full-length PLK1. They then progressed 
to compare kinase activity in the presence of both the optimal PBD phosphopeptide and 
non-phosphorylated peptide. Kinase activity more than doubled in the presence of the 
optimal phosphopeptide, with no change seen with the latter. This suggests that the PBD’s
binding to phosphorylated proteins not only serves to relieve its auto-inhibitory effect upon 
its kinase, but also direct its kinase partner towards target substrates. 
Further information has been gathered about this mutual inhibitory effect through the 
recently published crystal structure of Danio rerio (Zebrafish) kinase-PBD complex together 
with a PBD-binding motif of Drosophila melanogaster microtubule-associated protein 205 
(Map205)298 299. Various methods of kinase inhibition have been suggested, including 
structural changes within the kinase-PBD complex which prevents access to the Thr210 and 
Ser137 phosphorylation sites. A third pathway suggests that the binding of the PBD to 
Map205 stabilized this auto-inhibitory relationship and isolated the inactive kinase away 
from its substrate. 
Cessation of the mutual inhibitory effect between the kinase and polo-box domains
Phosphorylation of Map205 or the Ser137 site of PLK1 disrupts the inhibitory relationship 
between the kinase and PB domains. This effect, which is replicated by the binding of a 
substrate to the PBD, ceases the isolation of the Thr210 residue on the T-loop enabling it to 
interact with activating kinases280.
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Stimulation of PLK1 activity
PLK1 activity is stimulated via two main pathways – firstly by the phosphorylation of Thr210 
or Ser137 in the kinase domain280 and secondly, by phosphopeptide binding of the PBD. 
Aurora A and Bora are the main activating kinases of PLK1 in mitosis
Phosphorylation of the Thr210 residue commences in G2, leading to a gradual increase in 
PLK1 activity which peaks at mitosis300. Initial phosphorylation is undertaken by Aurora A 
kinase – a process which is also dependent on its cofactor, Bora301. Chan et al302 states that 
the Bora-PLK1 interaction is likely to be initiated by the CDK1-dependent phosphorylation of 
Bora, suggesting that CDK1 is required for the activation of PLK1 in G2. In turn, this feedback 
loop ensures that PLK1 activation is necessary for the subsequent activation of cyclin 
B/CDK1300 (Figure 8).
At the onset of mitosis, when PLK1 activity peaks, Bora is degraded in a PLK1-and 
Skp/Cullin/F-box-β-Trasducin repeat containing protein(SCF βTrCP)-dependent manner303, 
leaving Aurora A to interact with other co-activators. However, the continued activity of 
PLK1 is dependent on the ongoing phosphorylation of Thr210304 and until recently this 
mechanism was poorly understood. It has now been demonstrated that the continued 
phosphorylation of Thr210 remains Bora-Aurora-A dependent, with only minimal Bora-
Aurora-A activity necessary to maintain PLK1 activity. Therefore, the inactivation of PLK1 
during mitosis requires the complete absence of both Bora and Aurora-A301, which raises the 
possibility that they are responsible for the majority, if not all of the Thr210 phosphorylation 
in mitosis (Figure 9).
Aurora A-independent regulation of PLK1
As Bora is degraded, another cofactor, targeting protein for Xklp2 (TPX2) becomes 
responsible for the regulation of Aurora A305. At this time, regulation of PLK1 becomes 
Aurora A-independent, though the mechanism of this change is not currently known306. 
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Figure 8: The activation of PLK1 activity in G2
Phosphorylation of the Thr210 residue of PLK1 is undertaken by Aurora A kinase, though 
this can only occur in conjunction with its cofactor, Bora. The Bora-PLK1 interaction is 
likely to be initiated by the CDK1-dependent phosphorylation of Bora, suggesting that 
CDK1 is necessary for activation of PLK1 in G2. 
Figure 9: The maintenance of PLK1 activity at mitotic entry
Bora is degraded in a SCF-βTrCP-dependent manner. The maintenance of PLK1 activity 
requires the continued phosphorylation of its Thr210 residue and only requires minimal 
Aurora A-Bora activity. As Bora is degraded, another cofactor, targeting protein for Xklp2 
(TPX2) becomes responsible for the regulation of Aurora A. At this point, PLK1 activity 
becomes independent of Aurora A, though this mechanism is not currently understood.
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Other activating kinases of PLK1
Though Aurora A in combination with Bora are the main activating kinases of PLK1, other 
proteins have been shown to phosphorylate Thr210 and stimulate kinase activity including 
serine/threonine kinase 10 (STK10), Human STE20-like kinase (SLK)307 and lymphocyte 
oriented kinase (LOK)308. However, it has already been shown that siRNA knockdown of SLK 
and LOK is not reflected by a fall in Thr210 phosphorylation during interphase or mitosis, 
suggesting that their effects are marginal301.
Priming Kinases for PBD phosphopeptides and the subcellular localization of PLK1
The optimal binding peptide for the PBD contains the Ser-[pSer/pThr]-[Pro/X] motif,  
suggesting that other kinases may act as ‘primers’ by phosphorylating target proteins in 
preparation for preferential binding to PBD docking sites. Elia et al272showed that this 
optimal phosphoprotein will be favoured by the PBD over binding to centrosomes. Further 
evidence was presented282 displaying how mutations in the PBD could hinder cellular 
localization of PLK1 in centrosomes. This all strongly suggests that the PBDs phosphopeptide 
binding characteristics plays a key role in the subcellular localisation of PLK1 and therefore 
in cell cycle progression271.
Priming kinases are also likely to function as signposts, attracting PLK1 to various cellular 
locations at predetermined time points in the cell cycle.  Examples include the CDK1-primed 
inner centromere protein (INCENP)269 and PLK1-primed protein regulator of cytokinesis 1 
(PRC1)309 which binds to PLK1 and localises to the kinetochores and central spindle at key 
points during mitosis.
Priming Kinases for PBD binding
Kinases known to be responsible for ‘priming’ target proteins for PBD binding include Cyclin-
dependent kinase 1 (CDK1), MAPKs271 280 and ATR310. Self-priming of substrates by PLK1 has 
also been recognised280 311.
Phosphorylation of Downstream Targets by PLK1
The preferred substrate epitope for phosphorylation by PLK1 has been reported as Glu/Asp-
X-Ser/Thr-ϴ, where ϴ is usually hydrophobic312. Verified in vivo substrates of PLK1 include 
cyclin B313 314 315, cdc25315 316, Wee1317 318, BRCA2319, Myt1320, Nlp321, NudC322, TCTP323, 
Grasp65324 325, MKlp1326 327 and MKlp2328. However, very few of these substrates have PLK1-
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specific sites for PBD-binding or kinase phosphorylation, with many also being targets for 
phosphorylation by CDK1 and other mitotic kinases329.  
Cellular roles of PLK1
A complex picture of the cellular roles of PLK1 has developed over the past decade, 
involving several signalling pathways. Though PLK1 commences expression in G2, its kinase 
activity is not seen until the G2/M transition. Peak levels of PLK1 are achieved during 
mitosis330, though it is subsequently degraded by the time this phase is complete331. 
PLK1 in G2
Though PLK1-inhibited cells will eventually progress to mitosis, their entry will be delayed 
and cell cycle arrest will later ensue. In late G2/prophase332, a plentiful supply of stable 
cyclin B is available as it is net exported from the nucleus into the cytoplasm333. This enables 
its binding to CDK1 to create a cyclin B/CDK1 complex (also known as the M-phase 
promoting factor (MPF))334 which, in eukaryotes, drives mitosis335. In G2, the cyclin B/CDK1 
complex remains largely inactive due to the ongoing phosphorylation of residues Thr14 and 
Tyr15 of its kinase component by Wee1 and Myt1, preventing ATP-binding336 337 (Figure 10).
PLK1 at mitotic entry
For mitotic entry, cyclin B/CDK1 must be activated, meaning that the inhibitory effects 
described above need to be terminated. This is instigated in several ways through PLK1, 
which is located at the centrosomes throughout interphase and prophase275.
Firstly, CDK1 residues Thr14 and Tyr15 are both dephosphorylated by cdc25A, cdc25B and 
cdc25C, to enable CDK1-ATP binding. cdc25C is directly phosphorylated by PLK1315 338 339.
However, it is cdc25B that has been proposed as the ‘stimulus phosphatase’ for the 
activation of cytoplasmic cyclin B/CDK1340. Secondly, Wee1 and Myt1 are both 
phosphorylated by PLK1, ceasing their inhibitory effects upon CDK1. Cyclin B/CDK1 activity is 
also dependent on the phosphorylation of Thr161 located on the T-loop of its kinase domain 
by the CAK complex (CDK7, cyclin H and MAT1)341 342, resulting in increased kinase activity. 
Once stimulated, cyclin B/CDK1 ensures mitotic commitment by self-promoting its further 
activation via a positive feedback loop, by phosphorylating both Wee1343 and cdc25C344
(Figure 11). The former will later be further phosphorylated by PLK1 again suggesting a 
‘priming’ relationship between PLK1 and other kinases. Wee1 is then degraded through SCF 
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βTrCP343. PLK1 also phosphorylates the cyclin B/CDK1 complex in addition to both cdc25C 
and cyclin B315 which stimulates the entry of cells into mitosis which further promotes cyclin 
B/CDK1 at the centrosome. For a timely mitotic entry, it is necessary for the activated 
protein-kinase complex to translocate from the cytoplasm to the nucleus288 as the inability 
of either cyclin B345 or active CDK1346 to enter the nucleus will block or delay this event. PLK1 
has previously been implicated in the subcellular localization of cyclin B/CDK1 by 
phosphorylating Cyclin B’s Ser133313. However the deletion of this phosphorylation site 
failed to prevent the nuclear migration of the complex, suggesting that several factors 
influence its intracellular movement (Figure 11).
Figure 10: CDK1/Cyclin B in G2
Cyclin B is net exported into the cytoplasm from the nucleus and binds to CDK1. The cyclin
B/CDK1 complex remains largely inactive due to the phosphorylation of Thr14 and Tyr15 
by Wee1 and Myt1, preventing ATP binding.
CDK1   Cyclin B
Wee1
Myt1
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Figure 11: PLK1 at mitotic entry
cdc25A, B and C dephosphorylate CDK1 residues Thr14 and Tyr15. Cdc25C is 
phosphorylated by PLK1. Both Myt1 and Wee1 are also phosphorylated by PLK1, ceasing 
their inhibitory effects upon cyclin B/CDK1. This complex can then be activated by the 
phosphorylation of Thr161 by the CAK complex.
Once stimulated, cyclin B/CDK1 ensures mitotic commitment by self-promotion via a 
positive feedback loop. This involves the phosphorylation of cdc25C and Wee1 by the 
complex prior to the degradation of Wee1 by SCF-βTrCP. Cyclin B/CDK1 is phosphorylated 
by PLK1, which also stimulates the entry of cells into mitosis by phosphorylating cdc25C 
and cyclin B. For a timely mitotic entry, cyclin B/CDK1 translocates from the cytoplasm into 
the nucleus.
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PLK1 and the G2 DNA Damage Checkpoint
As a consequence of DNA damage in G2, the phosphatase cdc14B activates the anaphase-
promoting complex (APC)347. The purpose of this DNA damage checkpoint is to enable cells 
to repair damaged DNA, by inhibiting cyclin B/CDK1 to cease entry into mitosis348. Induction 
of the APC leads to the inactivation and degradation of PLK1349, and though PLK1 is not 
usually essential for mitotic entry, this changes once the DNA checkpoint has been activated 
in G2350.
Double strand DNA-breaks activates the checkpoint kinase ATM (ataxia telangiectasia 
mutated), with single stranded breaks activating ATR (ataxia telangiectasia and Rad3-related 
proteins)280. These kinases phosphorylate checkpoint kinases 2 and 1 (Chk2 and Chk1) 
respectively351. Phosphorylation of Chk1 by ATR requires the presence of the adaptor 
protein Claspin to fuse both proteins together352. This protein will later play an important 
role alongside PLK1 in checkpoint recovery. 
Chk1 and Chk2 both inactivate cdc25C which in its active state promotes CDK1. Chk1 also 
activates Wee1 which, in turn phosphorylates CDK1 on residues Thr14 and Tyr15 to inhibit 
substrate binding and cell cycle progression280 288. Inhibition of the cyclin B/CDK1 complex 
causes a G2 arrest (Figure 12).
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Figure 12: PLK1 and the DNA damage 
checkpoint
Activation of the APC by cdc14B leads to the 
inactivation and degradation of PLK1. The scale 
of DNA damage determines which checkpoint 
kinase is activated – ATM or ATR. These kinases 
phosphorylate Chk2 and Chk1 respectively, 
with Chk1 requiring Claspin for this to occur. 
Chk1 and 2 inactivate cdc25C, which in its 
active state promotes CDK1. Chk1 also 
activates Wee1, which phosphorylates CDK1 on 
residues Thr14 and Tyr15 to inhibit substrate 
binding and cell cycle progression.  
Result: G2 Block
DNA Damage
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DNA damage prevents phosphorylation at Thr210 and Ser137
PLK1 activity is inhibited in the event of DNA damage during mitosis353. Tsvetkov et al297
treated cells with a combination of nocodazole, a mitosis arresting agent and adriamycin, a 
DNA damaging agent. Their results suggest that there are two mechanisms for PLK1 
inhibition: the first prevents the phosphorylation of Ser137 and Thr210 in G2, while the 
second operates independently in mitosis. 
PLK1 and Cell Cycle Recovery Following the DNA Damage Checkpoint
PLK1 initiates the repair of damaged DNA and subsequent recovery from the DNA damage 
checkpoint in several ways. Firstly, the adapter protein claspin is phosphorylated by PLK1 
which leads to its degradation by SCF-βTrCP354. The presence of any nondegradable claspin 
inhibits a cell’s recovery from the DNA checkpoint arrest, emphasising the importance of 
PLK1 in DNA checkpoint recovery300 (Figure 13). In addition to this, PLK1 inactivates the DNA 
damage checkpoint by phosphorylating the tumour suppressor p53-binding protein 1 
(p53BP1) and Chk2. p53BP1 is firstly primed by Cyclin B/CDK1, before phosphorylation by 
PLK1 promotes its self-dissociation from DNA300 and negative regulation of Chk2, preventing 
its binding to substrates355. PLK1 also promotes the repair of damaged DNA by 
phosphorylating RAD51 homologue 1 (RAD51) on Ser14, which is later phosphorylated again 
on Thr15 by casein kinase. This subsequently promotes the accumulation of p53BP1 at the 
site of damage356, promotes degradation of Wee1 and inactivates both Chk1 and Chk2.  
As DNA is repaired, CDK1 is reactivated to enable the cell cycle to progress. It has been 
suggested that Wee1 degradation is dependent on phosphorylation by both PLK1 and cyclin 
B/CDK1 after DNA damage356. These observations are consistent with findings made in yeast 
where active cyclin B/CDK1 is required for cell cycle re-entry after checkpoint arrest357
(Figure 14).
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Figure 13: PLK1 is involved in initiating DNA repair
To initiate DNA repair, claspin is phosphorylated by PLK1, prior to its degradation by SCF-
βTrCP. The presence of any nondegradable claspin inhibits a cell’s ability to recover from a 
DNA checkpoint arrest.
Figure 14: Cell cycle recovery following DNA damage checkpoint arrest
PLK1 inactivates the DNA damage checkpoint by phosphorylating p53BP1 and Chk2. 
p53BP1 is firstly primed by cyclin B/CDK1, before phosphorylation by PLK1. PLK1 also 
promotes the repair of damaged DNA by phosphorylating RAD51 on Ser14, which is later 
phosphorylated again on Thr15 by casein kinase. This promotes the accumulation of 
p53BP1 at the site of DNA damage, promotes degradation of Wee1 and inactivates both 
Chk1 and Chk2. As DNA is repaired, CDK1 is reactivated to enable the cell cycle to progress. 
Wee1 degradation is dependent on phosphorylation by both PLK1 and cyclin B/CDK1 after 
DNA damage.
Claspin
PLK1
SCF-βTrCP
CDK1   Cyclin B
cdc25C
PLK1
Wee1
PLK1
RAD51
Caesein 
kinase
p53BP1
Chk2 DNA 
Damage
Result: Mitosis 
Progresses
Chk1
Activates
81 | P a g e
PLK1 and the Centrosomes 
The centrosome consists of two centrioles positioned in a pericentriolar matrix (PCM). In G2, 
PLK1 localizes to the centrosomes where it recruits pericentriolar material and enables the 
centrosome to become a microtubule-nucleating centre358. Regulatory factors such as γ-
tubulin are activated and arranged into complexes such as γ-tubulin ring complexes 
(γTuRCs) and γ-tubulin small complexes (γTuSCs) which are incorporated into the 
cytoskeleton280. During cell division, the two centrosomes migrate to establish the poles of 
the bipolar mitotic spindle that controls the equal division of chromosomes359.
PLK1 phosphorylates two proteins which play a key role in centrosome maturation. Firstly, 
ninein-like protein (NLP) is phosphorylated by PLK1 which disturbs the protein’s interaction 
with both the centrosome and γTuRC leading to its exit from the centrosome and promotion 
of microtubule nucleation321. The second protein, pericentrin (PCNT) has only recently been 
identified as a PLK1 target at the centrosome. Phosphoresistant PCNT mutants lose the 
ability to attract essential PCM ingredients such as PLK1, Aurora A, γ-tubulin and 
centrosomal protein of 192kDA (CEP192) to the centrosome which again prevents 
centrosome maturation360. 
PLK1 also promotes the disengagement and separation of mature centrosomes. A linker 
protein containing centrosome-associated protein (CNAP1 or CEP250) and rootletin tethers 
the two dividing centrioles together361. This connection is broken by the phosphorylation of 
both linker proteins by the serine-threonine kinase NIMA-related kinase (NEK2A), resulting 
in their dissociation from the centrioles. The activation of NEK2A is positively regulated by 
Serine/Threonine protein kinase 3 (MST2 or STK3) and human Salvador homolog 1 
(nSAV1)362, with a further protein, Serine/Threonine phosphatase PP1γ rendering it 
inactive363. The phosphorylation of MST2 by PLK1 inhibits PP1γ from binding to NEK2A, 
therefore enhancing NEK2A activity. These intricate interactions explains how increased 
PLK1 activity in G2/prophase initiates centrosome disjunction. 
A further pathway, exclusive to NEK2A also implicates PLK1 with EG5 (also known as KIF11) 
in the disjunction of centrosomes. Bertram et al364 and Smith et al365 have both shown that 
the phosphorylation of NEK9 is PLK1- and CDK1-dependent, which in turn activates NEK6 
and NEK7 leading to the phosphorylation of EG5. Phosphorylation of EG5 leads to its 
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accumulation at the centrosomes in prophase and this protein has been shown to be 
responsible for the full separation of the centrosomes during this phase366. 
PLK1 in Sister Chromatid Separation
As DNA replication occurs, cohesin is recruited to chromosome arms and to the 
centromeres288. Cohesin binds together two newly divided chromatids until M-phase when 
it is mostly removed280 via a CDK1-mediated pathway. 
During prophase, PLK1 is drawn to chromosome arms through the CDK1-dependent 
phosphorylation of both soronin and condensin 2 complex subunit D3 (CAPD3)367. The 
former of which acts as a docking protein for PLK1 to phosphorylate the cohesion complex 
subunit SA2, leading to the removal of cohesion complexes368 (Figure 15). PLK1 also 
encourages the release of cohesin from chromosome arms by phosphorylating early mitotic 
inhibitor 1 (EMI1), leading to its degradation. This contributes to the activation of the 
anaphase-promoting complex (APC)-cdc20 which promotes cohesin breakdown and 
chromatid separation369.
Nevertheless, the divided chromatids will remain linked until the remaining cohesin is also 
freed from the centromeres370 . Cohesin complexes are protected during prophase by 
protein phosphatase 2A (PP2A) and Shugoshin (sgo1) as they dephosphorylate SA2371. PLK1 
is recruited to both the kinetochore372 and centrosome by its PBD, where it both binds and 
phosphorylates polo-box interacting protein 1 (PBIP1)373. At the centrosome, the cohesion 
subunit sister chromatid cohesion protein 1 (Scc1 or RAD21 in vertebrates), is 
phosphorylated by PLK1, facilitating its cleavage by the protease separase374.
Just prior to the commencement of the separation of sister chromatids, PLK1 is released 
from the kinetochores via its monoubiquitation by the ubiquitin ligase cullin 3 (CUL3) –
Kelch-like protein 22 (KLH22)375 (Figure 16).
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Figure 15: PLK1 in sister 
chromatid separation -
prophase
During prophase, PLK1 is 
drawn to chromosome arms 
through the CDK1-dependent 
phosphorylation of both 
soronin and CAPD3. The 
former of which acts as a 
docking protein for PLK1 to 
phosphorylate the cohesion 
complex subunit SA2, leading 
to the removal of cohesion 
complexes. Cohesin 
complexes are usually 
protected by PP2A and Sgo1 
as they dephosphorylate SA2.
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Figure 16: PLK1 in sister chromatid separation – prometaphase and metaphase
During prometaphase and metaphase, PLK1 is recruited to both the kinetochore and centrosome 
by PBIP1. PLK1 promotes the release of cohesin from chromosome arms by the phosphorylation of 
EMI1. Activation of the APC promotes cohesin breakdown and chromatid separation. At the 
centrosome, Scc1 (or RAD21 in vertebrates), is phosphorylated by PLK1, facilitating its cleavage by 
the protease separase. During anaphase, prior to the separation of sister chromatids, PLK1 is 
released from the kinetochores via its monoubiquitation by CUL3-KLH22 Both figures are based on 
Zitouni et al280
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PLK1 and Activation of the Anaphase-Promoting Complex 
In addition to other spindle assembly checkpoint proteins, the activation of the APC-
promoter, cdc20, is regulated by EMI1. The phosphorylation of this mitotic inhibitor by PLK1 
leads to its degradation by SCF-βTrCP376, enabling the activation of the APC. PLK1 inhibition 
has been demonstrated to delay EMI1 degradation, though this isn’t a prerequisite for APC 
activation at mitotic onset377. 
PLK1 in Kinetochore-microtubule Attachment
Kinetochores and spindle microtubules assemble on the centromeres in mitosis and are 
critical for accurate chromosomal alignment and separation280. Despite the degradation of 
PBIP1 in early mitosis372, PLK1 remains at the centrosomes and kinetochores following 
nuclear envelope breakdown to regulate the kinetochore-microtubule (KT-MT) 
attachment378. This is thought to be due the actions of BUBR1 and the inner centromere 
protein (INCENP) which have both been shown to contribute to the localisation of PLK1379
380 381. 
CLIP-associating protein 2 (CLASP2), which is primed by CDK1 in preparation for 
phosphorylation by PLK1 increases PLK1 recruitment to the kinetochore and stabilises the 
attachment to the microtubule382. Incorrectly attached spindle microtubules will be 
destabilised by the chromosomal passenger complex (Aurora B, INCENP, survivin and 
borealin) which also regulates the spindle assembly checkpoint (SAC). CDK1 and PLK1 
regulate the kinase haspin, which promotes the phosphorylation of histone H3 which 
attracts Aurora B to the centromere for this passenger complex383.
During metaphase, PLK1 has been shown to phosphorylate BUBR1381 and CAP-Gly domain-
containing linker protein 1 (CLIP170)384, which has been shown to regulate KT-MT 
attachment and SAC signalling280. These attachments are further stabilised385 by the 
activation of PLK1 by Aurora B and INCENP at the centrosomes386. The later phosphorylation 
of BUBR1 by PLK1, promotes its binding to the B56α regulatory subunit of PP2A which 
dephosphorylates Aurora B and regulates mitotic progression387 388. B56α-PP2A also 
dephosphorylates the KNM network (kinetochore-null protein, MIS12 complex and 
kinetochore protein NDC80 homologue complex), which is responsible for the initial 
attachment of microtubules to the kinetochore280.
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PLK1 and Cytokinesis
During cytokinesis, sister chromatids separate into two cells resulting in the formation of 
two physically separate cells. As these chromatids part, PLK1 translocates to the central 
spindle and the midzone in anaphase and telophase respectively389. This localization of PLK1 
is dependent on several substrates including mitotic kinesin-like protein 1 (MKLP1), MKLP2, 
golgi-associate protein (PYK2), N-terminal domain-interacting receptor 2 (NIR2), dynein-
associated nuclear distribution protein C homologue (NUDC), CEP57 and the protein 
regulator of cytokinesis (PRC1)280. PRC1 is an antiparallel microtubule-bundling protein 
which plays a key role in organizing the spindle midzone and is negatively regulated by both 
CDK1390 and PLK1391. PLK1 self-primes PRC1 prior to its phosphorylation on Thr602 in 
metaphase. This process not only inhibits PRC1 activity and therefore prevents premature 
midzone formation, but also targets PLK1 to the midzone by creating docking sites for the 
protein to bind390.
PLK1 and AMPK
AMP-activated protein kinase (AMPK) is a multifunctional fuel-sensing enzyme, involved in 
the regulation of protein, lipid and glucose metabolism. Vasquez-Martin et al392 393 has 
shown that its active form, PP-AMPKαThr172, shares both temporal and spatial similarities to 
PLK1 during mitosis and cytokinesis and that PLK1 inihbition extinguishes the mitotic 
activation of AMPKα.
AMPK is an inhibitor of acetyl-CoA carboxylase 1 (ACC), which is the rate-limiting enzyme 
involved in fatty acid synthesis. AMPK’s activity towards ACC is high at the commencement 
of mitosis and decreases towards its termination – consistent with the rate of fatty acid 
synthesis. The continued expression of AMPK has been shown to cause mitotic arrest, 
suggesting that AMPK also plays a key role in the final stages of mitosis394 395. 
PLK1 and p53
The tumour suppressor p53 is intricately involved in several events essential for cell survival 
including DNA repair, cell cycle arrest and apoptosis396. These p53-dependent events ensure 
the repair and continuing survival of healthy cells or alternatively, programmed cell death. 
This should result in the prevention of tumour formation, which explains why the loss of p53 
function is commonly seen in various human cancers397. 
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Studies have demonstrated a mutual negative regulatory relationship between PLK1 and 
p53. The phosphorylation of p53 by PLK1 has been shown to result in the inhibition of its 
pro-apoptotic characteristics398, while depleting PLK1 in HeLa cells has been shown to 
increase the stability of p53399. In addition, a further study proposes the negative influence 
that p53 imposes upon PLK1400.
Several pathways have been proposed to explain the negative influence of PLK1 upon p53. 
Firstly, PLK1 inhibits the phosphorylation of p53 on Ser15, leading to its nuclear export and 
degradation401. Secondly, PLK1 phosphorylates topoisomerase I-binding protein (Topors) at 
Ser78 which enhances this process402. Lastly, is a pathway involving the largely nuclear 
protein, GTSE1 (G2 and S phase-expressed-1). PLK1 phosphorylates GTSE1 and endorses its 
transportation of p53 from the nucleus to the cytoplasm for degradation during the G2 
checkpoint recovery403.
The evidence surrounding PLK1 inhibition and p53 status in the treatment of cancer is 
conflicting. Sanhaji et al404 utilized PLK1 siRNA in addition to both a kinase- and polo-box 
domain-targeting PLK1 inhibitor in HCT116 (colonic cancer) cells of varying p53 status. With 
PLK1 knockdown, though the difference was minimal, results showed greater induction of 
apoptosis and reduced cell proliferation in p53 proficient cells compared with p53(-/-) cells. 
The PLK1 kinase domain-targeting agents BI 2536 and BI 6727 showed contrasting results 
with regards to cell proliferation, with BI 2536 slightly more effective in HCT116p53(-/-) cells 
and BI 6727 showing the opposite. However BI 6727 inhibited cell proliferation with greater 
potency than BI 2536.
In addition to causing a host of other cell cycle disturbances, the polo-box domain-targeting 
agent Poloxin has been shown to induce apoptosis in a variety of cell lines405 406. The agent 
caused significant apoptosis in both HCT116p53(-/-) and HCT116p53(+/+) cell lines, but was 
slightly more effective in the latter. The experiment was repeated in other cell lines with 
PLK1 inhibition induced by the same agents but in combination with and without p53 siRNA. 
More apoptosis was evident in MCF (breast cancer), A549 (non-small cell lung cancer) and 
HeLa (cervical cancer) cells with a functional p53 as opposed to without. Overall, these 
results strongly suggest that a preserved p53 status could be a predictor of a cell’s 
susceptibility to the inhibition of PLK1. 
87 | P a g e
However, as other studies proposed the opposite of these findings407 408 409, Sanhaji and 
colleagues set out to determine whether mitotic stress, as commonly seen in cancer cells, 
would affect a cell’s susceptibility to PLK1 inhibition dependent on their p53 status410. PLK1 
inhibition was again instigated by the same compounds as previously used with mitotic 
stress induced by pretreating HCT116 cells with the microtubule destabilizers nocodazole 
and vincristine, the microtubule stabilizer paclitaxel and the kinesin Eg5 inhibitor monastrol. 
Results suggest that by inducing PLK1 inhibition in cells undergoing mitotic stress, those cells 
with a functional p53 will trigger a strong apoptotic response whereas p53 null cells will 
arrest in mitosis with less apoptosis. Interestingly, this was despite the fact that HCT116p53(-
/-) cells showed evidence of greater DNA damage than HCT116p53(+/+) cells after treatment, 
but these DNA-damaged cells survived longer in comparison. Proliferation and colony-
formation assays showed that HCT116p53(+/+) cell growth was better inhibited than 
HCT116p53(-/-) cells and these observations were further strengthened when it was shown 
that p53 knockdown in HCT116 and U2OS (osteosarcoma) cells led to less apoptosis, 
suggesting that apoptosis is p53-dependent in PLK1 inhibited cells. The authors conclude 
that based on their results and the available published literature, that loss of p53 is not 
directly the cause of increased PLK1 toxicity. It is suggested that the efficacy of PLK1 
inhibitors is enhanced by an active p53. This may be due to its stimulation of other signalling 
pathways and its prevention of genome instability, which has been previously described as a 
result of PLK1 inhibition411. 
The identification of tumour biomarkers is a critical step in the treatment of any malignancy 
and the hunt for a predictive biomarker for PLK1 inhibition is ongoing. Retrospective 
immunohistochemical analysis of 215 breast cancers found that 11% expressed PLK1, with 
its presence significantly associated with mutant p53412.  The survival of individuals with 
both a mutated TP53 and ‘high’ PLK1 expression was significantly poorer than in individuals 
possessing only one of these prognostic factors. PLK1 expression was also significantly 
associated with aggressive triple-negative tumours (p=0.01) and MDM2, a negative 
regulator of p53 (p=0.04). Overall it could be argued that breast tumours with raised PLK1 
expression in association with a TP53 mutation is a promising target for PLK1 inhibitors.
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Sur and colleagues413 developed a series of matched colorectal cancer cell lines that differed 
only in their endogenous p53 status. They then progressed to impose DNA damage to these 
cells through ionising radiation. Their first discovery was the elevated expression of PLK1 in 
p53 mutant cells in comparison with wild-type p53 cells, suggesting that the ongoing 
survival of mutant p53 cancer cells may be PLK1-dependent. Ionising radiation was found to 
cause G1 arrest in p53-proficient cells, but showed no PLK1-inhibition-related effect, likely 
as a result of the cells not entering mitosis. However, similarly treated, matched, p53-null 
cells entered mitosis and succumbed to PLK1 inhibition.  
PLK1 and KRAS
KRAS mutations are known to be amongst the earliest in the development of pancreatic 
cancer.  Importantly, oncogenic KRAS has been shown to be necessary for both the initiation 
and maintenance of pancreatic cancer in mice414. Though direct KRAS-targeting is yet to be 
successful415, this finding still has treatment implications in emphasising the importance of 
its downstream proteins as potential targets416.
Luo et al417 utilised retroviral short hairpin RNAs to target over 30 000 transcripts to identify 
vulnerabilities in RAS-mutated cancers. The group then progressed to treating both mutant
and wild-type RAS tumour cells with a polo-like kinase inhibitor, BI 2536 and PLK1 siRNA.
Mutant RAS cells were highly sensitized to treatment, with evidence suggesting that these 
cells were unable to recover from even transient exposure to BI 2536. Given the prevalence 
of KRAS mutations in pancreatic ductal adenocarcinoma this seems particularly promising.
This suggests that PLK1 is essential to the survival of RAS-driven cells exposed to mitotic 
stress, suggesting that such cells may be particularly sensitive to PLK1-inhibition. Moreover, 
this raises the question whether PLK1 inhibitors should be specifically targeted towards 
patients with tumours that are both mutant KRAS and overexpress PLK1418 - an area that is 
yet to be explored in any great detail. 
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PLK1 and Cancer
In keeping with its role in promoting cell proliferation, PLK1 is overexpressed in a variety of 
tumours419 420 and this has been suggested to contribute to carcinogenesis by causing 
chromosome instability421 and other mitotic defects422. Malignancies thus far associated 
with overexpression of PLK1 include pancreatic423, hepatocellular424, hepatoblastoma425, 
oesophageal426, gastric427 428 429, colorectal430 431 432, breast433 434, prostate435, head and 
neck436, thyroid437, gliomas438, non small-cell lung439, melanoma440 and cutaneous T-cell 
lymphoma441. In addition to this, elevated levels of the protein has been shown to be a poor 
prognostic indicator in the majority of these cancers, including hepatocellular carcinoma423, 
hepatoblastoma424, oesophageal426, gastric428 429, prostate435, urothelial442, head and 
neck436, non small-cell lung cancer439 443, non-Hodgkins lymphoma444 445, myeloma446, 
melanoma440 447, ovarian448 449, endometrial450 and cervical451 (Figure 17). 
Though some argue that this overexpression is simply a reflection of rapidly proliferating 
cells in tumours, there is plentiful evidence to support PLK1 as a potentially valuable anti-
cancer target452. One of the earliest publications to support this theory was Smith et al453
who showed that by constitutively expressing PLK1 in NIH3T3 fibroblasts the cells became 
transformed, enabling the cell line to grow in soft agar and induce tumour growth when 
injected into nude mice. A second example is that PLK1 expression has already been shown 
to be a predictor of response of rectal cancer to radiotherapy454.
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Figure 17: mRNA expression profile of PLK1 in normal and malignant human tissue  
This panel shows whisker-box plots for normal tissues (yellow/brown) and malignant 
lesions (blue). The vertical lines in each box indicate median values, and box limits 
represent the first and third quartiles; the whiskers extend to 1.5 times this interquartile 
range. The circles represent outliers. Abbreviations : LCC, large-cell carcinoma; SCLC, small-
cell lung carcinoma; SCC,squamous-cell carcinoma. The number of samples for each tissue 
from top to bottom is n = 278, 84, 95, 215, 73, 10, 5, 134, 66, 51, 11, 27, 6, 175, 64, and 14, 
respectively. Taken without permission from Steegmaier455.
PLK1 and Pancreatic Cancer
Gray et al423 assessed the suitability of PLK1 as a potential therapeutic target in pancreatic 
cancer. PCR demonstrated the upregulation of PLK1 in 9 of 10 pancreatic cancer cell lines 
examined, in comparison to HPDE6c7, a non-transformed pancreatic epithelial cell line. 
Genetic overexpression ranged from 8-fold in Panc-1 cells, to 58-fold, seen in MiaPaCa-2. 
mRNA isolated from 4 tumours revealed up-regulation of PLK1 signal in all samples with one 
tumour expressing a 20-fold increase compared with normal pancreatic tissue. To delineate 
whether overexpression at the RNA level led to an increase in protein levels, a tissue 
microarray of 35 pancreatic adenocarcinoma samples from their facility was examined. 74% 
of tumours stained positively for PLK1 with 31% demonstrating high staining. Overall, this 
suggests vastly heterogenous behaviour between tumours with regards to PLK1 expression. 
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PLK1 Inhibition
Inhibiting PLK1 Gene Expression
Germline knockout of PLK1 result in embryos that failed to survive past the 8-cell stage 
demonstrating the vital function of PLK1 in early development456. Furthermore, inhibiting 
PLK1 at a translational level has been extensively described in the literature. One method is 
RNA interference, which involves the enzymatic cleavage of 21-nucleotide siRNA fragments 
into single RNA strands, which when bound to complementary mRNA leads to its 
degradation. Secondly are single-stranded DNA antisense oligonucleotides, which can also 
reduce the genetic expression of PLK1 by binding to complementary mRNA275.
Studies have already described successfully utilising PLK1 siRNA to inhibit PLK1 in cancer 
cells, leading to mitotic arrest and apoptosis457 458, suggesting that cancer cells may not 
possess an alternate signalling pathway to overcome PLK1 inhibition.
Attaining RNA interference in vivo is challenging, though this was successfully achieved by 
Strebhardt459, who demonstrated the survival of normal cells in the presence of cancer-cell 
death. The exact mechanism of this finding is a mystery though it is proposed that PLK1 
siRNA may leave enough residual PLK1 activity to ensure the continued viability of normal 
cells. Another potential explanation would be that cancer cells lose a mechanism to bypass 
the absence of PLK1, which is conserved in normal cells. A final suggestion is that this finding 
is exclusive to PLK1 siRNA-treated cells, as both cancer and normal cells have been to 
respond in a similar manner when treated by PLK1 inhibiting compounds as opposed to 
being impeded on a genetic basis275. 
Functional PLK1 Inhibitors
Detailed knowledge regarding the structural configuration of PLK1 is imperative in order to 
manufacture specific inhibitors. Current compounds can be divided into two distinct classes: 
ATP-competitive, which target the kinase domain, and Non-ATP-competitive which target 
the PBD. A single compound possessing both these characteristics is yet to be developed460. 
ATP-Competitive Inhibitors
ATP-competitive PLK1 inhibitors target the ATP-binding site on the kinase domain of PLK1. 
However, developing a highly specific PLK1 inhibitor is extremely challenging, given that the 
kinase component of PLK1 shares a sequence identity of 53%, 54% and 37% with PLK2, PLK3 
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and PLK4 respectively. The residues comprising the ATP-binding pockets are more greatly
conserved, with PLK1 sharing 90%, 86% and 60% sequence homology with PLK2, 3 and 4461. 
It is therefore unsurprising to discover that the ATP-competitive inhibitors PHA-680626 and 
BI 2536 interferes with PLKs1-3 with little difference in selectivity290 455 462.
Non-ATP-Competitive Inhibitors
Despite the protein kinase family consisting of over 2000 members463, PLKs are unique in 
containing a PBD. Therefore, the PBD’s potential as a target to develop a highly specific 
polo-like kinase inhibitor is unrivalled. Non-ATP competitive PLK1 inhibitors function by 
inhibiting the protein-protein interactions of the PBD and the first compound of this nature 
to be developed was Poloxin. 
PLK1 Inhibitors – Preclinical Findings and Results of Early Clinical Trials in 
Solid Tumours
Non-ATP Competitive Inhibitors
Poloxin
Preclinical Findings with Poloxin
Poloxin is a small molecule that impairs the PBDs interaction with its binding peptide. It was 
the first non-peptidic inhibitor that prevents the inter-protein reactions of PLK1’s PBD. 
Poloxin arrests cells in mitosis with phenotypic changes including dissociated centrosomes, 
misaligned chromosomes and abnormal spindles noted464. In contrast to ATP-competitive 
inhibitors, peptidic PBD inhibitors cause bipolar, as opposed mono or multipolar spindles. 
Though poloxin assisted in the understanding of PLK1 it was weakly potent and non-
specific465.
ON 01910.Na
Preclinical Findings with ON 01910.Na
The substrate-dependent PLK1 inhibitor ON 01910.Na inhibits the PLK1 pathway activity at 
9-10nM in addition to inhibiting other kinases such as PLK2. The compound induces a G2-M 
phase arrest with phenotype abnormalities including multipolar spindles, centrosome 
fragmentation and chromosomal misalignment noted, leading to apoptosis. In xenograft
models this ATP-independent drug was found to be highly efficacious both as a single agent 
and in combination with established chemotherapeutic agents, including gemcitabine466.
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Clinical Studies with ON 01910.Na
The first Phase I study investigating the effects of ON 01910.Na on solid tumours revealed 
rapid distribution and slow elimination of the drug, with lower haematological toxicity 
compared with other PLK1 inhibitors467. One patient with ovarian cancer remained 
progression-free for 2 years, though this finding was not replicated in a later Phase I trial in 
solid tumours468. The current development of ON 01910.Na now seems focused on 
myelodysplastic syndrome.
ATP-Competitive PLK1 Inhibitors
GSK461364A
Preclinical Findings with GSK461364A
The thiophene derivative GSK461364A has been shown to have a 1000-fold greater 
selectivity for PLK1 compared to nearly 50 other examined kinases469. In vitro, GSK461364A
has demonstrated antiproliferative activity in over 120 cancer cell lines, with its effects 
shown to be concentration-dependent. Low nanomolar concentrations cause moderate 
mitotic effects and the inhibition of cytokinesis with moderate to high concentrations 
leading to abnormal mitotic spindles, misaligned chromosomes and mitotic arrest470 471. One 
in vitro study suggested that cells possessing a TP53 mutation may be more sensitive to 
GSK461364A with cells exhibiting increased chromosome instability472, though this effect is 
yet to be replicated in vivo. Intravenous infusion of the compound in xenograft tumour 
models reported successes ranging from tumour growth inhibition to tumour shrinkage473
474.
Clinical Studies with GSK461364A 
A phase I study of GSK461361364A in 40 patients with solid tumours showed dose-
proportional pharmacokinetics and anti-cancer activity with increased phosphorylated 
histone H3 (pHH3) seen in circulating tumour cells475 476. Only 15% of patients showed stable 
disease at 4 months and it was concluded that the drug should be administered in 
conjunction with anticoagulation in future due to the significantly increased risk of venous 
thrombosis (20%). A further trial to ascertain the efficacy of GSK461364A in the prevention 
of large brain metastases in breast cancer yielded more positive results, though further 
investigation is required477.
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HMN-214 and HMN-176
Preclinical Findings with HMN-214 and HMN-176
HMN-214 is an orally administered prodrug of the active agent HMN-176478. HMN-214 
interferes with the subcellular distribution of PLK1 as opposed to directly inhibiting the 
kinase. This results in G2-M phase arrest, abnormal spindle polar bodies and DNA 
destruction479. In vivo, HMN-176 has shown potent anticancer activity against a spectrum of 
human tumour xenografts, including pancreatic cancer480. 
Clinical Studies with HMN-214 and HMN-176
Phase I studies of HMN-214 in patients with advanced solid malignancies resulted in 24%478
and 9%481 of patients achieving stable disease respectively. However, these studies were not 
specifically targeted at tumours with PLK1 overexpression, suggesting this may be an area 
for further development482.
TAK-960
Preclinical Findings with TAK-960
TAK-960 (Takada Pharmaceuticals) in an orally administered pyrimidodiazepinone with 
potent PLK1 inhibitory properties483. The drug has been shown to induce the accumulation 
of cells in G2-M phase in addition to causing a ‘polo’ arrest and increased level of pHH3 in 
treated cells. In a mouse xenograft, TAK-960 inhibited the growth of the colorectal cancer 
HT-29 with good tolerance of the drug484.
Clinical Studies with TAK-960
Unfortunately, a recent trial investigating TAK-960 in non-haematological malignancies 
(NCT01179399) was terminated early by the sponsor due to business reasons485 and its 
development was ceased in 2013486. 
NMS-P937
Preclinical Studies with NMS-P937
The pyrazolo-quinazoline derivative NMS-P937, also recognised as NMS-1286937, is an ATP-
competitive, orally administered PLK1 inhibitor. In keeping with other PLK1 inhibitors, the 
agent has been shown to induce a G2-M phase arrest and shown antiproliferative activity 
against over a hundred haematological and solid malignant cell lines487. In a xenograft 
model, NMS-P937 has demonstrated synergy in inhibiting tumour growth, in combination 
95 | P a g e
with irinotecan488. This provides further weight to the argument that PLK1 inhibitors’ future 
may be in combination with other anticancer agents, as opposed to monotherapy.
Clinical Studies with NMS-937
NMS-937 is currently being evaluated in a Phase I trial in adult patient with advanced or 
metastatic solid tumours (NCT01014429489), though the results are yet to be published. 
BI 2536
Preclinical Findings with BI 2536
The dihydropteridnone derivative BI 2536 was the first-in-class prototype PLK1 inhibitor 
developed by Boehringer Ingelheim. It showed high selectivity for PLK1 (IC50 0.83nM) but 
was also potent in inhibiting both PLK2 (IC50 3.5nM) and PLK3 (IC50 9nM)455.
In vitro, BI 2536 was demonstrated to block the proliferation of multiple human cancer-cell 
types at concentrations of 2-25nM. Further work with HeLa cells, revealed the accumulation 
of treated cells with a 4N DNA content, indicative of a G2 or mitotic block. Phenotypic 
observation revealed monopolar spindles, described as ‘polo’ spindles surrounded by a ring 
of chromosomes, similar to those seen in PLK1 siRNA-treated samples490 491 492.  
Synchronised HeLa cells released into BI 2536-containing media arrested in G2/M phase, 
with evidence of apoptosis at 24-48 hours455 493
Intravenous BI 2536 is highly efficacious in inhibiting tumour growth in several xenograft 
models including colonic, pancreatic and non-small-cell lung cancer. In vivo results indicated 
that tumour regression was induced by a mitotic arrest within the tumour leading to cell 
death455.
Clinical Studies with BI 2536
Unfortunately, BI 2536’s initial promise in the preclinical setting failed to translate into the 
clinical environment. A multitude of phase I and II trials494 495 496 497 498 showed no clinical 
benefit in BI 2536 monotherapy, including in patients with advanced pancreatic cancer499. 
These results, coupled with the emergence of BI 6727, a second dihydropteridinone 
derivative with an improved safety profile and PLK1 specificity, terminated the further 
development of BI 2536500.
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BI 6727
Preclinical Findings with BI 6727
BI 6727 (molecular weight 728.21 g/mol), also known as Volasertib, is the second 
dihydropteridinone derivative developed by Boehringer Ingelheim. Compared to the 
previous generation, it has a large volume distribution and long half-life in mouse models 
enabling the drug to be administered both intravenously and orally501. The drug is highly 
potent and is currently the most specific ATP-competitive Plk1 inhibitor commercially 
available, with an IC50 of 0.87nM. It has also been shown to inhibit PLK2 and PLK3 at IC50 
values of 5nM and 56nM respectively, but is ineffective against 64 other known kinases at 
concentrations of up to 10μM502.
BI 6727 functions by attaching to the ATP binding pocket of PLK1 resulting in abnormal 
monopolar mitotic spindles and ‘polo-arrest’ in mitosis due to the cell’s inability to separate 
their chromosomes. Flow cytometry of such cells shows a prominent G2-M block, a picture 
consistent with that caused by PLK1 siRNA490 and this prolonged mitotic arrest will 
eventually lead to cell death by apoptosis.  
In preclinical studies, BI 6727 demonstrated in vitro efficacy against cervical cancer503 and 
prostate cancer504, in addition to showing anti-tumour activity in numerous xenograft 
models of human cancers, including taxane-resistant colonic, breast, lung, haemopoetic490
502, pancreatic293 and a variety of paediatric tumours (Rhabdoid and Wilms renal tumours, 
Ewings and osteosarcomas and a variety of neurological tumours)505. 
Clinical Studies with BI 6727 Monotherapy
An initial Phase I trial was undertaken in 65 patients with advanced solid tumours500, with
the final results later presented at the American Society of Clinical Oncology506. The 
Caucasian cohort’s malignancies included soft tissue sarcoma, melanoma, non-small cell 
lung, colorectal, urothelial and prostate cancers, with 28% classified as ‘other’. BI 6727 was 
confirmed to have al ong half-life of 100 hours and was administered intravenously every 
three weeks to a maximum tolerated dose of 400mg per infusion. However, due to the 
frequency of dose reductions in later courses, adverse events and dose-limiting toxicities, 
300mg per dose was chosen for further development. 
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Overall, the drug was well tolerated with the main side-effects encountered being 
haematological, with thrombocytopenia, neutropenia and febrile neutropenia becoming 
dose-limiting. These toxicities were reversible with no evidence of cumulative toxicity. 
Clinical outcomes were favourable with 48% of patients experiencing stable disease. Partial 
response was seen with a variety of tumour types with a further six patients remaining 
progression-free for over 6 months.
A second phase I trial in 59 Asian patients with advanced solid tumours507 included patients 
with soft tissue sarcoma, melanoma, colorectal, urothelial, oesophageal, liver and biliary, 
lung and head and neck cancers. This trial compared two infusion regimes: BI 6727 every 
three weeks vs. BI 6727 on day 1 and day 8 of a three week cycle. The mean tolerated dose 
was similar to the first trial, being 300mg per 3-weekly infusion and 150mg in the opposing 
arm. Haematological and dose-limiting toxicities were seen in both treatment arms but 
were much less prevalent in those patients receiving the drug in two infusions. As in the first 
Phase I trial, clinical outcomes were favourable with 44.1% of patients showing stable 
disease and two patients with urothelial cancer and melanoma displaying a partial response. 
A Phase II trial in advanced urothelial cancer508 reported a 14% partial response and 26% 
with stable disease in patients undergoing three weekly infusions of BI 6727, which was 
deemed insufficient to justify further trials in the disease.
A further Phase II trial (NCT01121406509) compared BI 6727 with the investigator’s choice of 
alternative monotherapy, as 3rd or 4th line treatment in advanced ovarian cancer. In 
summary, outcomes were similar in both groups, with fewer adverse events noted in 
patients receiving BI 6727. The investigators conclude that the identification of a biomarker 
to predict response to BI 6727 would be the next step. 
Clinical Studies with BI 6727 in Combination with other Compounds
Combining novel agents with established drugs has the potential to improve efficacy and 
given the relatively poor results thus far achieved with BI 6727 monotherapy this may be 
where this drug’s future lies. In a Phase II trial, Ellis et al510 combined BI 6727 with the 
established agent for non small-cell lung cancer, pemetrexed, and compared responses to 
those receiving pemetrexed monotherapy. However, no improvement in progression-free or 
overall survival was seen.
98 | P a g e
BI 6727 was combined with platinum agents (cisplatin and carboplatin) in a Phase I study of 
61 patients with advanced solid tumours511 512, with 44% achieving either stable disease or a 
partial response. Though the cohort had already previously been heavily pretreated, 
combination therapy was well tolerated, suggesting that BI 6727 can be administered in 
combination with cytotoxic agents at full monotherapy dose513. 
Other studies combined BI 6727 with kinase inhibitors afatinib514 and nintedanib515 in 
patients with advanced solid tumours. Though results were generally poor with only 2/29 
and 2/30 patients respectively showing any response, one patient with breast cancer 
showed a complete response in the latter study, suggesting that a specific cohort of patients 
could benefit from such treatment.
With regards to haematological malignancy, a Phase II trial combined BI 6727 with low-dose 
cytarabine (LD-AraC) versus cytarabine alone in the treatment of acute myeloid leukemia 
(AML) in 87 frail elderly patients.  Preliminary results from this randomised trial showed a 
significant benefit with combination therapy with a median event-free survival of 5.6 
months compared to 2.3 months (HR: 0.57, 95%CI 0.35-0.92, p=0.021) and a median overall 
survival of 8 months compared with 5.2 months (HR 0.63, 95% CI 0.4-1, p=0.047)516. On this 
basis, BI 6727 in combination with LD-AraC was granted ‘breakthrough status’ by the FDA in 
2013, with the aim of expediting the development of BI 6727 as a potential therapy for AML.
Current Trials with BI 6727
At the time of writing, a few trials remain ongoing with BI 6727 as both monotherapy and in 
combination517. The overwhelming majority of these trials are understandably focused on 
haematological malignancies where BI 6727 shows most promise. 
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Chapter 2 – Materials and Methods
Materials
Chemical or Reagent and Supplier
Albumin from Bovine Serum Sigma Chemical Co, Poole, Dorset
BI 6727 Boehringer Ingelheim, Germany
β-actin Primary Antibody Cell Signalling, Hitchin, Hertfordshire
Bradford dye reagent BioRad, Hemel Hempstead, 
Hertfordshire
Bromophenol blue Sigma Chemical Co, Poole, Dorset
Caspase-3 Primary Antibody Cell Signalling, Hitchin, Hertfordshire
Cell lines: Suit-2, MiaPaCa-2, Panc-1, American Type Culture Collection 
BxPC-3 (ATCC), Rockville, MD, USA
Dimethyl Sulfoxide (DMSO) Fisher Scientific, Loughborough, 
Leicestershire
Distilled water University of Liverpool stores
DL-Dithiothreitol (DTT) Sigma Chemical Co, Poole, Dorset
Ethanol University of Liverpool stores
EZ4U Assay Biomedica, Austria
Foetal Bovine Serum (FBS) Life technologies, Paisley, Renfrewshire
Gemcitabine Eli-Lilly, Basingstoke, Hampshire
Glycerol Sigma Chemical Co, Poole, Dorset
Glycine Fisher Scientific, Loughborough, 
Leicestershire
Goat anti-rabbit Immunoglobulin HRP Dako Ltd, High Wycombe, 
Buckinghamshire
Hydrochloric acid University of Liverpool stores
L-glutamine Life technologies, Paisley, Renfrewshire
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Non fat Dry Milk – Blotting Grade BioRad, Hemel Hempstead, 
Hertfordshire
Nonidet P-40 Abcam, Cambridge, Cambridgeshire
Restore™ Western Blot Stripping Buffer Thermo Scientific, Loughborough, 
Leicestershire
Phosphate Buffered Saline (PBS) Tablets Fisher Scientific, Loughborough, 
Leicestershire
Pipettes - 5, 10, 25ml Corning Inc., New York
Pipette tips - 10, 200 and 100μl Starlab, Milton Keynes, Buckinghamshire
Penicillin-streptomycin Sigma Chemical Co, Poole, Dorset
Phosphate Buffered Saline (PBS) Sigma Chemical Co, Poole, Dorset
Propidium Iodide Sigma Chemical Co, Poole, Dorset
Protease inhibitor tablets, EDTA-free Roche, Welwyn Garden City, 
Hertfordshire
Protein ladder Life technologies, Paisley, Renfrewshire
RNAse A Thermo Scientific, Loughborough, 
Leicestershire
RPMI-1640 Media Sigma Chemical Co, Poole, Dorset
Sodium chloride Sigma Chemical Co, Poole, Dorset
Sodium deoxycholate Sigma Chemical Co, Poole, Dorset
Sodium Dodecyl Sulfate (SDS) Fisher Scientific, Loughborough, 
Leicestershire
Sodium hydroxide pellets VWR, Lutterworth, Leicestershire
Tris Base EMD Chemicals, San Diego
Tris HCL Sigma Chemical Co, Poole, Dorset
Triton X-100 Sigma Chemical Co, Poole, Dorset
Tween® 20 Sigma Chemical Co, Poole, Dorset
Trypsin Sigma Chemical Co, Poole, Dorset
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Virkon Antec International, Sudbury, Suffolk
Western Lightning Plus ECL PerkinElmer, Cambridge, 
Cambridgeshire
Equipment
0.5 and 1.5ml microcentrifuge tubes Eppendorf, Stevenage, Hertfordshire
96-well plates Corning Inc., New York
Annexin Apoptosis and Necrosis Quantitation Kit Biotium, Wembley, Middlesex
Axiovert 40C Microscope Zeiss, Cambridge, Cambridgeshire
Branson Sonicade Branson Ultrasonics Co, Shangai, China
Cell Counting Slides BioRad, Hemel Hempstead, 
Hertfordshire
Cell scrapers Corning Inc., New York
DC126291 Camera Canon 
FACSDiva Software Beckton Dickinson, Oxford, Oxfordshire
FACS Tubes Beckton Dickinson, Oxford, Oxfordshire
Falcon Tubes - 15 and 50ml Corning Inc., New York
Mr. Frosty™ freezing container Thermo Scientific, Loughborough, 
Leicestershire
Photograph film Kodak
Heraeus Biofuge Primo Centrifuge Thermo Scientific, Loughborough, 
Leicestershire
Heraeus Pico17 Mini Centrifuge Thermo Scientific, Loughborough, 
Leicestershire
Procell Incubator Jencons Scientific Ltd, Leighton Buzzard, 
Bedfordshire 
JB Aqua 26 Plus Water Bath Grant, Shepreth, Cambridgeshire
Kodak GBX Developer and Fixer Kodak
LSRFortressa™ Flow Activated Cell Sorter Beckton Dickinson, Oxford, Oxfordshire
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Mini Protean® Tetra System/AnyKD gels BioRad, Hemel Hempstead, 
Hertfordshire
Multiscan Ex Plate Reader Thermo Scientific, Loughborough, 
Leicestershire
Seven Compact pH Meter Mettler-Toledo, Beaumont Leys, 
Leicestershire
QBTP Heat Block Grant, Shepreth, Cambridgeshire
Reagent Resevoirs Thermo Scientific, Loughborough, 
Leicestershire
Sonicade Branson Ultrasonics, Connecticut
TC10™ Automated Cell Counter BioRad, Hemel Hempstead, 
Hertfordshire
Trans-Blot® Turbo™ Transfer System BioRad, Hemel Hempstead, 
Hertfordshire
T25 and T75 Flasks Thermo Scientific, Loughborough, 
Leicestershire
Vortex Genie 2 Scientific Industries, New York
Weighing Scales VWR, Lutterworth, Leicestershire
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Preparation of Solutions
1M DL-Dithiothreitol (DTT)
0.154g DTT
1ml distilled water
Storage: Aliquoted and stored at -20°c
1M Tris
30.29g Tris HCl
200ml distilled water
pH as required
Storage: Room temperature
RNAse (10mg/ml)
100mg RNAse
10ml PBS
Storage: Aliquoted and stored at -20°c
Propidium iodide (1mg/ml)
10mg Propidium iodide
10ml PBS
Storage: Aliquoted and stored at -20°c
Running Buffer x10
50ml 20% Sodium dodecyl sulphate (SDS)
144g Glycine
30g Tris Base
Make up to 1L with distilled water
Storage: Room temperature
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PBST x1
10 phosphate buffered saline (PBS) tablets
1L distilled water
1ml Tween per 0.1% concentration desired
Storage: Room temperature
TBST x10
87.66g Sodium chloride
121g Tris Base
1L distilled water
pH to 7.5 with sodium chloride and/or sodium hydroxide
Titrate to x1 with distilled water, then add 1ml Tween per 0.1% concentration desired
Storage: Room temperature
Reducing Sample Buffer x5
1g Sodium dodecyl sulphate (SDS) powder
3ml 1M Tris HCl pH 6.8
5ml Glycerol
2ml distilled water
0.05g bromophenol blue
Storage: Aliquoted and stored at -20°c
RIPA Buffer
50nM Tris HCL pH 8
150mM NaCl
1% NP-40
0.5% Sodium deoxycholate
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0.1% SDS
Storage: Stored  at 4°c. 10ml aliquoted when required with a protease inhibitor tablet added
Freezing Media
90% Foetal bovine serum
10% DMSO
Storage: Aliquoted and stored at -20°c
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Methods
Drugs 
BI 6727
BI 6727 was provided by Boehringer Ingelheim. The powdered agent was stored away from 
light at room temperature. Dimethyl sulfoxide (DMSO) was utilised to formulate a 
10millimolar (mM) stock solution and kept in 100μl aliquots at -20°C. Further dilutions were 
formulated from the stock solution with 0.1% DMSO-containing RPMI-1640 tissue culture 
media.
Gemcitabine
Powdered gemicitabine was purchased from Eli lilly Ltd. A stock solution of 0.05molar (M)
was formulated in PBS and stored at -20°C in 1ml aliquots. Further dilutions were made with 
RPMI-1640 tissue culture media. 
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In Vitro Cell Work
Cell Lines
The pancreatic cell lines utilised in this research are detailed below (Table 9).
Table 9: The names and origins of pancreatic cell lines utilised in this research
Cell Line Origin
Suit-2
Liver metastasis from a 73-year old male secondary to pancreatic ductal 
adenocarcinoma
BxPC-3 61-year old female with adenocarcinoma of the pancreatic body
MiaPaCa-2 65-year old male with an adenocarcinoma of the pancreatic body and tail
Panc-1 56-year old male with an adenocarcinoma of the head of the pancreas
The cell lines in this research have diverse characteristics but all are pancreatic in origin.
All cell lines were sourced from the stores in the Department of Molecular and Clinical 
Cancer Medicine. Their genetic alterations have been characterised and are well 
documented in the literature (Table 10).
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Table 10: The genetic mutations and tumour marker expression of the pancreatic cell lines 
utilised in this research
Cell Line KRAS TP53 CDKN2A DPC4 Tumour Marker
alteration alteration alteration alteration Expression
Suit-2 p.G12D p.R273H p.E69* Wt CA 19-9
CEA
BxPC-3 Wt p.Y220C Homozygous Homozygous CA 19-9
deletion deletion CEA
MiaPaCa-2 p.G12C p.R248W Homozygous Wt ____
deletion
Panc-1 p.G12D p.R273H Homozygous Wt ____
deletion
The genetic mutations and tumour marker expression varied widely between the
pancreatic cell lines 
Authentication and Mycoplasma Testing
Cell lines were verified as the specified type by genotyping via PCR. Cells were regularly 
screened for mycoplasma by Departmental technical services using Hoechst 33258 or by 
PCR.
Risk assessment and Universal precautions
Universal precautions were taken at all times including Howie coat and gloves and a face 
mask when necessary. Good clinical practice course, induction procedures and risk 
assessments were completed in accordance with University policy on working with clinical 
samples.
Tissue Culture
All tissue culture work was undertaken in a containment level class II hood with laminar flow 
which was cleaned with 70% ethanol both prior to, and after use. Tissue culture reagents 
were all stored at 4°C and warmed to 37°C before use. All bottles and materials were 
cleaned with 70% ethanol prior to transfer to the hood, with an aseptic technique.
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Defrosting Cell Stocks
Cryotubes were defrosted in a waterbath and the contents pipetted into tissue culture 
media to a total volume of 10ml. The flask was incubated for 24 hours at 37°C (5% CO2) prior 
to changing the media to eliminate the DMSO from the freezing media. 
Sub-culturing
Tissue culture media was removed and the cells washed with PBS. Trypsin was added until 
the cells were no longer adhered to the base of the flask (Table 11). The trypsin was
neutralised with FCS in culture media to make a total volume of 10ml. The desired 
concentration of cells was then returned to the flask (with the addition of further culture 
media) and the remainder either discarded, or harvested for experiments. 
Table 11: The routine trypsin time and sub-culture split ratios of pancreatic cell lines
Cell Line
Trypsin Time 
(minutes)
Routine sub-culture split 
(Cells:Media)
Suit-2 3 1:10
BxPC-3 5 1:5
MiaPaCa-2 3 1:10
Panc-1 2 1:5
The times taken to routinely remove adherent cell from incubated flasks and their 
respective sub-culture split rations when transferred into fresh media
Freezing Cell Stocks
The cell-containing media mixture was spun at 200g for 5 minutes prior to the media being
extracted and PBS added to agitate the cell pellet. This was followed by a further centrifuge 
prior to the PBS being removed. Freezing media was added and the cell pellet agitated. This 
was aliquoted into cryotubes and placed in a ‘Mr. Frosty™’ freezing container to be stored at 
-80°C for 24 hours, prior to transfer to long term storage in liquid nitrogen (<-150°C).
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MTS Assay
Cell pellets were washed in PBS prior to being dissolved in culture media. 10μl of this 
solution was inserted into a cell counter to calculate the concentration of cells and the 
dilution required to attain a desired final concentration for a MTS Assay at 100μl per well in 
a 96-well plate. All cell lines - Suit-2, Panc-1, BxPC-3 and MiaPaCa-2 cells were seeded at 2.0 
x10⁴/ml (2000 cells per well).
The plates were incubated at 37°C to enable the cells to adhere. After 24 hours, the culture 
media was removed and the required drug(s) concentrations administered at 100μl per 
well. A typical MTS plate is shown below (Figure 18).
Figure 18: A typical example of a 96-well plate when undertaking a MTS assay
Rows of wells with increasing drug concentrations were established, in addition to a 
media-only and a blank/empty row for control purposes.
Drug treatments were undertaken for 24, 48 and 72 hours prior to the MTS assay. One plate 
was required per time point and all time points were repeated in triplicate. 
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Determination of IC50
EZ4U substrate was dissolved in 2.5ml of activator and warmed to 37°C. This was added to 
22.5ml of tissue culture media and mixed. The drug-containing media was extracted from 
the 96-well plates and replaced with 100µl of the EZ4U reagent mixture prior to the plate 
being incubated. 
Isobolar Analysis of Drug Combinations
The concentrations of both drugs to be utilised during this analysis was determined from 
their respective IC50 readings from previous single-agent MTS assay results. The typical 
distribution of drug concentrations for an isobolar analysis 96-well plate is displayed below
(Figure 19) with the IC50 of each drug equating to the highest concentrations utilised. 
MiaPaCa-2 cells were seeded at 2000 cells per well for 24 hours prior to the removal of the 
media and the commencing of drug treatment. 
Figure 19: A typical example of a 96-well plate when undertaking an isobolar analysis
The rows of cells were treated in accordance with the seven regimes below. As previously 
mentioned, both media-only and blank/empty rows were established for control purposes.
Seven isobolar experiments were undertaken in total to ascertain the effects of adding both 
drugs together and sequentially, as demonstrated in (
Table 12).
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Table 12: The isobolar analyses undertaken and their respective timing protocol
Experiment Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
1
Seeding 
Cells
Drug 1 
added
Drug 1
added
MTS assay 
(72 hours)
2
Seeding 
Cells
Drug 1 
added
Drug 2 
added
MTS assay 
(72 hours)
3
Seeding 
Cells
Drug 2 
added
Drug 2 
added
MTS assay 
(72 hours)
4
Seeding 
Cells
Drug 2 
added
Drug 1 
added
MTS assay 
(72 hours)
5
Seeding 
Cells
Drug 1+2 
added
MTS assay 
(72 hours)
6
Seeding 
Cells
Drug 1 
added
Drugs 1+2 
added
MTS assay 
(72 hours)
7
Seeding 
Cells
Drug 2 
added
Drugs 1+2 
added
MTS assay 
(72 hours)
Timing protocol for isobolar analyses of combination drug therapy with BI 6727 and 
gemcitabine
Plate Reading for IC50s, MTS Assays and Isobolar Analyses
As cell lines vary in their metabolic capacity, readings were taken at hourly intervals after 
incubation from 1 to 4 hours as necessary to ascertain a control reading close to 1. The plate 
was re-incubated between readings. Absorbance was measured at a wavelength of 450nm, 
with a further reading at 620nm as a reference to correct for nonspecific background or 
other potential interferences. 
Western Blotting
Preparation of Cell Lysate for Western Blotting
The culture media was collected prior to twice washing the adherent cells with PBS which 
was also collected. The adherent cells were trypsinised and reincubated before further 
culture media was added to neutralise the trypsin and all contents harvested. These were 
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spun for 2 minutes at 1000g and the media removed. The formed cell pellet was suspended 
in PBS prior to being re-spun at 1000g for 2 minutes. The cell pellet was re-suspended in 
200-600μl of RIPA buffer, sonicated at 13amps for 10 seconds and stored at -20°C. 
Following the first thaw, the sonicated mixture was centrifuged at 1000g for 5 minutes. The 
resulting cell lysis supernatant was then aliquoted and stored at -20°C and the debris 
discarded. 
Bradford Protein Assay 
The Quick Start Bradford dye reagent was left to reach room temperature prior to use.  A
stock solution of BSA was formulated by dissolving 0.005g of bovine albumin in 1ml of 
distilled water. Five standard concentrations were made as detailed in (Table 13).
Table 13: The composition ratios for BSA standards
Concentration
BSA Stock Solution 
(μl)
Distilled Water 
(μl)
10 100 0
7 70 30
5 50 50
2 20 80
1 10 90
The formulation of BSA standards for the purpose of producing a standard curve, utilised 
in determining the protein concentration of samples.
The spectrophotometer was calibrated and zeroed by utilising a blank curvette containing 
800µl of Bradford Reagent and 200μl of distilled water. Standards were made by adding 2µl 
of each concentration to 798μl of Bradford reagent and 200μl of distilled water. Prior to 
analysis, each microcentrifuge tube of Bradford-Protein combination was briefly vortexed 
and left at room temperature for a minimum of five minutes as instructed by the 
manufacturer’s protocol. This process was done only once for each standard, but repeated 
in triplicate for each sample of cell lysate to obtain a mean reading. The standard readings 
were utilised to produce a standard curve, with a formula applied to calculate the volume of 
each sample required to include 20µg of protein.
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Preparation of Samples for Western Blotting
The representative volume from each sample to include 20μg of protein (as previously 
determined by a Bradford assay) was aliquoted into a microcentrifuge tube. Reducing 
sample buffer and 1M DL-Dithiothreitol were combined at a volume ratio of 3:2 and an 
equal volume of this solution added to each sample to a maximum volume of 50μl in each 
microcentrifuge tube. To ensure that each final sample were of equal volume, the necessary 
volume of reducing sample buffer and water (to a ratio of 1:4) was added to each sample. 
Due to the capacity of each well on the precast gels, sample volumes did not exceed 50μl. 
Each sample was warmed on a hotplate for 15 minutes at 96°C and then spun at 1000g for 
20 seconds in preparation for loading onto a gel.
Running Western Blotting Gels
BioRad 10-well Any kD Mini-PROTEAN TGX Precast Gels were placed into the negative 
electrode chamber with the wells facing inwards, prior to being placed into the tank which 
was then filled to the desired level with running buffer. Any air bubbles trapped in the 
running chambers were removed with a syringe and a 25 gauge needle.
The protein ladder was pipetted into the leftmost lane of each gel prior to the running lanes 
being filled with the required volume of samples. The gels were run at 300 Volts until the 
dye front had run to the bottom of the gel.
The gel cassettes were removed, trimmed and then sandwiched within two ion reservoir 
stacks containing a PVDF blotting membrane (BioRad Trans-Blot Turbo Transfer Pack). This 
was carefully rolled to remove any trapped air bubbles, prior to being placed within a locked 
cassette and the Trans-Blot machine programmed to run on a low molecular weight setting.
The PVDF blotting membrane was then placed into a tray containing the desired blocking 
agent and then placed on a rocker.
Antibody Probing for Caspase-3
After blocking the membrane for the desired period, the blocking agent was replaced like-
for-like but with the addition of a caspase-3 antibody at a concentration of 1:1000 (Table 
14). Optimal antibody probing for caspase-3 was concluded to be overnight for 16 hours at 
4°c.
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This was followed by three, ten minute washes with 10mls of 0.1% TBST, with the liquid 
discarded after each wash. A secondary antibody was than added, diluted to the necessary 
concentration in 10mls of 5% Milk in 0.1% TBST (Table 15). Optimal conditions for probing 
for secondary antibody (Table 15) was for an hour and a half at room temperature. This 
process was again followed by three, ten minute washes, after which membrane was 
immersed in 4mls of enhanced chemiluminescence (ECL) for 2 minutes. The membrane was 
then removed from the rocker and taken to the dark room for developing.
Stripping Membranes
After probing for the caspase-3 antibody as described and after the film was developed, the 
membrane was repositioned in a tray containing 10ml of stripping buffer and placed on a 
rocker at room temperature for 10 minutes. The stripping buffer was then discarded and 
three, five-minute washes with 10mls of 0.3% TBST undertaken.
Beta Actin
The stripping and washing of the membrane was followed by blocking with 5% milk in 0.1% 
TBS for 30 minutes on the rocker followed by a the addition of 10mls of 5% Milk in 0.1% 
TBST containing 1:10 000 monoclonal anti-beta-actin antibody produced in mouse for a 
further 30 minutes (Table 14). Three 0.3% TBS wash were then repeated prior to the 
addition of 10mls 5% Milk in 0.1% TBST with 1:3000 anti mouse secondary antibody for 30 
minutes. The membrane then underwent a final round of 0.3% TBST washes prior to the 
addition of ECL in preparation for developing as previously described.
Table 14: Primary antibodies utilised in Western Blotting
Antibody Manufacturer
Molecular 
Weight Code Source Dilution
Incubation and 
Blocking Agent
Caspase-3 Cell Signalling
17, 19 and 
35 kDa #9662 Rabbit 1:1000
5% Milk in 0.1% 
TBST
Beta Actin Cell Signalling 45kDa #4967 Rabbit 1:10 000
5% Milk in 0.1% 
TBST
A table of the primary antibodies utilised, in addition to their optimal concentration and 
dilutent. 
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Table 15: Secondary antibody utilised in Western Blotting
Antibody Manufacturer Code Source Dilution
Incubation and 
Blocking Agent
Anti-Rabbit
IgG HRP Dako P0448 Goat 1:3000
5% Milk in 0.1% 
TBST
A table of the secondary antibody utilised, in addition to its optimal concentration and 
dilutent.
Freezing Membranes
Membranes were wrapped in cling film and stored at -80°C. To re-use the membrane, it was 
quickly defrosted at room temperature and stripped.  The membrane could then be washed, 
blocked and re-probed with a further antibody if required. No membrane was frozen or 
stripped more than once. 
FACS Analysis
At time of cell harvest the media was removed and discarded to exclude floating cells. 
Further media was added to the culture flask and a cell scraper utilised to release all 
adherent cells. These were spun for 5 minutes at 1000g at 4°C and the resulting supernatant 
aspirated. The cells were then re-suspended in PBS and re-centriguged. All but a few drops 
of the supernatant was then aspirated and the microcentrifuge tube vortexed to commence 
re-suspension of the cell pellet. 1ml of cold 70% ethanol was then added drop-wise to each 
tube during a further vortex, prior to storage at 4°C for a minimum of 16 hours to fix the 
cells.
When ready to undertake FACS analysis, the microcentrifuge tubes were spun at 1000g for 5 
minutes at 4°C and the alcohol discarded. PBS was added to re-suspend the cell pellet and a 
cell count performed. 150 000 cells per sample was transferred to a microcentrifuge tube, 
re-spun as previously described and the supernatant aspirated. 350µl of 50µg/ml propidium 
iodide containing 0.2% triton was added to each sample, along with 50µl of 10mg/ml 
RNAse. The samples were vortexed and transferred to BD FACS tubes prior to being stored 
on ice in the dark room for 15 minutes. FACS analysis was kindly undertaken by on Dr. 
Asmaa Salman and Dr. Melaine Oates on LSRFortressa™ Flow Activated Cell Sorter and the 
data analysed with FACSDiva Software.
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Annexin V Apoptosis and Necrosis Assay
An Annexin Apoptosis and Necrosis Quantification Kit (Biotium) was stored at 4°C in the 
dark. This kit contained:
- FITC-Annexin V stain
- Ethidium Homodimer III (EthD-III) stain
- X5 Annexin V binding buffer
Floating and adherent cells were harvested and spun for 5 minutes at 1000g at 4°C with the 
resulting supernatant aspirated. Cells were re-suspended in 1ml of PBS, and again spun at 
1000g. The supernatant was aspirated and discarded and the remaining cell pellet 
processed immediately. Cell pellets were re-suspended at 2-3 x 106 cells/ml in X1 binding 
buffer (diluted in distilled water) with 5µl of both FITC-Annexin V and EthD-III added. 
Samples were incubated at room temperature in the dark room for 15 minutes prior to the 
addition of a further 400µl of X1 binding buffer to each sample. Flow cytometric analysis to 
measure fluorescence in FITC and propidium iodide channels was kindly undertaken by Dr. 
Melanie Oakes within an hour of staining, using LSRFortressa™ Flow Activated Cell Sorter, 
with the data analysed by BD FACSDiva 7.0 Software.
118 | P a g e
Hypothesis
PKL1 inhibition arrests cells in G2 and gemcitabine requires dividing cells to work optimally.  
Combining both BI 6727 and gemcitabine will therefore not be as effective as gemcitabine 
monotherapy in pancreatic cancer cells in vitro. 
Aim
In vitro evaluation of the potential role of a novel PLK1 inhibitor, BI 6727, in pancreatic 
cancer – both as monotherapy and in combination with gemcitabine.
Objectives
1. Establish the IC50 concentrations of both BI 6727 and gemcitabine in pancreatic 
cancer cell lines.
2. Establish an optimal drug sequencing and combination regime for BI 6727 and 
gemcitabine in pancreatic cancer cells in vitro.
3. Identify the mode of cell death when BI 6727 and gemcitabine are utilised in 
combination in pancreatic cancer cells in vitro.
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Chapter 3 – Results
Cell-Line Experiments
The aim of this thesis is to examine the role of a novel PLK1 inhibitor, BI 6727 in pancreatic 
cancer. According to the World Medical Association’s revised Decleration of Helsinki, clinical 
trial participants in every country are entitled to the best standard of care518. As 
gemcitabine is an established chemotherapeutic agent in the treatment of the disease and 
any new drug should arguably be tested in combination with gemcitabine: therefore, BI 
6727 was also investigated in combination with this drug. 
Tissue culture is the most convenient way of investigating the efficacy of a novel drug with 
the National Cancer Institute recognising that in vitro evaluation utilising cell lines is an 
appropriate method of developing chemotherapeutic agents519. Following the drug 
discovery and development pathway, successful in vitro results with a chemotherapeutic 
agent may progress to human tumour xenograft models and eventually, clinical trials. Taking 
into account the massive failure rate of novel anticancer agents520, the estimated cost of 
developing a new drug to attain market approval currently exceeds $2.5 billion and takes 
over a decade521. 
These results must be appreciated and interpreted within the limitations of cell culture.
Cancer cells growing in a culture plate will not behave as tumour cells in situ. Over time, cell 
lines often acquire additional mutations and adapt to growth in culture media. Given the 
absence of a heterogenous cell population and lack of tissue architecture such as stroma, 
some cell characteristics will be lost or altered522. 
Single Drug Experiments
Establishing the IC50s of BI 6727 and Gemcitabine
The first step in assessing the properties of BI 6727 was to establish the IC50 concentration 
of the drug in four pancreatic cancer cell lines: MiaPaCa-2, Suit-2, Panc-1 and BxPC-3 - a task 
which was replicated with gemcitabine. The IC50 is universally recognised as half maximal 
inhibitory concentration, which is the concentration of a specified drug which halves the 
number of viable cells in comparison to a control containing no drug523. This was done by 
treating the various cell lines with increasing concentrations of the drug for 24, 48 and 72 
hours prior to undertaking a viability assay with a spectrophotometer (Figure 20) with the 
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mean ‘blank’ reading subtracted from the final values. A curve was plotted against the 
control which was standardised as 100% at the plateau (the highest point on the curve) and 
0% at the lowest point. The concentration at the midpoint of the curve was then 
determined at the IC50 concentration. Each cell line was repeated in triplicate with a mean 
reading across the three experiments declared as the IC50.
Figure 20: A photograph of an MTS experiment to determine an IC50 in a 96-well plate
An example of a typical MTS plate prepared for the plate reader with eight rows prepared 
per condition/drug concentration. The EZ4U reagent has already been added to each well. 
The control lane (pure media with no drug) is the left-most column. From left to right the 
concentration of drug increases, reflected in a paler orange colour indicating a lower 
number of viable cells. The right-most column in this example is left blank.
The IC50 Concentration of BI 6727 in Pancreatic Cancer Cell Lines
In the literature, the IC50 concentration of BI 6727 in cell lines is widely variable. Most cell 
lines are declared in the low nanomolar range with one prostate cancer cell line, PC3 
reported as having an IC50 as high as 600nM504. Plasma levels established in patients safely 
treated with BI 6727 far exceeds this level507.
Pancreatic cancer cell lines MiaPaCa-2 (Figure 21), Suit-2, Panc-1 and BxPC-3 exhibited 
similar IC50 readings of 53-77nM during our experiments (Table 16) Their response to 
increasing concentrations of BI 6727 was similar, in being able to maintain near control level 
number of viable cells at the lower nanomolar concentrations, before exhibiting a sharp 
drop in cell numbers in comparison to the control, as the IC50 concentration was 
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approached. Complete IC50 graphs at the 72 hour time point, repeated in triplicate for all 
pancreatic cancer cell lines treated with BI 6727 can be seen in Appendix B
Figure 21: Determining the IC50 concentration of BI 6727 in MiaPaCa-2 cells
A graph displaying how the IC50 of BI 6727 was determined in the MiaPaCa-2 cell line. This 
is a typical appearance of a dose-response curve with BI 6727 across all the studied 
pancreatic cancer cell lines. MiaPaCa-2 cells seem resistant to BI 6727 at low nanomolar 
concentrations. All cell line experiments were repeated in triplicate with a mean reading 
calculated to determine a final IC50 concentration.
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BI 6727’s Antiproliferative Effect on Pancreatic Cancer Cells
In order to compare data across cell lines MTS assays were standardised to a control reading 
with no drug (100%) at 24, 48 and 72 hours. The ‘blank’ absorbance reading was universally 
subtracted prior to standardisation and the results plotted on a line graph (Figure 22).
As early as 24 hours, BI 6727 can be seen to reduce viable cell numbers in all pancreatic 
cancer cell lines in comparison to an untreated control, even at very low nanomolar 
concentrations. The only exception to this statement seems to be with concentrations of up 
to 10nM in Panc-1 cells, which generally is the most resistant of the cell lines at 24 hours. 
MiaPaCa-2, BxPC-3 and Suit-2 show similar sensitivity at concentrations below 10nM and 
above 250nM with some disparity between these concentrations. Notably, BxPC-3 seems to 
have two phases of MTS reduction, one at below 10nM and one at above 100 nM.
At 48 hours, all cell lines show sensitivity to BI 6727 with prolonged exposure and display a 
linear response to increasing drug concentrations. Suit-2 and MiaPaCa-2 exhibit marginally 
greater sensitivity than BxPC-3 and Panc-1, though MiaPaCa-2 plateaus at a slightly lower 
drug concentration than other cell lines. As noted at the 24 hour timepoint, there appears 
to be no further benefit in exposing any of the aforementioned cell lines to concentrations 
of BI 6727 in excess of 250nM.
At 72 hours, the plotted graph from each cell line becomes strikingly similar. A sharp drop in 
viable cell number is seen between 50 and 100nM of BI 6727, which is echoed in their 
respective IC50 readings. Interestingly, the lower concentrations (<50nM) of BI 6727 seem 
increasingly ineffective in pancreatic cancer cells as time progresses suggesting that its 
effects can be transient at low doses. However, at higher concentrations (>250nM) where a 
plateau is reached by all cell lines, BI 6727’s efficacy in maintaining cell populations at under 
20% of control level is maintained. 
Given how genetically diverse cell lines responds in such a similar fashion to BI 6727, it could 
be argued that genetic background (e.g. KRAS, TP53, CDK2A or DPC4 status) has little impact 
on pancreatic cancer cell resistance to BI 6727, although it could also be argued that this is 
absence of evidence rather than evidence of absence.
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Figure 22: BI 6727 displays antiproliferative action against pancreatic cancer cells 
Graphs comparing pancreatic cancer cell line response to BI 6727 across 24, 48 and 72 
hours of exposure. Their dose-response curves show remarkable similarity at 72 hours. All 
cell lines achieve a plateau at concentrations of 250nM and above, with viable cell 
numbers being at least 80% lower than in controls.Full MTS readings in Appendix A.
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The IC50 Concentration of Gemcitabine in Pancreatic Cancer Cell Lines 
To evaluate the cytotoxicity of gemcitabine, the same pancreatic cancer cell lines were 
continually exposed to various concentrations of the drug for 72 hours prior to undertaking 
a viability assay. The concentration-dependent cytotoxicity of gemcitabine in pancreatic 
cancer cell lines has been widely published over the last quarter-century. These 
experiments and resulting IC50 concentrations vary considerably not only between relative 
degree of sensitivity exhibited between individual cell lines, but also for the same cell lines 
between studies. Each cell line was investigated in triplicate, with a final IC50 determined as 
a mean of the three IC50 readings. Our results suggest that Suit-2 and Panc-1 exhibit similar 
sensitivity to gemcitabine with IC50 of 11.1-13.8nM with MiaPaCa-2 (Figure 23) and BxPC-3 
showing greater resistance with IC50 concentrations above 20nM. These low nanomolar 
concentrations fall safely below the serum concentration of 20-60μM achieved with a 
standard 30-minute intravenous infusion of 1,000–1,200 mg/m2of gemcitabine524. Complete 
IC50 graphs at the 72 hour time point, repeated in triplicate for all pancreatic cancer cell lines 
treated with BI 6727 can be seen in Appendix C.
Figure 23: Determining the IC50 concentration of gemcitabine in MiaPaCa-2 cells
A graph displaying how the IC50 of gemcitabine was determined in the MiaPaCa-2 cell line. 
This dose-response curve is representative of gemcitabine’s effect on the pancreatic cancer 
cell lines studies achieving IC50 values in the low nanomolar range.
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Table 16: Complete IC50 results of BI 6727 and gemcitabine in pancreatic cancer cell lines
Experiment BI 6727 IC50 at 72h (95% CI) (nM)
Mean 
(nM) Gemcitabine IC50 at 72h (95% CI) (nM)
Mean 
(nM)
BxPC-3 1 85.659 (68.311-110.024) 77.483 14.149 (12.28-15.924) 22.102
2 84.357 (53.753-136.301) 39.562 (36.445-42.413)
3 62.434 (56.511-68.233) 12.595 (11.114-14.206)
MiaPaCa-2 1 71.681 (66.954-76.022) 68.362 36.870 (32.580-40.420) 34.47
2 69.007 (61.693-75.573) 27.812 (24.750-30.920)
3 64.398 (61.388-67.198) 38.740 (34.904-41.861)
Panc-1 1 58.058 (36.848-76.465) 63.514 9.407 (7.16-11.669) 13.797
2 74.98 (67.304-81.954) 15.598 (13.511-17.687)
3 57.505 (40.076-74.999) 16.385 (14.84-17.944)
Suit-2 1 53.629 (49.593-57.911) 53.527 10.943 (9.815-12.034) 11.084
2 61.911 (54.508-70.461) 13.760 (10.798-16.746)
3 45.037 (36.755-53.02) 8.550 (6.935-10.127)
The IC50 concentrations of BI 6727 and gemcitabine were largely reproducible in all four cell lines investigated. Some variation in results 
within certain cell lines were occasionally encountered. Individual IC50 graphs can be seen in Appendix B and C.
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Gemcitabine’s Antiproliferative Effect on Pancreatic Cancer Cells
To delineate further the effects of gemcitabine on pancreatic cancer cells, MTS data was 
again extracted and processed as described for BI 6727.  
From the data displayed in Figure 24, it can be argued that 24 hours of gemcitabine 
exposure, even at concentrations of up to 2M, has little effect on the proliferation of 
pancreatic cancer cells. This statement certainly seems applicable to BxPC-3, MiaPaCa-2 and 
Panc-1 cells though in comparison, Suit-2 cells seem to display slightly greater sensitivity at 
this early time point. This marked lack of gemcitabine activity at 24 hours is explained by the 
requirement of active cell division for the drug to be incorporated into DNA and exert its 
cytotoxic properties. At 24 hours, it is likely to be too early to observe these effects, as most 
cells will not yet have completed a full cell cycle. Panc-1 cells are reported to possess a 
doubling time of 52 hours525, which is slightly slower in comparison to Suit-2 at 38 hours526, 
MiaPaCa-2 at 40 hours527 and BxPC-3 at approximately 48 hours528.
At 48 hours’ gemcitabine exposure, all cell lines show a degree of sensitivity to gemcitabine, 
even at a low nanomolar concentration. BxPC-3, MiaPaCa-2 and Suit-2 exhibit a similar 
response, showing at best a 60% reduction in viable cell numbers compared to an untreated 
control. Panc-1 cells are more resistant however, showing only a 40% reduction compared 
to a control, which is possibly explained by their comparatively slower doubling time.
By 72 hours of drug exposure it becomes apparent that the IC50 of all cell lines is between 10 
and 50nM with a marked drop in viable cell numbers between these concentrations. As 
noted for 24 hours, Panc-1 cells seem more resistant to gemcitabine than the remaining cell 
lines investigated, with little reduction In MTS values. Though all cell lines show 
progressively diminished cell numbers compared to an untreated control, it is unclear 
whether this is due to increased drug toxicity or solely explained by the exponential
proliferation of control cells. 
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Figure 24: Gemcitabine displays antiproliferative activity in pancreatic cancer cells
Gemcitabine has minimal effect on pancreatic cancer cell lines within the first 24 hours of 
exposure. BxPC-3, MiaPaCa-2 and Suit-2 cells exhibit similar responses and sensitivity to 
the drug over time with Panc-1 cells being comparatively resistant to even high drug 
concentrations. Full MTS readings can be seen in Appendix D.
0
0.2
0.4
0.6
0.8
1
1.2
A
bs
or
ba
nc
e 
%
 v
s.
 C
on
tr
ol
Gemcitabine Concentration (nM)
Proliferation Inhibition of Pancreatic Cancer Cell Lines 
Treated with Gemcitabine for 24 Hours
BxPC-3
MiaPaCa-2
Panc-1
Suit-2
0
0.2
0.4
0.6
0.8
1
1.2
A
bs
or
ba
nc
e 
%
 v
s.
 C
on
tr
ol
Gemcitabine Concentration (nM)
Proliferation Inhibition of Pancreatic Cancer Cell Lines 
Treated with Gemcitabine for 48 Hours
BxPC-3
MiaPaCa-2
Panc-1
Suit-2
0
0.2
0.4
0.6
0.8
1
1.2
Ab
so
rb
an
ce
 %
 v
s.
 C
on
tr
ol
Gemcitabine Concentration (nM)
Proliferation Inhibition of Pancreatic Cancer Cell Lines 
Treated with Gemcitabine for 72 Hours
BxPC-3
MiaPaCa-2
Panc1
Suit-2
128 | P a g e
The Selection of MiaPaCa-2 Cells for Further Experiments 
Due to pressures on time and resources, it was decided to utilise only one cell line for 
further experiments. Due to a relatively rapid doubling time and its reproducible behaviour 
with both gemcitabine and BI 6727, MiaPaCa-2 cells were selected. This cell line also 
possesses several common mutations seen in pancreatic cancer, with mutations in KRAS, 
p16 and p53.
BI 6727’s Effects on MiaPaCa-2 Cells
MiaPaCa-2 proliferation data was extracted from MTS assay results by utilising the readings 
taken an hour following the application of EZ4U assay to cells at the 24, 48 and 72 hour time 
points with the ‘blank’ absorbance reading universally subtracted as previously described.
Figure 25 shows that continued MiaPaCa-2 cell exposure to concentrations of up to 5nM of 
BI 6727 does not seem to affect viable cell numbers at 72 hours. Though at the 24 and 48 
hour time points cell numbers gradually fall at increasing drug concentrations, exponential
cell growth does seem to continue at concentrations of up to 50nM. However, this growth 
seems delayed at concentrations in excess of 5nM in comparison to lower concentrations. 
The IC50 concentration of BI 6727 (68nM) can be identified as being 50-100nM from this 
graph due to the sharp drop in the number of viable cells between these concentrations. At 
100nM it can be said that cell proliferation is minimal after 24 hours with very little increase 
in cell numbers with continued exposure to BI 6727.
It is not possible to state from this experiment whether the gradual decrease in viable cell 
number at the 24 hour time point with increasing drug concentration is a result of delayed 
cell division, by cell death or a combination of both effects. However what can be stated is 
at concentrations of 250-1000nM we see a marginal fall in the number of viable cells as time 
progresses. This is a clear indication that at high concentrations of the novel PLK1 inhibitor, 
cell death may occur, possibly as a result of polo arrest (spindle malformation) and 
apoptosis.
Despite BI 6727 having previously been shown to possess a half-life of approximately 110 
hours529 it was observed that recovery was seen much earlier than this under certain 
conditions. To delineate this further, absorbance data from an MTS experiment with 
MiaPaCa-2 was converted to a percentage of the control reading from each time point as 
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seen previously in Figure 22. From this data (Figure 26) we can clearly see that even as early 
as 24 hours, MiaPaCa-2 proliferation in general is reduced in comparison to control with 
rising drug concentrations. The effects of low BI 6727 concentrations (<25nM) seem to 
diminish as time progresses, with cells being able to almost recover completely at 
concentrations of up to 5nM. However, at higher concentrations (>100nM), cells seem 
unable to recover, with proportionally fewer viable cells at 48 and 72 hours in comparison 
to earlier time point. Nevertheless, on the basis of this data there seems to be no benefit in 
utilising concentrations above 250nM as a plateau effect is observed.
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Figure 25: BI 6727’s effect on the proliferation of MiaPaCa-2 cells 
BI 6727 has limited effect on MiaPaCa-2 proliferation at concentrations of up to 5nM. Cell 
division seems restricted at concentrations of up to 50nM with the IC50 likely to be 
between 50 and 100nM on the basis of this graph. Cell death is likely at concentrations of 
250nM and above with progressive time points showing less absorbance. Full MTS 
readings can be seen in Appendix E.
Figure 26: BI 6727’s effect on viable cell numbers vs. untreated control
Low concentrations (0.1-25nM) of BI 6727 seem to be effective in reducing MiaPaCa-2 
proliferation only in the short-term. Its effects are likely to have expired by 72 hours at 
concentrations of up to 5nM. Full MTS readings ican be seen in Appendix F.
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Control (0.1% DMSO) 75nM  BI 6727
8h   
24h     
48h  
72h  
Figure 27: Photographs of BI 6727 vs. control (0.1% DMSO) in MiaPaCa-2 cells
x25 000 magnification photographs showing MiaPaCa-2 cell growth at 8, 24, 48 and 72 
hours at 0.1% DMSO/untreated control condition (left column) and 75nM BI 6727 (right 
column) treatment. Exponential cell growth is seen under control conditions with cell 
division vastly reduced in comparison when treated with BI 6727. 
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Gemcitabine’s Effect on MiaPaCa-2 Cells
It is seen in Figure 28 that viable cell numbers at 24 hours seems generally unaffected by 
gemcitabine - a phenomenon likely to be explained by MiaPaCa-2’s doubling time of 
approximately 40 hours as previously discussed. However, by 48 hours, evidence of 
gemcitabine activity can be seen. At increasing drug concentrations up to 50nM, a gradual 
reduction is seen in the number of viable cells to under half of that seen in controls. A 
plateau is seen at a concentration of above 50nM suggesting that gemcitabine saturation 
may have been achieved.  
At 72 hours of exposure, very low levels of gemcitabine (<5nM) seems only marginally 
effective in restricting logarithmic cell division, before the IC50 landmark which is evident 
after the 25nM point. At concentrations above this, viable cells drop dramatically in
number. It is probable that cell death is occurring at concentrations above 25nM due to the 
observed fall in viable cell numbers as time progresses. In comparison to BI 6727, this 
discrepancy in cell numbers between the specified time points is vast, suggesting a more 
toxic drug, whose effect in killing cells remains active for at least 72 hours with its continued 
exposure. Unlike the results summarised in Figure 25 for BI 6727, Figure 28 demonstrates 
that at higher doses of gemcitabine there is a decrease in cell number between 24 and 72 
hours.
When the MTS readings were standardised versus control (Figure 29), it becomes even more 
evident that gemcitabine’s properties are such that it has a limited effect on MiaPaCa-2 cells 
at 24 hours exposure. On the basis of this data it seems that at concentrations of 
gemcitabine of 10nM and under, MiaPaca-2 cells may be able to recover, with the 
proportion of viable cells versus the untreated control having increased by 72 hours. 
However, we must be open to the possibility that these readings may be anomalous. As with 
BI 6727, it also seems that a saturation point can be reached with gemcitabine, with this 
data suggesting a concentration of approximately 100nM. Very little benefit is seen in 
increasing the drug concentration beyond this. 
When looking at both BI 6727 and gemcitabine monotherapies, the graphs in Figure 26 and 
Figure 29 show that both drugs can independently reduce MiaPaCa-2 populations by over 
80% at 72 hours with continued drug exposure at adequate concentrations. Comparison of 
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Figure 27Figure 30 also shows that neither drug results in resistant colonies but in both 
cases the inhibitory effect seems to be fairly uniform (most cells at 72 hours existing in small 
colonies or even remaining as single entities). However, there is an impression that colonies 
appear smaller at 72 hours with gemcitabine than with BI 6727 and perhaps there is an 
indication that colonies regress with gemcitabine between 48 and 72 hours rather than just 
not forming.
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Figure 28: Gemcitabine’s effects on the proliferation of MiaPaCa-2 cells
Gemcitabine has limited effect on MiaPaCa-2 proliferation at 24 hours of exposure. Cell 
death is evident at concentrations of 50nM and above with progressive time points 
showing less absorbance indicating a fall in the number of living cells. Full MTS readings 
can be seen in Appendix G.
Figure 29: Gemcitabine maintains its toxic properties for at least 72 hours
At 24 hours treatment, gemcitabine seems to have a limited effect on MiaPaCa-2 cell 
population though continued exposure drastically reduces viable cell numbers in 
comparison to control. There seems to be little to no benefit in utilising concentrations of 
gemcitabine in excess of 100nM.Full MTS readings can be seen in Appendix H.
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Control (0.1% PBS) 40nM Gemcitabine
8h  
24h  
48h  
72h  
Figure 30: Photographs of gemcitabine vs. control (0.1% PBS) in MiaPaCa-2 cells
x25 000 magnification photographs showing MiaPaCa-2 cell growth at 8, 24, 48 and 72 
hours at both 0.1% PBS/control (left column) and 40nM gemcitabine (right column) 
conditions. Exponential cell growth is seen in the control condition with evidence of cell 
death and debris, likely to be secondary to apoptosis, when treated with gemcitabine.
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Flow Cytometry
Background
To establish the cell cycle effects of BI 6727 and gemcitabine, MiaPaCa-2 cells were treated 
at the IC50 concentration of the drugs for the desired amount of time, and harvested
alongside an equivalent untreated control. Samples were stained with propidium iodide and 
then fixed in ethanol for at least 24 hours prior to FACS analysis. Though 10,000 events were 
analysed and gated in the vast majority of samples during this project, a small number of 
samples were subject to an error therefore this number was not always reached.
Flow Cytometry in Untreated Control MiaPaCa-2 Cells
Looking at the control condition, the typical prominent cell cycle G1 peaks is noted. Cells 
spend most of their life in the G1/G0 phase containing what is recognised as the 2N amount 
of DNA, representing the two copies of each chromosome in the nucleus of each cell. 
As a cell prepares to divide, it first duplicates its DNA so that when division occurs, each 
daughter cell has the same amount of DNA as the parent cell. This duplication of the DNA is 
called the S-phase for synthesis of the DNA. 
Once the duplication of DNA has been completed, it has double the DNA content of the 
original cell so contains 4N of DNA. This stage of the cell cycle is called the G2/M and is 
represented by the second peak on the histogram. Next, the cell undergoes mitosis which 
divides the 4N amount of DNA back into 2N and the cell returns to G1/G0. 
Almost all cell or nuclear suspensions analysed by DNA content flow cytometry contain 
some damaged or fragmented nuclei (debris). Apoptotic cells often contain fractional DNA 
content, with some cells also losing chromatin by shedding apoptotic bodies. As these cells 
no longer possess the expected 2N quantity of DNA, these events are usually visible to the 
left of the diploid G1 (pre-G1).
Flow Cytometry in MiaPaCa-2 Cells Treated with BI 6727
As expected with a polo-like kinase 1 inhibitor, a large increase in the number of cells 
accumulating in G2/M is seen in comparison to controls. This is most noticeable at the 
earliest timepoints of 8 and 24 hours where 50.6% and 56.3% of cells are gated within G2, as 
opposed to 30.7% and 32.8% in untreated MiaPaCa-2 cells (Table 17). The proportion of G2 
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cells falls by 48 hours – a trend that continues towards the 72 hour point. The increase in G2 
cells seems to be reflected by an almost equivalent fall in the percentage of G1 cells, with 
the proportion of S-phase cells remaining comparatively constant. This suggests that 
MiaPaCa-2 cells maintain the ability to duplicate its DNA when exposed to BI 6727, but is 
then unable to undergo mitosis and divide into two daughter cells. 
As the purpose of this experiment was to delineate the cell cycle effects of BI 6727 and not 
to establish cell death, MiaPaca-2 cells floating in culture media in addition to the PBS used 
to wash the adherent cells was discarded. This was done with the aim of excluding the 
majority of dead cells, for the same reason pre-G1 cells were excluded from gates applied 
for counting and therefore were not included in Table 17. Small numbers of cells can be 
expected pre-G1 even under control conditions, which is reflected in the resulting 
histograms. However, also of note is the large number of pre-G1 MiaPaCa-2 cells seen at the 
24 hour, and to a lesser extent, the 48 hour timepoint when treated with BI 6727. The 
reason for this is unclear, and is confused even further by the near-absence of these 
fragmented cells at 72 hours. It could be argued that if these were true apoptotic cells as a 
direct result of BI 6727, a substantial presence would be maintained at 72 hours. However,
it could also be argued that these cells are dying and are not yet dead. Dead cells and even 
their fragments could also possibly remain adhered to the surface of a culture flask for a 
short period of time but would eventually detach. It is quite possible that a proportion of 
cells seen in the most prominent G2 arrests, seen at 8 and 24 hours, had moved into pre-G1 
by 24 and 48 hours respectively. The less prominent G2 peak at 48 hours may then explain 
why very few events are recorded pre-G1 at 72 hours, as all the cells pre-G1 during the 
earlier timepoints may now have detached and therefore been discarded. 
These results suggest that BI 6727 is most effective in arresting MiaPaCa-2 cells in G2 within 
the first 24 hours of exposure. There is already a 65% increase in G2 (compared to control) 
by 8 hours, rising to a 72% increase by 24 hours, but falling back to just 35% by 72 hours. 
Conclusions regarding cell death cannot be made based on these flow cytometry results 
alone due to the exclusion of floating cells from the experiment. 
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Table 17: The distribution of MiaPaCa-2 cells when treated with BI 6727 for 72 hours
Time Point and Condition
8h (Figure 31) 24h (Figure 32) 48h (Figure 33) 72h (Figure 34)
Phase 0.1% DMSO BI 6727 0.1% DMSO BI 6727 0.1% DMSO BI 6727 0.1% DMSO BI 6727
G1 50.9% 31.3% 51.5% 30.9% 52.4% 40.5% 56.9% 43.9%
S 18.4% 18.1% 15.7% 12.8% 20.5% 13.3% 12.8% 15.2%
G2 30.7% 50.6% 32.8% 56.3% 27.1% 46.2% 30.3% 40.9%
BI 6727 causes a large increase in the proportion of cells in G2 within the first 24 hours of exposure (56 vs. 33%) before returning to being 
similar to the control by 72 hours. The increase in G2 cells seems to be at the expense of G1 cells where numbers fall significantly while the 
proportion of S-phase cells remains comparatively static. Each phase has been gated as a percentage of the total number of cells seen in G1, 
S and G2 phases.
Table 18: The distribution of MiaPaCa-2 cells when treated with gemcitabine for 72 hours
Time Point and Condition
8h (Figure 35) 24h (Figure 36) 48h (Figure 37) 72h (Figure 38)
Phase 0.1% PBS Gemcitabine 0.1% PBS Gemcitabine 0.1% PBS Gemcitabine 0.1% PBS Gemcitabine
G1 51.1% 60.8% 48.4% 43.6% 55% 28.9% 61.4% 32.2%
S 14.6% 20.1% 16.3% 38.1% 15.5% 47% 10.7% 47.7%
G2 34.3% 19.1% 35.3% 18.3% 29.5% 24.1% 27.9% 20.1%
In comparison to an untreated control, gemcitabine causes an increase in the proportion of MiaPaCa-2 cells in S-phase, which is most 
prominent after at least 48 hours of exposure. This seems to mainly be at the expense of G1 cells suggesting that cells are unable to advance 
any further. Each phase has been gated as a percentage of the total number of cells seen in G1, S and G2 phases.
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Figure 31: Flow cytometry of MiaPaCa-2 cells treated with 75nM BI 6727 for 8 hours vs. 
control
Treating MiaPaCa-2 cells at the IC50 concentration of BI 6727 (lower histogram) causes a 
prominent increase in G2 cells after 8 hours in comparison with untreated control (upper 
histogram). Control 10,000 events, BI 6727 8,600 events.
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Figure 32: Flow cytometry of MiaPaCa-2 cells treated with 75nM BI 6727 for 24 hours vs. 
control
The proportion of MiaPaCa-2 cells seen in G2 peaks in the first 24 hours with BI 6727 
treatment. Though this experiment was undertaken on adherent cells, a large number of 
pre-G1 cells are seen which possess subnormal DNA levels. Control 10,000 events, BI 6727 
4,600 events.
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Figure 33: Flow cytometry of MiaPaCa-2 cells treated with 75nM BI 6727 for 48 hours vs. 
control
Though the G2 peak remains prominent after 48 hours’ exposure to BI 6727, its population 
has now been overtaken in size by G1. Pre G1 cells are again seen in significant numbers in 
comparison to the untreated control. Control 10,000 events, BI 6727 16,800 events.
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Figure 34: Flow cytometry of MiaPaCa-2 cells treated with 75nM BI 6727 for 72 hours vs. 
control
The proportion of MiaPaCa-2 cells in G2 phase has returned to near-control levels by 72 
hours of exposure to BI 6727. The pre-G1 peak seen at 24 and 48 hours has also largely 
disappeared, suggesting that these cells may by now have detached and have been 
discarded. Control and BI 6727 experiments both included 10,000 events.
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Flow Cytometry in MiaPaCa-2 Cells Treated with Gemcitabine
Gemcitabine’s metabolites have several intracellular targets, of which many affect the 
synthesis of DNA. It is therefore not surprising that the main cell-cycle-related change seen 
in gemcitabine-treated cells is the accumulation of cells in S-phase. Though relatively 
unchanged at 8 hours, data after 1-3 days of gemcitabine exposure shows an S-phase 
population size two to three-fold that seen in control samples (Table 18).
The proportion of MiaPaCa-2 cells in G1 remains comparable to control-levels during the 
first 24 hours. This is likely to be a reflection of the cell’s doubling time, which takes a while 
longer. By 48 hours and beyond, these cells should be expected to have completed a full cell 
cycle. However, instead of progressing through mitosis and restarting another cycle, the 
cells seen in G1 at 8 and 24 hours have accumulated in S-phase. This fall in G1 cells is also 
reflected in a fall in G2 cells, which is evident as early as 8 hours and is seen across the 
duration of the experimental data. 
As mentioned when discussing the flow cytometry data of BI 6727-treated cells, this 
experiment was not planned to directly observe the cell killing effects of drugs as all floating 
cells were discarded.  Nevertheless, it is prudent to observe that the histograms of 
gemcitabine-treated cells all exhibit ungated pre-G1 events indicative of cell death. As 
gemcitabine inhibits DNA synthesis, MiapaCa-2 cells will be killed either by the induction of 
apoptosis or from necrosis which could also result from from mitotic catastrophe in cells 
that lack the ability to undergo programmed cell death. Up to 24 hours, these pre-G1 peaks 
are comparable in size to those seen in control conditions. A time-dependent significant 
increase is then seen in this population up to 72 hours, likely to be secondary to prolonged 
gemcitabine exposure and subsequent toxicity.
144 | P a g e
Figure 35: Flow cytometry of MiaPaCa-2 cells treated with 40nM gemcitabine for 8 hours 
vs. control
After as little as 8 hours of gemcitabine treatment, MiaPaCa-2 cells are already 
accumulating in both G1 and S-phases. Control 10,000 events, gemcitabine 7,800 events.
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Figure 36: Flow cytometry of MiaPaCa-2 cells treated with 40nM gemcitabine for 24 hours
vs. control
Following 24 hours of exposure to gemcitabine, cells previously seen in G1 are collecting in 
S-phase. Proportionally, the S-phase population is now double the size in gemcitabine-
treated cells compared to control. Control 8,200 events, gemcitabine 10,000 events.
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Figure 37: Flow cytometry of MiaPaCa-2 cells treated with 40nM gemcitabine for 48 hours 
vs. control
After 48 hours of gemcitabine exposure, the G1 population is half of that seen under 
control conditions, with the S-phase population now being thrice the size. Control and 
gemcitabine experiments both included 10,000 events.
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Figure 38: Flow cytometry of MiaPaCa-2 cells treated with 40nM gemcitabine for 72 hours 
vs. control
A similar pattern as seen at 48 hours is seen with gemcitabine treatment with almost half 
the total of gated cells now in S-phase. A progressively large pre-G1 peak is seen indicative 
of dead cells. Control and gemcitabine experiments both included 10,000 events.
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Dual Drug Experiments
Isobolar Analysis of Drug Combinations
To delineate the effects of combining both BI 6727 and gemcitabine on MiaPaCa-2 cells, 
both drugs were administered simultaneously in concentrations ranging from zero, up to 
the IC50 of each agent. Following 72 hours of combination therapy, an MTS assay was 
undertaken with the mean blank reading deducted from each well. The concentrations of 
each drug when used in combination that gave the equivalent inhibition of the drugs used in 
isolation (IC50 or other fixed point) were plotted against each other in order to compare the 
combinations with an additive line that would imply the drugs acted independently.
When plotting an isobologram the doses of drugs A and B give abscissa and ordinate, with 
the effect of combining the drugs plotted as a graph. In the example overleaf (Figure 39), 
the IC50 of each drug in isolation can be read from the axes – 500nM for drug A and 50nM 
for drug B. For two drugs to be additive, their simultaneous combined effect would equate 
to the effects of both drugs in isolation. For example, for these two drugs to be additive, a 
combination of 250nM of drug A and 25nM of drug B should equate to the same effect of 
either 500nM of drug A or 50nM of drug B as single agents. Should the IC50 effect be 
achieved at lower concentrations of the two drugs - for example 150nM of drug A and 20nM 
of B, the drugs would show synergy. If the observed inhibition by the drug combination was 
less than 50 %, the graph’s plots would be located above the additive line and would 
indicate antagonism.
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Figure 39: Example isobologram to demonstrate drug interaction
The additive line joins both the drugs’ IC50 lines. The plotted curve falling below this line 
indicates synergy, with the opposite indicating antagonism.
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Gemcitabine BI 6727 Concentration (nM)
Concentration (nM) 0 1 5 10 25 35 50 75 Control Control Control Blank
0 1.101 1.094 0.909 0.846 0.682 0.624 0.616 0.556 1.257 1.274 1.273 0.036
5 0.981 1.081 0.959 0.62 0.597 0.55 0.556 0.5 1.236 1.255 1.265 0.035
10 0.806 0.759 0.988 0.703 0.575 0.497 0.5 0.444 1.179 1.181 1.216 0.036
20 0.948 0.772 0.988 0.566 0.607 0.506 0.483 0.441 1.14 1.192 1.228 0.035
25 0.844 0.691 0.787 0.539 0.445 0.527 0.434 0.439 1.187 1.263 1.295 0.036
30 0.753 0.773 0.806 0.426 0.465 0.407 0.373 0.383 1.068 1.129 1.139 0.037
35 0.631 0.644 0.625 0.383 0.489 0.373 0.402 0.432 1.241 1.274 1.062 0.035
40 0.46 0.471 0.359 0.343 0.344 0.354 0.409 0.445 1.332 1.337 1.106 0.037
Figure 40: Isobolar analysis of combination therapy with BI 6727 and gemcitabine in MiaPaCa-2 cells for 72 hours
Isobolar analysis of utilising a combination of BI 6727 and gemcitabine in MiaPaCa-2 cells seems generally additive, though a degree of 
synergy could be argued. Both drugs were administered together, with cells treated for 72 hours. 
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Isobolar Experiment of the Combination Treatment of MiaPaCa-2 Cells with BI 6727 and 
Gemcitabine
When looking at the isobolar analysis in 
Figure 40 the first aspect to note is that both extremities of the blue isobolar plot (i.e. the 
individual drug IC50s) is matched to the red additive line as should be expected in this 
instance.  
The isobolar line plotting the effect of combining BI 6727 and gemcitabine on MiaPaCa-2 
cells crosses the additive line at one point, and with one only notable exception, all plots are 
either on, or very near to the additive line. The point representing the combination of 35nM 
of BI 6727 and 5nM gemcitabine gives the impression of a strong degree of synergy, but 
whether this is an anomalous reading or not is difficult to ascertain. However, when 
examining the numerical readings gathered from the MTS assay, the logical progressive 
reduction in the MTS readings with the increased drug concentrations is lost at this 
particular point. This certainly raises the suspicion of an anomaly and may be giving the 
impression of a more impressive result than is true. In excluding this point on the plotted 
graph, it is the author’s opinion that this isobolar graph demonstrates a largely additive 
effect between the combination of BI 6727 and gemcitabine with no overwhelming 
evidence of synergy and no evidence of antagnonism. 
The Additive Effect of Combining BI 6727 and Gemcitabine 
Prior to undertaking this isobolar analysis, it was hypothesised that the combination of a 
PLK1 inhibitor and gemcitabine would be antagonistic. This was based on the simplistic 
theory that BI 6727 is a mitotic inhibitor arresting cells in G2 (Table 17) and gemcitabine 
requires dividing cells to be at its most effective in incorporating into DNA. 
By moving from left to right along the isobolar line their combined effects may be 
hypothesised.
- 40nM gemcitabine + 0nM BI 6727: It has already been demonstrated in Table 18 that 
gemcitabine causes a surge in the S-phase population, which takes approximately 24 
hours to come to prominence on flow cytometry.  A fall in the MiaPaCa-2 cell 
population number will be seen with continued exposure of 40nM of gemcitabine, 
with cells being terminated either by apoptosis or possibly mitotic catastrophe.
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- 25nM gemcitabine + 10nM BI 6727/25nM gemcitabine +25nM BI 6727: Lower 
concentrations  of BI 6727 in isolation has already been shown to reduce the rate of 
MiaPaCa-2 proliferation in comparison to untreated controls as early as 24 hours
(Figure 26). Flow cytometry has revealed that its mechanism of action in causing a 
G2 block is most prominent at this early timepoint, however, cells seem able to 
overcome the effects of this low drug concentration by 72 hours of exposure (Table 
17). Administering 25-30nM of gemcitabine alone would result in no great effect to 
cell numbers at 24 hours though fewer viable cells would be seen in comparison by 
72 hours (Figure 29). By combining the two drugs, the early effects of BI 6727 is 
added to the later effects of gemcitabine resulting in a prolonged period of cellular 
stress. 
- 5nM gemcitabine + 50nM BI 6727: At a concentration of 5nM, gemcitabine has been 
previously shown to marginally reduce MiaPaCa-2 proliferation in comparison to 
untreated control (Figure 28), though no evidence is yet presented to support 
cytotoxicity at this concentration. The same cytostatic effect has been observed at 
50nM of BI 6727 (Figure 25), though it is seen earlier than with gemcitabine. It could 
therefore be hypothesised that the additive effect of combining both drugs at these 
concentrations may be cytostatic in nature, but again a contributory factor may be 
the extended period of cellular stress
- 0nM gemcitabine + 75nM BI 6727: Effective by causing a G2 arrest and inhibits 
daughter cellular division following DNA synthesis.  No evidence is yet presented to 
indicate cell death, though proliferation is dramatically reduced in comparison to 
control (Figure 25). 
In summary, the hypothesised antagonism between BI 6727 and gemcitabine is not seen, 
with an additive effect seen at worst. It is a possibility that the varied concentration 
combinations of the two drugs may result in a differing mechanism in cellular insult. This 
may involve, to varying extents, a prolonged period of cellular stress, increasing cytostatic 
properties with resultant mitotic catastrophe or an increase in apoptotic cell death. 
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Isobolar Experiments of the Consecutive Treatment of MiaPaCa-2 Cells with BI 6727 and 
Gemcitabine
To delineate the effects of the consecutive treatment of pancreatic cancer cells with the two 
compounds, four isobolar analyses were undertaken. This involved treating cells with 
compound 1 in isolation for 24 hours, followed by compound 2 alone for a further 72 hours 
prior to a viability assay.
Figure 41: Photograph of isobolar experiments on 96-well plates with the sequential 
addition of each drug
A photograph of isobolar experiments on 96-well plates following consecutive drug 
treatment. Viable cells convert the EZ4U assay into an orange colour with decreasing 
density of colour indicating a fall in the number of viable cells in the well. The rightmost 
row in each plate is left blank, with the three adjacent rows including untreated control 
cells. 
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Following the administration of the EZ4U assay, inspection of the four plates (Figure 41) 
suggest that MiaPaCa-2 cells were most sensitive to two consecutive treatments with 
gemcitabine (right upper plate) and least sensitive to two treatments with BI 6727 (right 
lower plate). Interestingly, the initial administration of BI 6727 followed by gemcitabine (left 
upper plate) seemed more effective in reducing viable cell numbers than vice versa (left 
lower plate). 
Although the experiment was only undertaken once, the results are strengthened by the 
fact that all four drug combinations experiments were undertaken concurrently and could 
simply be directly visually compared to ascertain superiority.
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Isobolar Analyses with Gemcitabine as the Initial Drug
Gemcitabine followed by Gemcitabine
As is apparent from the photograph in Figure 41, two consecutive doses of gemcitabine 
within 24 hours of each other is highly effective in reducing cell viability. The isobolar graph 
in Figure 42 shows that this phasing is more effective than simply treating the cells with 
gemcitabine once, though doubts must be raised as to the clinical relevance of this regime, 
given gemcitabine’s recognised toxicity.
Of note from the MTS readings seen in Figure 42 and later in Figure 43, is that the 
administration of up to 40nM of gemcitabine for 24 hours, followed by its replacement with 
un-drugged media for 72 hours, seems to only have a modest effect on MiaPaCa-2 viability. 
Though some cell death will inevitably have occurred, it seems that this transient period of 
drug exposure is inadequate to cause significant harm to the cell population. Importantly, 
for this very reason, in this series of isobolar analyses, the plot representing the IC50
concentration of the first drug administered, which should correspond to the x-axis 
extremity of the additive line, is often not reached.
Despite the minimal effect of transient gemcitabine exposure, initial treatment with a 
moderate to high concentration of gemcitabine followed by continued exposure to a very 
low concentration i.e.5nM seems very effective, supporting the theory that the length of 
gemcitabine exposure is an important factor in its toxicity. Initial viability assays with 
gemcitabine (Figure 29) suggests that MiaPaCa-2 cells are only slightly affected by 5nM of 
gemcitabine at 72 hours, supporting synergy when combined with pre-exposed cells. 
Despite there being no doubt as to this drug regime being the most effective, it must be 
argued that this demonstrated synergy may be due to the fact that what is being compared 
is 96 hours of gemcitabine treatment against 72 hours – i.e the leftmost plot on the graph 
represents MiaPaCa-2 cells that were untreated for 24 hours, followed by 72 hours of 
gemcitabine. It is also of interest in these MTS results that the apparent IC50 of gemcitabine 
is 25-35nM as half the control reading (0.809) is reached at this point in the first vertical 
column.
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Concentration of Second Concentration of First Drug Added (Gemcitabine) (nM)
Drug Added (Gemcitabine) (nM) 0 5 10 20 25 30 35 40 Control Control Control Blank
0 0.809 0.799 0.751 0.745 0.733 0.769 0.725 0.641 0.968 0.965 1.064 0.035
5 0.896 0.678 0.671 0.426 0.521 0.478 0.39 0.37 0.943 0.938 0.961 0.037
10 0.471 0.427 0.328 0.291 0.266 0.291 0.235 0.237 0.936 0.858 0.919 0.05
20 0.364 0.296 0.258 0.236 0.254 0.252 0.19 0.196 0.873 0.908 0.999 0.041
25 0.329 0.293 0.22 0.193 0.203 0.212 0.2 0.177 0.997 0.917 0.916 0.041
30 0.413 0.275 0.23 0.214 0.2 0.216 0.186 0.207 0.915 0.869 0.931 0.049
35 0.346 0.253 0.226 0.193 0.177 0.181 0.176 0.16 0.959 0.783 0.782 0.034
40 0.34 0.281 0.242 0.211 0.215 0.196 0.196 0.189 1.001 0.848 1.029 0.034
Figure 42: Isobolar analysis of the sequential addition of gemcitabine in MiaPaCa-2 cells
This isobolar analysis suggests that administering gemcitabine to MiaPaCa-2 cells for 24 hours, followed by a second dose for a further 72 
hours, is synergistic.  
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Gemcitabine followed by BI 6727
Figure 41 clearly shows the superiority of two consecutive treatments with gemcitabine, in 
comparison with gemcitabine followed by BI 6727. The isobolar graph in Figure 43 suggests 
that the effect of pre-treating MiaPaCa-2 cells with gemcitabine for 24 hours prior to 72 
hours of BI 6727 exposure is additive. 
As previously described, the effects of transiently treating MiaPaCa-2 cells for 24 hours with 
gemcitabine is moderate at best by 96 hours (Figure 42 Figure 43). However, sequentially 
adding only a very small concentration i.e. 1-5nM of BI 6727 for 72 hours following 
gemcitabine exposure seems to greatly decrease cell viability in comparison. This benefit 
seems concentration dependent up to the maximum dose of 75nM of BI 6727 utilised in this 
experiment. At this point it must be remembered that previously discussed data in Figure 25
Figure 26 suggest that such low concentrations of BI 6727 as a monotherapy has little to no 
effect on cell numbers compared to control at 72 hours. This supports the conclusion that 
there is some benefit in combining gemcitabine with this novel PLK1 inhibitor.
On the other hand, this isobolar curve suggests that there is little benefit in pre-treating 
MiaPaCa-2 cells with a low concentration (5-10nM) of gemcitabine prior to PLK1 inhibition. 
Continued exposure to such low concentrations have previously been shown to reduce cell 
viability, however it could again be argued that transient exposure to gemcitabine is 
ineffective in killing cells in comparison to continuing treatment. 
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Concentration of Second Concentration of First Drug Added (Gemcitabine) (nM)
Drug Added (BI 6727) (nM)↓ 0 5 10 20 30 35 40 Control Control Control Blank
0 0.938 0.892 0.924 0.784 0.689 0.64 0.64 0.924 0.913 0.94 0.033
1 0.886 0.85 0.725 0.743 0.499 0.557 0.478 1.093 0.925 0.962 0.032
5 0.888 0.725 0.922 0.621 0.513 0.605 0.448 0.86 0.861 0.925 0.034
10 0.897 0.772 0.646 0.64 0.509 0.491 0.433 0.84 0.864 0.884 0.033
25 0.828 0.781 0.658 0.645 0.518 0.529 0.393 0.872 0.884 0.948 0.034
35 0.757 0.643 0.697 0.463 0.621 0.528 0.462 0.838 0.881 0.901 0.035
50 0.749 0.653 0.593 0.585 0.442 0.429 0.498 0.937 0.913 0.922 0.033
75 0.47 0.463 0.41 0.367 0.394 0.331 0.306 0.932 0.934 1.063 0.035
Figure 43: Isobolar analysis of the sequential addition of gemcitabine for 24 Hours, followed by BI 6727 for 72 hours in MiaPaCa-2 cells
This isobolar analysis of treating MiaPaCa-2 cells with BI 6727 for 72 hours following 24 hours of gemcitabine exposure suggests an additive 
effect.
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Isobolar Analyses with BI 727 as the Initial Drug
BI 6727 followed by BI 6727
Administering BI 6727 on consecutive days seems to be of no benefit with a strong 
suggestion of antagonistic behaviour, which is challenging to explain. Nevertheless, on 
superficial inspection of the isobolar plates in Figure 41, it was already apparent that this 
treatment regime is the most ineffective of the four investigated. 
As noted with gemcitabine, the transient exposure of cells for 24 hours to the IC50
concentration of BI 6727 followed by its removal seems to have only a slight effect on cell 
viability by 96 hours. This suggests that MiaPaCa-2 cells can recover from a short period G2 
arrest, and that prolonged exposure is necessary to be effective. 
From earlier results (Figure 25Figure 26) it is already shown that concentrations of up to 
5nM of BI 6727 are ineffective against MiaPaCa-2, even with 72 hours of treatment. Higher 
concentrations of up to 50nM reduces the viable cell population to around 70% of control 
levels by 72 hours, as is also evident in this isobolar experiment (Figure 44, MTS reading of 
0.757 vs. 1.166 in control). 
What is evident from the MTS readings in Figure 44, is that administering an initial 
concentration of up to 50nM of BI 6727 is irrelevant, and that any reduction in cell viability 
seems entirely dependent on the second ‘hit’ being at a concentration of 35nM or higher. 
When the initial concentration administered is at the IC50 concentration of 75nM, this seems 
to sensitize cells to concentrations as low as 10nM as the second dose. Interestingly, 
previous results in Figure 25 Figure 26 demonstrate that concentrations this low of BI 6727 
are ineffective when administered in isolation.
In summary, it can be concluded that if two consecutive doses of BI 6727 are to be 
administered, utilising concentrations below the IC50 are generally ineffective.
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Concentration of Second Concentration of First Drug Added (BI 6727) (nM)
Drug Added (BI 6727) (nM)↓ 0 1 5 10 25 35 50 75 Control Control Control Blank
0 1.166 1.247 1.041 1.241 0.908 0.891 1.01 0.895 1.005 1.117 0.731 0.034
1 1.165 1.26 1.204 1.226 1.154 1.183 1.158 0.892 0.967 1.078 1.116 0.032
5 1.225 1.268 1.187 1.211 1.108 1.12 1.086 0.934 1.105 1.11 1.198 0.041
10 1.088 1.23 1.179 1.109 1.122 1.139 1.03 0.788 0.965 1.144 1.171 0.033
25 1.122 1.303 1.128 1.144 1.221 0.844 1.005 0.559 1.048 1.15 1.056 0.035
35 0.815 0.96 1.042 0.973 0.749 0.703 0.719 0.487 1.018 0.926 0.874 0.035
50 0.757 1.046 1.12 1.053 1.075 0.899 0.86 0.577 0.932 0.94 0.916 0.033
75 0.687 1.067 0.796 0.921 1.133 0.53 0.507 0.361 1.123 1.095 0.448 0.041
Figure 44 : Isobolar analysis of the sequential addition of BI 6727 in MiaPaCa-2 cells
The addition of BI 6727 to MiaPaCa-2 cells for 72 hours, treated with the same drug only 24 hours earlier seems antagonistic with all plots 
being above the additive line.
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BI 6727 Followed by Gemcitabine
It is apparent from Figure 41 that administering BI 6727 prior to gemcitabine is more 
effective than vice versa, however, the benefits when examining the isobolar graph in Figure 
45 seems marginal with evidence of synergy at high gemcitabine concentrations and low BI 
6727 concentrations, but antagonism when these concentrations are reversed.
A closer look at the MTS readings reveals that partly responsible for this confusion is the fact 
that 50% inhibition point (IC50) seems to have been achieved by a far lower concentration 
than the gemcitabine concentration previously demonstrated. The first column in Figure 45
shows that this point has been reached at 10-25nM of gemcitabine as opposed to the 
expected 40nM and the reason for this is unclear. 
Secondly, a further anomaly seen on these results is that there was a clear technical error 
with the multipipette with the bottom row of the plate, likely meaning that possibly no cells
or indeed very few cells were seeded. For this reason, the MTS reading for the 0nM BI 
6727/40nM gemcitabine well on which the graph is based, has been estimated.
Though difficult to draw conclusions from this experiment it could be argued that low-dose 
BI 6727 helps sensitize MiaPaCa-2 cells to moderate-high concentrations of gemcitabine. 
Gemcitabine exposure in isolation for 72 hours has already been shown to be cytotoxic, and 
this is again evident with these results, particularly at concentrations of 20nM and higher. 
However, pre-treating these cells with as little as 1-5nM of BI 6727 prior to gemcitabine 
therapy improves its efficacy in comparison to gemcitabine monotherapy. 
In contrast, pre-dosing with the PLK1 inhibitor seems ineffective when followed by a low 
concentration of gemcitabine, as is evident by the blue isobolar line crossing the red 
additive line into the antagonistic zone of the graph. By looking at the MTS readings which 
the graph interprets as antagonism, it should be noted that cell viability continues to 
decrease with increasing BI 6727 concentration, though this fall is only marginal. What 
skews the graph somewhat is both the artificially low MTS readings from the 0nM BI 6727 
column, in addition to the negligible effect that transient BI 6727 exposure has on MiaPaCa-
2 cells. These two circumstances have influenced the results by pulling the isobolar curve to 
the right, perhaps giving a more negative result than is merited result than otherwise. 
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Concentration of Second Concentration of First Drug Added (BI 6727) (nM)
Drug Added (Gemcitabine) (nM) ↓ 0 1 5 10 25 35 50 75 Control Control Control Blank
0 1.041 0.87 0.676 0.917 0.833 1.017 0.926 0.865 1.044 1.036 1.051 0.034
5 1.114 0.817 0.895 0.735 0.741 0.907 0.877 0.815 1.064 1.419 1.03 0.035
10 0.752 0.739 0.626 0.701 0.74 0.767 0.713 0.603 1.064 0.968 1.026 0.035
20 0.511 0.467 0.532 0.501 0.442 0.504 0.458 0.386 0.964 0.999 1.071 0.033
25 0.504 0.468 0.383 0.348 0.394 0.386 0.387 0.311 0.99 1.159 1.13 0.034
30 0.436 0.372 0.35 0.326 0.356 0.338 0.308 0.253 1.264 0.846 0.991 0.035
35 0.425 0.359 0.286 0.346 0.365 0.267 0.295 0.23 0.99 1.021 1.029 0.034
40 0.125 0.124 0.124 0.125 0.125 0.126 0.122 0.125 0.126 0.128 0.124 0.036
Figure 45: Isobolar analysis of the sequential addition of BI 6727 for 24 hours followed by gemcitabine for 72 hours in MiaPaCa-2 cells
The treatment of MiaPaCa-2 cells with BI 6727 for 24 hours prior to gemcitabine for a further 72 hours seems synergistic at high 
gemcitabine and low BI 6727 concentrations, with the opposite becoming apparent when these concentrations are reversed. 
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Pretreatment of MiaPaCa-2 Cells Prior to Combination Drug Therapy
Thus far, it has been both demonstrated that combination therapy with BI 6727 and 
gemcitabine is at least additive in nature and that the sequential treatment with both drugs 
is arguably more effective when BI 6727 precedes gemcitabine administration. It was 
therefore decided to proceed to investigate the efficacy of pretreating MiaPaCa-2 cells for 
24 hours with monotherapy, prior to the administration of combination therapy.
Both isobolar experiments (monotherapy followed by combination therapy), were 
attempted in triplicate, with the mean MTS readings taken to produce a final isobolar 
analysis. Complete results can be seen in Appendix I and J.
Pretreatment with Gemcitabine Prior to Combination Therapy with BI 6727 and 
Gemcitabine
As is evident in Figure 46, the exposure of MiaPaCa-2 cells to gemcitabine prior to 
combination therapy produces an isobolar graph similar to that seen with both combination 
therapy alone. Figure 46 suggests additive-synergystic behaviour when the two compounds 
are administered in this sequence. However, as previously noted, the clinical application of 
administering two consecutive doses of gemcitabine only 24 hours apart seems unrealistic, 
and it was therefore decided to proceed to repeating this experiment with BI 6727 as the 
primary drug.
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Concentration of BI 6727(nM) Added In Concentration of Gemcitabine Added and Readministered 24 Hours later in Combination with BI 6727(nM)
CombinaƟ on with Gemcitabine at 24 hours↓ 0 5 10 20 25 35 40 Control Control Control Blank
0 0.636 0.609 0.623 0.573 0.487 0.461 0.388 0.544 0.473 0.42 0.062
1 0.616 0.674 0.678 0.653 0.511 0.493 0.442 0.692 0.681 0.693 0.061
5 0.635 0.65 0.607 0.566 0.495 0.424 0.41 0.674 0.685 0.708 0.062
10 0.591 0.64 0.584 0.469 0.299 0.381 0.379 0.661 0.676 0.706 0.061
25 0.584 0.612 0.597 0.414 0.389 0.37 0.369 0.663 0.685 0.724 0.065
50 0.508 0.578 0.262 0.271 0.181 0.296 0.231 0.707 0.712 0.717 0.062
75 0.405 0.225 0.204 0.18 0.169 0.126 0.134 0.683 0.488 0.677 0.064
Figure 46: Isobolar analysis of the sequential addition of gemcitabine for 24 hours, followed by a combination of gemcitabine and BI 6727 
for 72 hours in MiaPaCa-2 cells (mean readings taken from three experiments)
Exposure of MiaPaCa-2 cells to gemcitabine for 24 hours prior to combination therapy for a further 72 hours seems additive-synergystic, and 
produces a graph similar in appearance to both combination therapy alone. Triplicate results can be seen in Appendix I.
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Pretreatment with BI 6727 Prior to Combination Therapy with BI 6727 and Gemcitabine
This experiment was performed in triplicate, but one set of data was lost. Therefore, Figure 
47 is based on two experiments as opposed to the planned three.
When looking at Figure 47, it can be reasonably concluded that exposing MiaPaCa-2 cells to 
BI 6727 prior to a second dose combined with gemcitabine demonstrates synergy. An 
anomaly has to be noted here:  the point at which the blue curve of synergy hits the zero 
gemcitabine concentration is at 50 and not 75nM of BI 6727. This suggests that treating 
MiaPaCa-2 with either concentration (50 or 75nM) of BI 6727, followed by a second 
identical dose is synergistic – a claim that is contradicted by Figure 44 which even suggests 
that this may even be antagonistic. It is not clear why this anomaly exists between the two 
experiments, but this may reflect undefined variations in experimental conditions (e.g. 
difference in growth phases of the cells when drugs were added, note these experiments 
were not undertaken with synchronised cells).
Line of Best Fit for Further Experiments
For further experiments, a line of best fit was established to demonstrate this synergy that is 
seen in Figure 48. For the remaining experiments – namely an Annexin V apoptosis and 
necrosis assay and Western blotting – the drug concentrations were established from 
various plots from this line. 
166 | P a g e
Concentration of Gemcitabine(nM) Added Concentration of BI 6727 Added and Readministered 24 Hours later in Combination with Gemcitabine(nM)       
In Combination with BI 6727 at 24 hours ↓ 0 1 5 10 25 50 75 Control Control Control Blank
0 0.687 0.616 0.543 0.5 0.54 0.47 0.475 0.703 0.709 0.703 0.108
5 0.693 0.557 0.565 0.548 0.541 0.46 0.475 0.669 0.679 0.688 0.109
10 0.672 0.609 0.56 0.477 0.46 0.465 0.474 0.641 0.627 0.692 0.107
20 0.642 0.575 0.508 0.438 0.474 0.429 0.423 0.601 0.623 0.681 0.11
25 0.633 0.481 0.463 0.443 0.454 0.412 0.409 0.607 0.64 0.707 0.112
40 0.427 0.421 0.419 0.407 0.42 0.235 0.248 0.697 0.713 0.725 0.116
Figure 47: Isobolar analysis of the sequential addition of BI 6727 for 24 hours, followed by a combination of BI 6727 and gemcitabine for 72 
hours in MiaPaCa-2 cells (mean readings taken from two experiments)
Treating MiaPaCa-2 cells with BI 6727 for 24 hours, followed by a combination of BI 6727 and gemcitabine for a further 72 hours seems to 
demonstrate synergy. Duplicate results can be seen in Appendix J. 
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Figure 48: : Isobolar analysis of the sequential addition of BI 6727 for 24 hours followed by a combination of BI 6727 and gemcitabine for 72 
hours in MiaPaCa-2 cells
The line of synergy from the previous figure has now been adapted with a line of best fit. Numbers 1-6 indicate points along the line of best 
fit that further experiments have been based upon (See Annexin Apoptosis and Necrosis V Assay and Westerns Blot). 
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Annexin V Assay for Apoptosis and Necrosis
During apoptosis, various morphological changes occur within the cell. In addition to the 
loss of plasma membrane attachment, changes include blebbing of the plasma membrane, 
cytoplasmic and nuclear condensation and DNA cleavage. An early event in this process 
includes the translocation of phosphatidylserine from the inner side of the plasma 
membrane to its exposed outer surface. The phospholipid-binding Annexin V is a 35-36kDa, 
calcium-dependent protein with high affinity for phosphatidylserine which can be utilised 
for the detection of exposed phosphatidylserine using flow cytometry. 
This early translocation of phophatidylserine occurs prior to the cessation of membrane 
integrity, which signals the later stages of cell death from either apoptosis or necrosis. For 
this reason, Annexin V is typically used in conjunction with a further stain such as propidium 
iodide (PI). In this experiment, Ethidium Homodimer III (EthD-III) was utilised to identify 
both early and late apoptotic cells as an alternative to PI. According to the manufacturer’s 
information, EthD-III is a superior alternative to PI due to its greater affinity for DNA and 
higher fluorescence quantum yield.  
Figure 49 shows that live cells with intact membranes exclude EthD-III, as opposed to the 
dead or damaged which are permeable and allow its entry. For this reason, viable cells are 
negative for both Annexin V and EthD-III, whilst early apoptotic cells are Annexin V positive 
but EthD-III negative. Late apoptotic or dead cells may stain positively for both Annexin V 
and EthD-III, whilst necrotic cells are identified by EthD-III positivity in isolation. 
For Annexin V experiments, a minimum of 30,000 events were recorded per condition, with 
P1 cells excluded in all experiments. On the scatter plots, Annexin V conjugated with 
fluorescein isothiocyante (FITC) is represented on the Y-axis, with the bright red staining of 
Ethidium Homodimer III represented on the x-axis. For each scatter plot, two histograms 
representing both stains can also be seen. 
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Figure 49: Annexin V apoptosis and necrosis assay with propidium iodide staining
Viable cells will be negative for both Annexin V and EthD-III stains but will progress to become positive for both by the later stages of 
apoptosis and subsequent secondary necrosis. Cells staining solely for EthD-III may have died from primary necrosis.
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Annexin V Results With Synergystic Drug Combinations
Untreated Control
With the untreated control, both the Annexin V and EthD-III histograms display a single, 
normally distributed population of MiaPaCa-2 cells in the centre of the graph. These 
populations were gated as negative for both stains for the purpose of comparing histograms 
between conditions. On this control scatter plot, a small number of cells is in the right upper 
quadrant is seen, representing a proportion of cells in various stages of apoptosis or 
necrosis, as can be expected in any colony of cells. 
The remaining Annexin V experiments discussed below are based on and represent the red 
numbered points along the line of synergy on the graph seen in Figure 48.
Figure 50: Annexin V assay of MiaPaCa-2 cells under control conditions
Histograms for both Annexin V (bottom left) and EthD-III stains (bottom right) show a 
largely normally distributed pattern. This is reflected in a single large cellular population 
in the scatter plot, with only very few dead/dying cells as expected in any cell population.
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1) 40nM Gemcitabine 0nM BI 6727 (30 000 events)
There is a definite shift towards increased positive staining on the Annexin V histogram. 
However, by comparison there is a dramatic increase in EthD-III positivity with the majority 
of cells staining positively. Though only two very distinct cell populations are visible on the 
scatter graph, based on the histograms, the cell population on the right of the scatter plot 
can be further subdivided into two further populations. In the right upper quadrant a large 
number of cells are seen in late apoptosis or necrosis and have stained positively for both 
Annexin V and EthD-III (Q2). The second population, located in the right lower quadrant (Q4) 
have stained positively solely for EthD-III and is therefore likely to represent primary 
necrotic cells. Though these cells are not also positive for Annexin V stain, it is clear is that 
this population of cells have had their cellular membrane compromised as the red-
fluorescent EthD-III stain binds to intracellular nucleic acid.
Figure 51: Annexin V assay of MiaPaCa-2 cells left untreated for 24 hours, followed by 
40nM of gemcitabine for 72 hours
Gemcitabine causes an increase in both Annexin V and EthD-III staining, represented by a 
right shift in both histograms. This is reflected in a significant cell population on the right 
side of the scatter plot with its upper pole indicative of dually stained calls and its lower 
pole indicating EthD-III stained cells only.
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2) 25nM Gemcitabine 5nM BI 6727 (30 000 events) 
Though still present, a lesser shift towards positive Annexin V staining is again seen in 
comparison to with 40nM gemcitabine alone. With regards to EthD-III staining, we see two 
separate cell populations represented by two peaks, one marginally shifted to the left of the 
control peak, and the second shifted dramatically to the right compared to the control, 
indicative of a pronounced positive EthD-III staining. The left shift may represent nuclear 
changes (possibly resulting from spindle malformation early in G2 preventing nuclear 
membrane breakdown) causing exclusion of the DNA binding agent or it may represent 
chromatin chages induced by gemcitabine, although both these hypotheses are highly 
speculative.
Again two distinct cell populations are seen on the scatter plot, with the right sided 
population being loaded primarily towards the lower as opposed to the upper quadrant. In 
comparison to 40nM of gemcitabine in isolation, this data suggest that though a proportion 
of cells treated with this drug combination undergoes apoptosis, the majority of cell death 
seems to be as a result of primary necrosis (Q4). 
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Figure 52: Annexin V assay of MiaPaCa-2 cells treated with 5nM of BI 6727 for 24 hours, 
followed by 5nM BI 6727 and 25nM gemcitabine for 72 hours
Though less than with 40nM of gemcitabine, a right shift is seen in Annexin V positivity 
compared to the untreated control. The mismatch betwween the EthD-III and Annexin V 
histograms suggests that the main mode of death may be primary necrosis. 
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3) 20nM Gemcitabine 10nM BI 6727 (30 000 events)
The right shift in Annexin V staining is minimal in comparison to an untreated control and is 
certainly less pronounced than the two previous treatments discussed. The bi-peaked 
pattern seen with EthD-III staining is very similar to that seen with 25nM gemcitabine and 
5nM BI 6727. Graphically, this suggests a similar pattern of MiaPaCa-2 cell distribution as 
that seen with the previous treatment, though the comparative drop in positive Annexin V 
staining (Q1 and Q2) suggests that a greater number of cells are dying of a primary necrotic 
pathway as opposed to apoptosis with possible subsequent secondary necrosis. 
Figure 53: Annexin V assay of MiaPaCa-2 cells treated with 10nM BI 6727 for 24 hours, 
followed by 10nM BI 6727 and 20nM gemcitabine for 72 hours
Though the right shift in Annexin V staining is slightly decreased compared to the previous 
condition discussed, the twin peaked appearance in EthD-III staining is similar. The right-
sided population on the scatter plot is again loaded at its inferior end suggestive of 
primary necrosis, as opposed to apoptosis and subsequent secondary necrosis.
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4) 10nM Gemcitabine 25nM BI 6727 (30 000 events)
Interestingly, this is the only Annexin V histogram in this experiment that demonstrates a 
twin-peaked appearance. The fact that the EthD-III histogram also demonstrates two peaks, 
with the rightmost indicating positivity, has resulted in two very distinct cell populations on 
the scatter graph. Discounting the main Annexin V negative/EthD-III negative population, 
the well-defined second population accounts for the vast majority of the remaining cells and 
is located in the contrasting bi-positive sector. This indicates that these MiaPaCa-2 cells are 
either in late apoptosis or secondary necrosis. Interestingly, very few cells are seen to be in 
early apoptosis (solely Annexin V positive, Q1) or having died of primary necrosis (solely Eth-
III positive, Q4).
Figure 54: Annexin V assay of MiaPaCa-2 cells treated with 25nM BI 6727 for 24 hours, 
followed by 25nM BI 6727 and 10nM gemcitabine for 72 hours
Two distinct cell populations are seen on the scatter plot, with the population based in the 
right upper quadrant indicating cells staining positively for both Annexin V and EthD-III, 
indicating cells in late apoptosis. Very few cells seem to stain for only a single stain.
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5) 5nM Gemcitabine 50nM BI 6727 (30 000 events)
A strong right shift is again seen with the Annexin V histogram, though this is represented by 
a single, as opposed to a twin peak as seen previously. Looking across each of the Annexin V 
histograms, it seems that an increase in BI 6727 and fall in gemcitabine concentrations 
respectively causes a greater right shift in the histogram’s peak, though this only applies 
when both drugs are utilised in combination. In contrast, the ever-present bi-peaked 
appearance seen across the EthD-III histograms reveals the constant location of the 
negatively-stained left-shifted peak. The right-shifted EthD-III-positive peak decreases in size 
with a fall in gemcitabine concentration and increasing PLK1 inhibition. This fall in EthD-III 
staining has resulted in a scatter plot which has fewer cells on its right side. However, the 
global right shift in the single-peaked Annexin V histogram has mobilized the main cell 
population upwards, indicating a strong presence in early apoptosis. 
Figure 55: Annexin V assay of MiaPaCa-2 cells treated with 50nM BI 6727 for 24 hours, 
followed by 50nM BI 6727 and 5nM gemcitabine for 72 hours
A strong right shift is seen with the Annexin V histogram, which is not reflected with EthD-
III. The result is the main cell population moving upwards on the scatter graph, suggesting 
that a significant number of these cells are in early apoptosis.
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6) 0nM Gemcitabine 75nM BI 6727 (54 000 events)
For some reason, nearly twice the number of events was recorded under this condition 
compared to the other drug combinations and this warrants taking into consideration when 
visually comparing scatter plots. In comparison to the untreated control, the Annexin V 
histogram shows a definite right shift, similar to that seen with 25nM gemcitabine and 5nM 
BI 6727. In contrast the EthD-III histogram is identical in appearance to that seen under 
control conditions. The resulting scatter plot’s most striking finding is that the main cell 
population has moved north on the y-axis, indicative of the increased Annexin V positivity 
suggesting early apoptosis. 
Figure 56: Annexin assay of MiaPaCa-2 cells treated with 75nM BI 6727 for 24 hours, 
followed by a further 75nM of BI 6727 for 72 hours
An increase is seen in positive Annexin V staining in comparison to untreated control, 
though this is not the case with EthD-III as evident on the histogram. This is reflected in 
the scatter graph’s main cell population migrating upwards and not particularly 
rightwards, indicative ofearly apoptosis. 
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Table 19: Sectoral cell numbers for annexin apoptosis and necrosis assays displayed in Figure 50 to Figure 56
Condition Total Events Not P1 (%) P2 P3
Q1 (%)
Annexin V 
Q2 (%)
Dual
Q3 (%)
Negative
Q4 (%)
EthD-III
Untreated Control 30 000 21228 (70.8) 16567 15209 7.3 12.2 77 3.4
40nM Gemcitabine/0nM BI 6727 30 000 19771 (65.9) 13032 3707 9.8 18.2 43.4 28.6
25nM Gemcitabine/5nM BI 6727 30 000 19974 (66.6) 13656 4481 11.8 15.2 45.2 27.8
20nM Gemcitabine/10nM BI 6727 30 000 21045 (70.2) 14948 5626 10.4 10.8 55.3 23.5
10nM Gemcitabine/25nM BI 6727 30 000 22786 (76) 15618 9716 10.3 18.7 67.1 3.9
5nM Gemcitabine/50nM BI 6727 30 000 20490 (68.3) 11488 5718 24.2 16.5 50.8 8.5
0nM Gemcitabine/75nM BI 6727 54 000 39873 (72.8) 28688 25975 9.8 14.6 64.4 11.2
All quartiles (Q1-4) are expressed as percentage of total number of non-P1 cells. Q1 respresents Annexin V staining alone, Q4 Ethidium 
Homodimer III alone, Q3 gated as per control and Q2 as dual stained with both Annexin V and EthD-III.
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Western Blotting for Cleaved Caspase-3 
MiaPaCa-2 Cells Treated with Gemcitabine Monotherapy
The Western blot in Figure 57 shows that MiaPaCa-2 cells treated with the IC50
concentration of gemcitabine for 72 hours have caspase-3 cleavage indicative of apoptosis. 
Even though the signal is weak, this was achieved after a prolonged period of film exposure, 
with overnight exposure showing no improvement in band intensity. Though no cleaved 
caspase-3 is detected with cells treated at half the IC50 concentration of gemcitabine, this 
must be taken in the context of the very weak band seen at the IC50 concentration. 
Gemcitabine is widely acknowledged to induce apoptosis, and I would suggest that the 
evidence presented here is not strong enough to insist that 20nM of gemcitabine does not 
induce caspase-dependent apoptosis in MiaPaCa-2 cells. 
Although it could be suggested that the beta-actin representative of the gemcitabine IC50 is 
overloaded I would argue that it is comparable to the BI 6727 IC50 equivalent and therefore 
it is sufficient to make a reasoned conclusion. I would concede that the untreated control 
actin is underloaded in comparison to the gemcitabine IC50. However, a comparison 
between these two is also seen at the second experiment, from which I can confidently 
exclude any significant caspase-3 cleavage in untreated cells in comparison to those treated 
with 40nM of gemcitabine for 72 hours.
MiaPaCa-2 Cells Treated with BI 6727 Monotherapy
MiaPaCa-2 cells treated with concentrations of up to 75nM of BI 6727 for 72 hours show no 
evidence of caspase-3 cleavage, similar to the untreated control (Figure 57). BI 6727 has 
previously been described to induce polo-arrest and subsequently apoptosis in exposed cells 
with both cleaved caspase-3 and PARP documented as markers. Though the Western blot 
suggests the opposite, it must again be taken in the context of the very weak band attained 
by gemcitabine-treated cells, as the Western was run on the same gel, transferred, 
developed and exposed in the same experiment.
Cell proliferation evidence presented in Figure 25 shows that MiaPaCa-2 cell death is not 
definitively caused by BI 6727 at concentrations of under 250nM. At lower concentrations, a 
cytostatic effect is certainly evident, which may or may not be accompanied by apoptotic 
180 | P a g e
cell death suggesting that caspase-3 cleavage may well not be occurring at the IC50
concentration and this western blot is an accurate representation of events.
Evidence to the contrary may be provided by the flow cytometry data in Table 17, which 
was undertaken with only adherent cells and therefore may be of limited use in helping 
dissect the result of this Western blot. However, it suggests that the induction of G2 arrest is 
most prominent within the first 8-24 hours of exposure, with the number of cells with 
abnormal DNA content peaking at 24-48 hours (Figure 31, Figure 32, Figure 33 and Figure
34). Therefore, there is definitive evidence of cell death, though there are two caveats to 
this – firstly, the cause of cell death is yet unproven and secondly, this predominantly occurs 
earlier than the 72 hour time point from which this Western blot is based. Whether the 
dead adherent cells seen at 24-48 hours during flow cytometry would be floating in the 
media at the 72 hour mark is unclear. Also unknown is whether caspase-3 was ever 
activated or moreso even peaked at this earlier time and has therefore been missed on the 
Western undertaken. These questions could potentially have been answered by including a 
high (>1000nM) concentration of BI 6727 in the experiment, in addition to including a 
greater variety of time points such as 8, 24 and 48 hours.
The other notable factor to consider from this experiment is that both adherent and floating 
cells were utilised to create the cell lysate. This may have a significant bearing on the 
conclusions drawn when comparing both monotherapies, as the ratio of live to dead cells 
may vary between the two drugs. As an MTS assay (utilised to determine the respective 
drug IC50s) is based solely on determining an equal number of live cells, the number of dead 
cells may vary drastically between treatments.  Therefore any disparity in the ratio of live to 
dead cells would clearly alter the cleaved caspase-3 band intensity when comparing an 
equal protein yield from their respective lysates. This potential deficiency could be 
overcome by utilising dead cells alone to formulate the lysates for this experiment.
MiaPaCa-2 Cells Pre-Treated with BI 6727 Followed by BI 6727 and Gemcitabine 
Combination Therapy
Isobolar analyses have previously shown that treating MiaPaCa-2 cells with BI 6727 for 24 
hours prior to combination therapy with both BI 6727 and gemcitabine is synergistic (Figure 
47). Annexin V apoptosis and necrosis data from multiple points on the curve of synergy
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(Figure 48) has shown large quantities of cells staining positively for either Annexin V, EthD-
III, or both, indicative of cell death. 
Western blotting for cleaved caspsase-3 was undertaken with cell lysate obtained from 
those treated identically to that included in the Annexin V experiments. Compared to the 
Western blot undertaken with drug monotherapy, MiaPaCa-2 cells treated with 40nM of 
gemcitabine has this time produced a higher intensity band, despite undergoing the same 
experiment protocol. Taking into account the absence of a signal at 19kDa with untreated 
control, it can be concluded that exposing MiaPaCa-2 cells to gemcitabine monotherapy at 
the IC50 concentration will produce caspase-dependent apoptosis.
Moving from left to right, a comparatively very weak band is seen at 19kDa with the next 
drug combination of 5nM BI 6727 followed by its combination with 25nM of gemcitabine. 
When observing its equivalent Annexin V scatter plot (Figure 52), it can be argued that this 
comparatively major drop in band intensity does not equate to the rather lesser fall in the 
proportion of non-viable cells. 
Further along to the right, where cells were treated with 25nM of BI 6727 followed by its 
combination with 10nM gemcitabine, there is a complete absence of any cleaved caspase-3 
activity. Once again, by inspecting its related Annexin V scatter plot in Figure 54, it is difficult 
to comprehend how such an evidently large proportion of cells staining positively for both 
Annexin V and EthD-III could be undergoing caspase-dependent apoptosis yet not show any 
sign of cleaved caspase-3 on this Western blot. It must then be considered that the synergy 
demonstrated by combining the novel PLK1 inhibitor, BI 6727 with gemcitabine is not 
entirely due to caspase-dependent apoptosis and other lethal pathways may be in effect.
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Figure 57: Western Blot for cleaved caspase-3 in MiaPaCa-2 cells treated with BI 6727 and gemcitabine monotherapy and in combination
Evidence of Caspase-3 cleavage, indicative of apoptosis is seen with gemcitabine but not BI 6727 monotherapy. When MiaPaCa-2 cells are 
treated with BI 6727 prior to combination therapy, which has previously been shown to be synergistic, cleaved caspases-3 is not seen, 
suggesting an alternative mode of cell death. Both experiments were independently performed and cannot therefore be used for direct 
comparative purposes.
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Chapter 4 - Discussion
Summary of Main Findings
On commencing this project, there were specific objectives including establishing the IC50
concentrations of BI 6727 and gemcitabine in pancreatic cancer cell lines in vitro. The IC50
concentrations of both drugs were established across a range of pancreatic cell lines: Suit-2, 
MiaPaCa-2, Panc-1 and BxPC-3. Together, these cell lines carry the commonest known 
mutations in pancreatic cancer: including KRAS, CDKN2A, TP53 and DPC4. 
Utilised as monotherapy, BI 6727 has been shown to be effective against a variety of 
pancreatic cancer cell lines at low nanomolar concentrations and reduces cell numbers as 
early as 24 hours in comparison to an untreated control. However, after 72 hours of 
exposure to lower concentrations (<50nM) of BI 6727, this response seems to be transient, 
with pancreatic cancer cells seeming to recover somewhat. Exposure to higher 
concentrations (>250nM), maintains viable pancreatic cell numbers at below 20% of that of 
untreated control. 
Further proliferation assays with MiaPaCa-2 cells suggest that logarithmic cell division 
continues at the lower concentrations of BI 6727, though this is reduced in comparison to 
control. Flow cytometry of only adherent/viable MiaPaCa-2 cells treated with the IC50
concentration (75nM) demonstrated an increase in the proportion of G2/M cells, 
particularly during the first 24 hours of exposure. Further data support these cells 
maintaining the ability to duplicate their DNA but being unable to divide into two daughter 
cells, suggesting a mainly cytostatic mechanism. At concentrations of 100nM, viable cell 
numbers barely increase over 72 hours, with cell numbers falling with continued exposure 
to concentrations in excess of this. This is indicative of cytotoxicity, possibly as a result of 
polo arrest and apoptosis.
Gemcitabine monotherapy is already widely acknowledged to be effective against 
pancreatic cancer cells, which was reflected in this project’s results with IC50 concentrations 
ranging 11-34nM. The nucleoside analogue’s effects were limited within the first 24 hours 
due to its need to be incorporated in cellular DNA to be effective, with its toxic properties 
coming to prominence at later time points. This is demonstrated in a proliferation assay of 
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treated MiaPaCa-2 cells, with viable cell numbers diminishing over time at concentrations in 
excess of 50nM. Flow cytometry of treated adherent/viable MiaPaCa-2 cells showed their 
accumulation in S-phase, reflecting their inability to synthesise DNA. Evidence of cell death 
by apoptosis was later demonstrated by Western blotting.  
The second objective was to establish an optimal drug sequencing and combination regime 
for BI 6727 and gemcitabine in pancreatic cancer cells in vitro, which was undertaken in 
MiaPaCa-2 cells. It was hypothesised that combining both a PLK1 inhibitor and gemcitabine 
would be antagonistic given that gemcitabine requires dividing cells to be at its most 
effective. However, an initial isobolar analysis demonstrated that combining these drugs 
resulted in an additive effect at worst. 
This resulted in further isobolar experiments and by varying the addition of BI 6727 and 
gemcitabine, a hierarchy of sequential drug combination was clearly demonstrated. The 
preferred drug administration sequence, in order of superiority was shown to be:
1. Gemcitabine followed by more gemcitabine (most effective)
2. BI 6727 followed by gemcitabine
3. Gemcitabine followed by BI 6727
4. BI 6727 followed by more BI 6727 (least effective)
By taking this a step further MiaPaCa-2 cells were treated with BI 6727 or gemcitabine for 
24 hours, followed by a combination of both drugs for 72 hours. Pretreatment with 
gemcitabine resulted in a isobolar graph similar to combination therapy alone (additive) 
with BI 6727 pretreatment showing strong evidence of synergy.
The final objective of this project was to identify the mode of cell death when BI 6727 and 
gemcitabine are utilised in this synergistic combination in pancreatic cancer cells. This 
process was undertaken with a combination of Annexin V apoptosis and necrosis assay and 
Western blotting. Annexin V assay of BI 6727-treated MiaPaCa-2 cells suggested an increase 
in the number of cells in early apoptosis, with Western blotting excluding the presence of 
cleaved caspase-3. With gemcitabine monotherapy, MiaPaCa-2 cells increasingly stained 
positively for Annexin V, EthD-III and both together. This indicates cell death by a 
combination of both primary necrosis and apoptosis, with the presence of cleaved caspase-
3 confirmed with Western blotting. 
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When treating MiaPaCa-2 cells with various synergistic drug combinations, only one 
combination (25nM gemcitabine/5nM BI 6727) shows any evidence of cleaved caspase-3 
with Western blotting. However, the level seems negligible in comparison with gemcitabine 
monotherapy.
When assessing all the combination therapy Annexin V assays, it is noticeable that 
increasing the BI 6727 concentration and a reducing the gemcitabine concentration 
generally seems to cause an increase in Annexin V staining. This is exemplified by a right 
shift on histograms and a north shift of the main cell population on the scatter plot. In 
contrast, by combining BI 6727 and gemcitabine, a fall in the latter’s concentration, coupled 
with increasing PLK1 inhibition causes a left shift in the EthD-III histogram indicating a fall in 
positively stained cells. Coupled together, this alteration in the concentrations of 
combination therapy broadly causes a decrease in dual-stained cells and a global shift of the 
main cell population towards early apoptosis. Gemcitabine monotherapy, which exhibited 
the strong presence of cleaved caspase-3 has a large cellular population on the right side of 
its scatter plot, indicative of late apoptotic and necrotic cells. With combination therapy, the 
rather modest fall in cell numbers in this representative population seems disproportionate 
to the dramatic absence of cleaved-caspase-3 expression, suggesting an alternative method 
of cell death to caspase-dependent apoptosis. 
Potential Mechanism of Action for Synergy
This work has identified evidence of synergy when utilising the ATP-competitive PLK1 
inhibitor BI 6727 and the antimetabolite gemcitabine. Given that gemcitabine is a drug that 
incorporates its metabolites into a cell’s DNA in S-phase, how can the drug work 
synergistically with a drug that arrests cells in G2/M? The experiments undertaken during 
this work merely shows the end result of combining both drugs and very little about the 
underlying mechanism and interaction between the two. For this reason, potential theories 
are speculative at best. What is useful however, is that evidence has been published which 
may help shed light on this conundrum.
Zhang et al530 utilised DMTC, an alternative ATP-competitive PLK1 inhibitor in combination 
with gemcitabine. Interestingly, utilising low concentrations of both drugs resulted in 
synergy, with higher concentrations being antagonistic. It is already known that PKL1 is not 
essential for mitotic entry in the normal, healthy functioning cell. However, when the DNA 
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damage checkpoint is activated, as would be the case with gemcitabine-treated cells, its 
presence becomes crucial if mitosis is to be entered. Zhang suggests that as gemcitabine 
induces the DNA damage checkpoint, continued PKL1 inhibition by DMTC ensures that this 
checkpoint is not overcome. As these cells fail to enter mitosis they become apoptotic. 
Li et al531 used biochemical fractionation and RNA interference to show that PKL1 is required 
for both G1/S and G2/M phases. However the level of PLK1 required for G1/S transition was 
extremely low in comparison to the maximal activity necessary for cells to complete mitosis. 
In addition, it was also demonstrated that PLK1 inhibition significantly reduced the rate of 
DNA synthesis. Logically, it must be considered whether reducing the rate of DNA synthesis 
would either enhance the efficacy of gemcitabine by allowing more time for its metabolites 
to become incorporated, or disable its effects i.e. less DNA synthesis equating to less 
gemcitabine being incorporated. Interestingly, the ATP-competitive PKL1 inhibitor 
GSK461364A demonstrated synergy with gemcitabine, both in vitro in a variety of pancreatic 
cancer cells and in vivo in a Panc-1-derived orthotopic xenograft model.   
Aurora A, along with Bora are the main activating kinases of PKL1. Zhou532 observed an 
Aurora A kinase inhibitor in combination with gemcitabine in bladder cancer. Interestingly, 
concurrent therapy was additive/antagonistic, whereas sequential addition (Aurora A 
inhibitor first) became synergistic. It is suggested that the induction of spindle checkpoint 
dysfunction by Aurora A inhibition potentiates gemcitabine’s ability to arrest the cell cycle. 
Given PKL1’s critical role in mitosis and spindle assembly, it is of interest that the secondary 
effects of Aurora A inhibition, such as the downregulation of PLK1 activity, was not 
investigated.   Could the lack of PLK1 activity be a factor in the synergy demonstrated?
As synergy is demonstrated between BI 6727 and gemcitabine, both drugs’ mechanisms of 
action must cross paths. The question is does gemcitabine enhance the effects of PKL1 
inhibition, vice versa, or a combination of the two? Does a tumour actively expressing PLK1 
play a part in a pathway that eventually develops gemcitabine resistance? What effect does 
PLK1 have on thymidylate synthase, ribonucleotide reductase or DNA polymerase?  The full 
effects of gemcitabine’s effects on the subcellular localisation of PLK1 are also yet to be 
established, though it has been previously suggested that this could also be tumour 
dependent531. Gemcitabine metabolites could potentially increase the amount of a 
particular PBD ligand and therefore attract PKL1 to a particular cellular location at a 
particular phase of the cell cycle. Alternatively, gemcitabine metabolites may enhance BI 
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6727 in inhibiting PKL1, for example negatively regulating its cellular localisation, thereby 
preventing its presence in its most efficient location. It is certainly plausible that 
gemcitabine’s downstream protein targets inhibit the PBD domain’s binding capacity, or 
alternatively, inhibit the priming of its target ligands (for example CDK1, MAPKs and ATR), 
thereby rendering the kinase domain inactive. And even in the event of the PBD functioning, 
it is possible that gemcitabine may be responsible in negatively regulating proteins 
responsible for the phosphorylation of residues Thr210 or Ser137 and hence the eventual 
activation of the kinase domain.
Given that gemcitabine pretreatment prior to combination therapy is inferior to BI 6727 
pretreatment, the underlying reason for this must also be considered and speculated upon. 
At the cessation of that first 24 hours of gemcitabine monotherapy, it is evident that viable 
cell numbers will be largely unaffected. However an underlying cellular process would have 
taken place rendering the subsequent combination therapy less effective than had they 
been pretreated with BI 6727. This is likely to be a result of a combination of the direct drug-
dependent changes within the cell’s microenvironment, in addition to the specific phase of 
the cell cycle that these cells will be present at the time of treatment with combination 
therapy. It must therefore be speculated that gemcitabine and BI 6727 are best added when 
cells are in G2/M phase as opposed to S-phase.
Interestingly, it has previously been reported that cells synchronised in S phase are more 
susceptible to gemcitabine toxicity533. It is suggested that a low initial dose of gemcitabine 
acts as a primer, synchronising cells is S phase and therefore increasing the efficacy of any 
subsequent dose. To the contrary, a high initial dose completely arrests the cell cycle, but 
without the lethality thereby decreasing the drug efficacy. This theory may explain the 
synergy shown in this research’s isobolar analysis when utilising two consecutive doses of 
gemcitabine.
Evidence presented in this work suggests that over 50% cells will be in G2/M phase 
following 24 hours of treatment by BI 6727, the point at which further BI 6727 will be added 
alongside gemcitabine to demonstrate synergy. If we consider the ‘priming’ theory of 
gemcitabine described above, it would seem that the opposite applies to BI 6727 
monotherapy with two consecutive doses being antagonistic. However, the inclusion of 
gemcitabine transforming this into synergy suggests that the lethal effects of gemcitabine 
become amplified in PKL1-inhibited G2/M-arrested cells. In my opinion, the mechanism of 
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synergy is multifactorial and may even differ considerably as the concentrations of both 
drugs are altered. For example, there may be elements of prolonged cellular stress due to 
the early effects of PKL1 inhibition and the later effects of gemcitabine. The inability of PKL1 
inhibited cells to recover from gemcitabine induced DNA-damage checkpoint activation is 
almost certain to play a part. This may be in addition to PKL1-induced cytostasis and 
gemcitabine-induced caspase-dependent apoptosis. With regards to the mechanism of cell 
death in this research, there seems to be more than a single lethal pathway in play. Their
exact nature cannot be fully explained, but it is reasonable to speculate that there may be a 
truncated form of apoptosis leading to necrotic cell death (a form of mitotic catastrophe).
Clinical Relevance of Main Findings
There is ample evidence to show that only rarely can pancreatic cancer be cured by 
resection alone and that adjuvant therapy provides a significant survival advantage. In the 
palliative setting, chemotherapy is shown to result in a small yet significant increase in life 
expectancy in comparison to best supportive care. Though significant advances have been 
made over the past quarter of a century, the long-term outlook for pancreatic cancer 
patients remains poor, particularly when compared with other gastrointestinal malignant 
diseases. 
There are a multitude of tumour related factors that make pancreatic cancer such a 
formidable disease to overcome. Early undetectable micrometastases, the presence of a 
dense peri-tumoural stroma unlike other cancers and resistance to chemotherapy are just a 
few of those challenges. The fact that the majority of pancreatic tumours develop resistance 
to gemcitabine is a particular enigma for researchers developing appropriate alternative 
anti-cancer agents.
In addition to the factors listed above, the vast heterogeneity between tumours determines 
that it has become increasingly clear that ‘one size fits all’ chemotherapy is largely 
ineffective and in an ideal world, personalised therapy tailored to each individual tumour 
would be possible. However, this will not only require the identification of a biomarker for 
each cancer-triggering pathway and mutation, but also the development of a drug to 
counteract each facet. Even with the astonishing progress made in recent years, this will 
almost certainly remain a puzzle for the foreseeable future.
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Developing novel drugs is a costly and laborious process, which more often than not ends in 
failure. Though it is essential that novel therapies are continually developed, instead of 
confining these ‘failed’ monotherapies to the well populated drug graveyard, their 
combination with current gold-standard drugs is an area of great potential for researchers. 
Only very recently, ESPAC-4 presented their findings on adjuvant combination therapy with 
gemcitabine and capecitabine following pancreatic cancer resection. Median and 5-year 
survival were shown to be significantly improved with combination therapy compared with 
gemcitabine monotherapy (Median survival 28 vs. 25.5 months, 5-year survival 28.8% vs. 
16.3%)534. This supports the notion that combining drugs may be the way forward until 
further breakthroughs are made in developing novel and more targeted chemotherapeutic 
agents.
The main question that has arisen from this work is can PLK1 inhibition delay or avert 
gemcitabine resistance? Though the results from this work suggest this may be possible, it 
may be more credible to speculate that combining BI 6727 and gemcitabine will only be 
beneficial in a subset of patients with tumours that overexpress PLK1. Until pancreatic 
tumours are screened for PLK1 expression prior to the commencement of chemotherapy, its 
true potential may remain may remain undiscovered.
Limitations and Suggestions for Further Work
Be it academic or otherwise, the termination of any task or project provides an opportunity 
for reflection on what may have been done differently, or what any additional work could 
have been done. This work has demonstrated synergy between BI 6727 and gemcitabine in 
pancreatic cancer, though this must be taken within the context of its limitations. 
Experiments demonstrating synergy between BI 6727 and gemcitabine were only 
undertaken in a single cell line. Given that MiaPaCa-2 possesses amongst the commonest 
mutations in pancreatic cancer, it could reasonably be argued that this synergy is potentially 
transferrable to other pancreatic cancer cell lines that overexpress PLK1, especially given 
that the IC50 concentrations of all experimented cell lines: MiaPaCa-2, Suit-2, BxPC-3 and 
Panc-1 were all very alike. Evidence in the literature states that MiaPaCa-2 cells significantly
over-express PLK1, being 58-fold higher than that of a control cell line423423. A further 
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publication reports PLK1 mRNA expression in BxPC-3 and Panc-1 being >20-fold that of a 
control. It could therefore be argued that these cells should exhibit increased sensitivity to 
PLK1 inhibition than other pancreatic cell line expressing less PLK1, such as AsPC-1 or 
HPDE6. 
In retrospect, defining PLK1 expression on both an mRNA and protein level via PCR and 
Western blot respectively should have been undertaken as the very first experiment of this 
project. The inclusion of a PLK1-control, such as AsPC-1 or HPDE6 pancreatic cancer cells 
should also have been considered, which may have resulted in a wider range of IC50 
concentrations of BI 6727. The utilisation of a PLK1-inhibitor-resistant cell line may also have 
made a useful comparison to MiaPaCa-2, which displayed synergy with gemcitabine. 
At present, limited evidence exists in the literature with regards to PLK1 expression, p53, 
KRAS status and their subsequent sensitivity to PLK1 inhibitors. PLK1 has previously been 
demonstrated to be expressed in three quarters of pancreatic cancers, but its extent was 
extremely variable423. Preserved p53 status has been associated with increased apoptosis 
when treated with PLK1 inhibitors, though this has been disputed by others. Mutant KRAS 
has also been claimed to increase sensitivity to PLK1 inhibition. It is this tumour 
heterogeneity that presents such a challenge to the pharmaceutical industry and oncologist 
alike. PLK1 inhibitors are clearly unlikely to be to be an effective chemotherapeutic 
treatment for all pancreatic cancers, meaning further work is required to identify the subset 
of patients whose tumour biology predisposes sensitivity to such drugs. Further in vitro
work could include TP53 or KRAS knockdown in pancreatic cancer cells prior to the 
inhibition of PLK1. It would be of interest to note whether the IC50 of BI 6727 is reduced 
after either. 
The next step in assessing this drug combination’s relevance to clinical practice could 
involve progressing to a human tumour xenograft model. Though successful results are no 
guarantee of the same in humans, a negative result is a strong indicator that any further 
research with this drug combination should be abandoned. For example, there is a 
possibility that a simple tolerability study in a murine model could demonstrate that this 
drug combination is too toxic and therefore not feasible in clinical practice.
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This work raises the possibility that MiaPaCa-2 cell death by combining BI 6727 and 
gemcitabine may not be predominantly caspase-dependent, an alternative mode of cell 
death has not been demonstrated.  Western blotting revealed an absence of cleaved 
caspase-3 with both BI 6727 and the majority of combination therapy-treated cells, though 
a strong presence when treated with gemcitabine alone. In retrospect, a stronger result 
could have been achieved by utilising dead cells in isolation as there remains a possibility 
that a dilution-effect may have been in-play. Separating these non-viable cells by FACS or 
alternatively by a Ficoll-Paque technique would give a far more accurate result and exclude 
the potential for a sampling error through dilution. 
Another possibility for the absence of cleaved-caspase-3 is that these cells were harvested 
too early or too late to optimally demonstrate the presence of cleaved caspase-3. In some 
cell types, the half-life of some active caspase subunits can often be very short. In such cases 
a decrease in zymogen signal will be seen but a corresponding increase in the subunit signal
will be absent535. This is certainly something to consider as an alternative to caspase-3 in 
future work. In addition, experimenting with dead cells at a greater variety of time points 
could also help eliminate this problem, as opposed to the single 72-hourpoint used in this 
research.
As previously mentioned, an even better marker of cellular or tumour response would be in 
a xenograft model. This would give the additional benefit of being able to measure tumour 
sizes and observing the histopathological appearance of the tumour’s response to 
treatment. Immunohistochemistry for markers of cell death i.e. cleaved aspase-3 could also 
be undertaken, and is well documented in the literature.
In retrospect, an alternative experiment could have been undertaken to further distinguish 
between apoptosis and necrosis in vitro. Cells staining positively for both Annexin V and 
EthD-III are considered to be late apoptotic or secondary necrotic cells. This is due to the 
fact that in vitro, secondary necrosis, otherwise termed apoptotic necrosis will eventually 
follow apoptosis due to the absence of phagocytosis by macrophages536. Measured over 
time in a dynamic experiment, it should be possible to track these cells through the stages 
of apoptosis. In contrast, a single observation indicating that cells are both Annexin V and 
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EthD-III positive as undertaken in this work, reveals limited information about the process 
by which the cells underwent their downfall. 
One of the most valuable suggestions for a dynamic experiment for future work is 
prolonged light microscopy. This would provide invaluable new information regarding 
proliferation, colony formation, cell phenotype and mode of cell death. Such an experiment 
could demonstrate whether combination-therapy treated cells still undergo the 
characteristic malformed spindle changes characteristic of PK1-inhibited cells. It would also 
be of interest to investigate how cells in S phase and G2/M differ when treated with 
combination therapy. Cells would need to be synchronised prior to any such experiment, 
with FACS or alternatively by chemical blockade with compounds such as hydroxyurea (S 
phase) and nocodazole (M phase) being tried and tested methods in this task. With regards 
to microscopy, fluorescence imaging could also be undertaken, which could define the 
subcellular location and expression of PLK1 in gemcitabine and combination-therapy treated 
cells.
Though observing cellular morphology would be of great interest, the information gathered 
in isolation may mask significant variations in biochemical and immunological 
heterogeneity. Due to the vast spectrum of routes in which cells can reach their demise121, 
biochemical methods for assessing cell death do have advantages over morphological 
techniques in that they are quantitative, and therefore less prone to being misinterpreted 
by the operator.  The absence of cleaved caspase-3 in vitro should in future lead to a variety 
of markers representing other cell death pathways such as mitotic catastrophe (caspase-2 
activation) or necroptosis (RIP/RIP3 activation) amongst others.
Conclusion
The novel PLK1 inhibitor, BI 6727 is effective against a variety of pancreatic cancer cells in 
vitro. In MiaPaCa-2 cells, synergy has been demonstrated when BI 6727 is administered 
prior to combination therapy with gemcitabine, though the mode of cell death does not 
appear to be predominantly caspase-dependent.
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